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ABSTRACT 
The mechanisms which regulate the growth fraction of the 
haemopoietic stem cell (CFU-S) and granulocyte macrophage 
progenitor cell (GM-CFC) have been investigated. In normal murine 
bone marrow (NMBM) a small proportion of the CFU-S are synthesising 
DNA (-10%). In contrast, in the bone marrow from mice regenerating 
after treatment with cytotoxic drugs and in developing haemopoietic 
tissues such as murine fetal liver a large proportion of the CFU-S 
(-40%) are synthesising DNA. Medium conditioned by normal murine 
and human bone marrow cells inhibited the proliferation of rapidly 
cycling CFU-S from regenerating bone marrow. This inhibitor was 
contained in a 50-100K daltons ultrafiltration fraction. In 
contra-distinction medium conditioned by human fetal liver cells 
stimulated the proliferation of CFU-S from NMBM. The stimulator 
was produced by adherent cells and was contained in a 30-50K 
daltons ultrafiltration fraction. 
An alternative assay for the humoral regulators of CFU-S 
proliferation was developed. Different numbers of haemopoietic 
cells were injected into lethally irradiated mice. Five days later 
they were injected with 2iCi of 
125IUdR 
and sacrificed 2 hours 
later. There was a linear relationship between the log 125IUdR 
uptake into the spleen and femur and the log cell dose injected. 
Pre-treatment of haemopoietic cells with an S-phase specific 
cytotoxic drug resulted in a reduction in the 
125IUdR 
incorporation 
into the spleen. This enabled the kinetic properties of a 
haemopoietic stem cell population to be assessed and the humoral 
111 
factors which modulate the growth fraction of these cells to be 
investigated. 
At early stages of gestation (11-14 weeks) in human fetal 
liver few GM-CFC are synthesising DNA, whereas later in gestation 
(>14 weeks) a large proportion of GM-CFC are in S-phase, Moore and 
Williams (1973b). Incubation of NMBM GM-CFC (approx 40% in DNA 
synthesis) with a supernatant from an early human fetal liver 
(11-14 weeks) reduced the proportion synthesising DNA to <5%. In 
contrast, the proportion of murine GM-CFC synthesising DNA was not 
affected by incubation with a supernatant from a late human fetal 
liver (>14 weeks). GM-CFC that had been switched out of cycle by 
incubation with a supernatant from an early gestation human fetal 
liver were switched back into cycle following incubation with a 
late human fetal liver supernatant. The inhibitor and stimulator 
of GM-CFC proliferation were both produced by non-adherent cells 
and were contained in >100K and 30-50K daltons ultrafiltration 
fractions repectively. It is likely that changes in the relative 
levels of a proliferation inhibitor and stimulator throughout 
gestation might control the proportion of GM-CFC in cycle. 
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CHAPTER0NE 
THE REGULATION OF HAEMOPOIETIC 
STEM CELL PROLIFERATION 
I 
CHAPTER ONE : ABSTRACT 
The suicide technique, (Becker et al 1965), was used to 
determine the proportion of haemopoietic stem cells (CFU-S) which 
were synthesising DNA. In normal and post cytotoxic drug 
regenerating bone marrow a small and large proportion of the CFU-S 
were synthesising DNA respectively. 
Medium conditioned by suspensions of rat and guinea pig bone 
marrow and rat thymus cells were fractionated using Amicon filters 
to obtain nominal molecular weight bands of 50-100K and 30-50K 
daltons. An inhibitor was found in the 50-100K daltons fraction 
from normal rat and guinea pig bone marrow which reduced the 
proportion of CFU-S in regenerating bone marrow that were 
synthesizing DNA (>40 to <10%). This inhibitor did not reduce the 
proportion of granulocyte macrophage progenitors (GM-CFC) from 
normal murine bone marrow which were synthesising DNA. The 
inhibitor was not found in the 30-50K daltons fraction extracted 
from rat bone marrow or in the 50-100K daltons fraction extracted 
from rat thymus. 
In livers from day 15 gestational age murine fetuses 
approximately 40% of the CFU-S were synthesizing DNA. Normal 
murine bone marrow (NMBM) was incubated with medium conditioned by 
these fetal liver cells. This treatment increased the proportion 
of NMBM CFU-S which were synthesising DNA (<11 to >30%). 
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CHAPTER ONE 
THE REGULATION OF HAEMOPOIETIC STEM CELL PROLIFERATION 
1.1 INTRODUCTION 
1.1.1 Haemop. oiesis 
The mature peripheral blood cells have finite lifespans, 
(Thompson 1977), and most of them cannot proliferate, (Metcalf and 
Moore 1971). During adult life 6x1015 erythrocytes and 2x1015 
granulocytes are produced (over ten times the body weight), (Lajtha 
et al 1978). These blood cells are therefore not released from a 
preformed store but are produced by proliferating cells throughout 
life. The principal site of blood cell formation in the adult is 
the bone marrow, (Wickramasinghe 1975). Most of the bone marrow is 
occupied by morphologically recognisable precursor cells which can 
be ascribed to the different haemopoietic lineages, (Thompson 
1977); (MacDonald et al 1978). These cells have only a limited 
capacity to reproduce themselves, (Metcalf 1977); (Lajtha et al 
1978). Their numbers must therefore be maintained by an input 
from a small population of cells with an extensive self-replicative 
capacity. 
With the development of in vivo and in vitro clonogenic assays 
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for haemopoietic cells, (Ti11 and McCulloch 1961), (Metcalf 1977), 
it became apparent that the haemopoietic tissues were made up of 
three pyramidal shaped compartments, or hierarchies of cells, 
(Metcalf and Moore 1971) (Figure 1.1). 
The most ancestral of these cells are the pluripotential 
haemopoietic stem cells. A stem cell can divide to both reproduce 
itself and give rise to differentiated progeny of all the 
haemopoietic lineages, (Lajtha 1979). These cells because of their 
low incidence in the haemopoietic tissues can only be assayed 
indirectly. They form colonies in the spleens of lethally 
irradiated mice, (Till and McCulloch 1961). The haemopoietic stem 
cell undergoes a first differentiation step to form the committed 
progenitor cells. The progenitor cells are capable of only limited 
self replication and are restricted to one or two lines of 
differentiation. They are detected using in vitro cloning assays, 
('Metcalf 1977). The committed progenitors differentiate to form 
the morphologically recogisable precursors. These are the first 
haemopoietic cells which can be ascribed to a line of 
differentiation on the basis of their morphology. These cells 
undergo a maturation with a progressive increase in specific 
differentiated cell functions, and decrease in proliferative 
capacity, (Thompson 1977), (MacDonald et al 1978). 
These three tiers of haemopoietic cells in adult life are 
located in the bone marrow, (Wickramasinghe 1975). Ontogenetically 
these cells are derived from the yolk sac. This is the only site 
where haemopoietic stem cells are generated de novo, (Moore and 
The Three-Tiered Haemopoietic System 
Progenitor Cell 
Compartment 
Morphologically 
/ \\ Recognizable Cell 
,/ Compartment 
i Mature End Cells 
FIGURE 1.1 
f 
The haemopoietic tissues consist of three pyramidal-shaped 
compartments or hierarchies of cells. The only cells capable of 
extensive self-replication are the stem cells (CFU-S). They are 
pluripotential and by a first differentiation step form the 
committed progenitor cells (eg GM-CFC and BFU-E). These committed 
progenitors by a second differentiation step form the 
morphologically recognizable precursors (eg erythroblasts and 
myeloblasts). As the recognizable precursors mature they lose 
their proliferative potential and develop differentiated cell 
functions (eg haemoglobin synthesis). The mature end cells are 
released into the peripheral blood and have finite lifespans. 
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(Metcalf 1970), (Johnson and Metcalf 1978a). The yolk sac stem 
cells subsequently migrate and seed to the liver, spleen and bone 
marrow of the fetus, (Metcalf and Moore 1971). These organs then 
become haemopoietic tissues, (Wickramasinghe 1975) (see Section 
3.1). In adult life the spleen and liver are only haemopoietic 
tissues when there is a large demand for blood cell production. 
This occurs when a lot of the normal haemopoietic cells have been 
killed by cytotoxic drugs or irradiation, (Hanks 1964); (Rencricca 
et al 1970); (Tubiana et al 1974); (Lord 1976). In animals with 
myeloproliferative diseases such as the leukaemias, anaemias and 
myelofibrosis, there may also be compensatory haemopoiesis in the 
spleen and liver, (Thompson 1977). 
The three tiered organisation of the haemopoietic system has 
important properties, (Metcalf and Moore 1971); (Metcalf 1977); 
(Lajtha et al 1978): - 
(1) It allows extensive amplification divisions within each 
compartment; this can be altered to change the final output of 
mature cells, (Lord and Lajtha 1974). 
(2) There is a progressive loss of potential and concomitant 
specialization from compartment to compartment. 
(3) A cell cannot move from a mature to an immature compartment, eg 
from committed progenitor to stem cell. 
(4) A cell cannot move from one lineage to another, eg erythroid to 
granulocytic. 
(5) The final number of progeny which a cell produces is reduced in 
successive compartments. 
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The maturation of the recognizable precursors is expressed 
both functionally and morphologically (eg haemoglobin synthesis in 
erythroid precursors), (Erslev and Gabuzda 1975); (Lajtha 1979a). 
The pluripotential stem cells and progenitor cells also appear to 
undergo a functional maturation and are therefore not homogeneous 
populations either, 
(Metcalf 1977); (Schofield 1978 , 1979); 
(Jacobson et al 1979); (Rosendaal et al 1979). Thus the mature 
blood cells are formed by the haemopoietic tissues, which are 
composed of three heterogenous cell populations of increasing size, 
decreasing potential and increasing functional specialization. 
1.1.2 The Pluripotential Haemopoietic Stem Cell 
1.1.2.1 The colony forming unit spleen 
Because the haemopoietic stem cell is morphologically 
inconspicuous and constitutes only a small proportion of the 
haemopoietic cells, it can only be assayed indirectly. In lethally 
irradiated mice grafted with a critical dose of haemopoietic cells 
discrete colonies were seen in the spleen 8 to 10 days later, (Till 
and McCulloch 1961). The cells forming these colonies have 
therefore been called the Colony Forming Unit Spleen (CFU-S). 
These colonies were composed of granulocytic, erythroid and 
megakaryocytic cells, in some colonies all three lines of 
differentiation were present, (Siminovitch et al 1963). Few 
lymphoid cells were detected in these spleen colonies, (Micklem and 
Loutit 1966). Using irradiation induced chromosome markers and 
7 
enzyme markers, these colonies have been shown to be clones, (Wu et 
al 1967); (, Abramson et al 1977); (Prchal et al 1978). When a 
spleen colony was retranspalnted into a second group of lethally 
irradiated mice, they formed more spleen colonies, (Schofield and 
Lajtha 1973). The CFU-S therefore fits the definition of a stem 
cell, it reproduces itself, and gives rise to different types of 
differentiated progeny. The origin of lymphoid cells is not 
clearly established; some appear to be derived from the CFU-S, but 
others may be produced by a separate cell, (Adamson et al 1976); 
(Abramson et al 1977). 
1.1.2.2 CFU-S seeding efficiency 
When a lethally irradiated mouse is injected with haemopoietic 
cells, not all of those capable of forming spleen colonies do so. 
The proportion which do was determined by removing the spleen from 
the lethally irradiated mouse (primary recipient), between 2 and 24 
hours after the injection of bone marrow cells. A single cell 
suspension was prepared from the primary recipient's spleen. This 
was injected into a second lethally irradiated mouse (secondary 
recipient). The number of colonies formed in this secondary 
recipient were compared with those which developed in the spleen if 
it was left in the primary recipient. This was called the seeding 
efficiency or 'F' fraction, (Siminovitch et al 1963). 
When the spleen was removed from the primary recipient after 2 
hours, the 'F' fraction was 17%, (Siminovitch et al 1963). In 
contrast, if it was removed after 24 hours it was 8%, to 10%, 
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(Playfair and Cole 1965); (Lahiri and van Putten 1969); (Lord 
1971). This reduction is probably due to the expulsion of CFU-S 
from the spleen during its post irradiation shrinkage, (Lord and 
Hendry 1973). The 24 hour seeding efficiency is thus a more 
accurate reflection of the number of CFU which will form spleen 
colonies, (Lord and Hendry 1973); 
(Schofield 1979). The ratio 
between the 2 and 24 hour seeding efficiency was constant at 3: 1, 
(Lahiri and van Putten 1969); (Monette and Demello 1979). Thus 
the measurement of the relative seeding efficiencies of CFU-S from 
different haemopoietic tissues can equally be made at 2 and 24 
hours. The absolute CFU-S seeding efficiency can only be 
determined by removing the spleen from the primary recipient, 24 
hours after the injection of haemopoietic cells, 
(Lord and Hendry 
1973). 
The seeding efficiencies of CFU-S populations in different 
kinetic states are not the same. (Monette and Demello 1979) 
demonstrated that the seeding efficiency of rapidly proliferating 
CFU-S was 50% of those which were slowly proliferating, eg murine 
fetal liver compared with normal bone marrow. 
1.1.2.3 The cell cycle 
The cell cycle has been divided into four phases, (Aherne et al 
1977); (Baserga 1981) (Figure 1.2). The S-phase during which DNA 
is synthesized. The interval following the S-phase before the next 
mitosis is called G2. During mitosis the cell divides. The GI 
phase is situated between the previous mitoses and the S-phase. 
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The Cell Cycle 
G1 
M 
S 
?. =:. _ 
LGOJ 
The four phases of the cell cycle. M-mitosis is followed by a gap 
GI in which a cell may manifest its normal differentiated cell 
functions. The GI phase also represents a point of decision 
whether to enter a non-cycling phase or to progress to mitosis. A 
resting non-cycling Cn compartment has been proposed, its location 
in the cell cycle is not established. The position indicated has 
been proposed to explain the rapid triggering of non-cycling cells 
into DNA synthesis, Lahari and Van Putten 1972). DNA synthesis 
occurs during the S-phase. This is followed by a second gap, G2, 
prior to mitosis. 
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During the Cl phase the cell performs its normal metabolic 
functions, eg erythroblasts synthesize haemoglobin. The duration 
of the G, and S-phase are relatively constant. The length of the 
cell cycle is regulated by changing the duration of G1, (Lajtha 
1979). In some cell populations the interval between mitoses is 
very large, eg liver hepatocytes. It was therefore proposed that 
rather than having a very long Gl phase cells could leave the cell 
cycle and enter a resting 'Go state', '. Lajtha 1979). The position 
of the Gn state in the cell cycle is not established. It is 
probably either situated somewhere in the G, phase, or between the 
Cl and S-phase, (Byron 1975); (Aherne et al 1977). 
The proportion of cells in the different phases of the cell 
cycle can be determined using radio isotopes and metaphase 
arresting agents, ; Thomas 1974); ! Aherne et al 1977). The 
principal isotopes used have been, tritiated thymidine to indicate 
the proportion of cells synthesizing DNA and Fe55 or Fe59 as an 
index of haemoglobin synthesis. Drugs such as Vincristine and 
Vinblastine have been used to selectively arrest cells in mitosis. 
To use these techniques a cell population must be morphologically 
recognisable, eg the different stages of erythroblast maturation. 
1.1.2.4 CFU-S kinetics 
The proportion of haemopoietic stem cells synthesizing DNA is 
determined indirectly because of their paucity in the haemopoietic 
tissues and inconspicuous morphology. Haemopoietic cell 
suspensions are incubated with high specific activity tritiated 
II 
thymidine (3HTdR) in vitro, (Becker et al 1065); (Lord et al 
1973). The CF"-S synthesizing DNA incorporate sufficient 
3HTdR 
to 
be killed by self-irradiation. This has therefore been called the 
suicide technique. Cvtotoxic drugs which selectively kill cells 
which are synthesizing DNA, such as hydroxyurea (! J), (Renestad 
1977), and cytosine arahinoside (Ara-C), (Millard et al 1975), 
have also been used as suicide agents. Suicide agents have also 
been used in vivo, but determination of the proportion of CFU-S in 
S-phase was complicated by the reutilization of HTdR released form 
dead cells, (Yubaneck et al 1973); (Blackett et al 1974); 
(Schremal et al 1974). 
34TdR 
of less than 24 curies per millimole is used for the in 
vitro suicide assay. This is because when 
3HTdR is used at higher 
specific activities, the killing of CFU-S is increased. This is 
probably due to the uptake of 
3HTdR into non S-phase pools. This 
3HTdR 
could subsequently he incorporated into DNA at a level 
sufficient to kill the cell, (Lord et al 1974). The suicide 
technique can also be used to determine the proportion of the 
different progenitor cells which are synthesizing DNA, (Netcalf 
1972); (Testa 1979). 
In the normal steady state most of the CFTJ-S are not 
proliferating, less than 15% in S-phase, (Becker et al 1965). They 
are either in a prolonged G1 phase or in a non-cycling Co 
compartment, (Lahiri and Van Outten 1972); (Blackett 1976). In 
irradiated and cytotoxic drug treated mice a large proportion of 
the CF"-S are triggered into cycle, 30-40% in S-phase, (Becker et al 
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1965); (Croizat et al 1970); (Necas and Neuwirt 1977 , 
1978). 
These treatments kill a dose related proportion of the haemopoietic 
cells. The progenitors and recognizable precursors are normally 
more sensitive than the CFU-S because a larger proportion of them 
are in cycle. The differentiation of CFU-S into the progenitors is 
increased to compensate for these losses. The proportion of CFU-S 
in cycle therefore increases to maintain their own numbers. 
Various chemicals such as E type prostaglandins (PGE), cyclic 
AMP and testosterone also trigger resting CFU-S into cycle, 
(Byron 
1971 , 
1972 , 
1973 , 1975); 
(Feher and Gidali 1974). Byron 
suggested that this was because the CFU-S had specific receptors 
for these chemicals. 
The triggering of CFU-S into cycle following treatment with 
chemicals such as PGE and cytotoxic drugs is very rapid, (Byron 
1975). CFU-S are triggered into cycle within 30 minutes of 
exposure to hydroxyurea, (Vassort et al 1973); (Necas and Neuwirt 
1978). This led Lahiri and Van Putten (1972) to propose that the 
G0 compartment was situated at the end of the GI phase to allow the 
rapid entry of CFU-S from it into the S-phase. In developing 
haemopoietic tissues such as the yolk sac and fetal liver a large 
proportion of the CFU-S are synthesizing DNA, (Becker et al 1965); 
; Metcalf and Moore 1971). This is because there is a large demand 
for CFU-S differentiation and proliferation similar to that in 
haemopoietic tissues depopulated by irradiation or cytotoxic drug 
treatment. 
13 
The haemopoietic stem cells do not normally need to 
proliferate rapidly because of the extensive amplification 
divisions which can occur in the transit progenitor and 
recognisable precursor cell populations, (Lord and Lajtha 1974); 
(Lajtha 1979a). The number of these amplification divisions can be 
varied to alter the output of differentiated cells. The majority 
of CFU-S can therefore remain in a GD state. The maintenance of 
stem cells in a predominantly Gn state may be important in 
maintaining the genome free from errors. Errors can occur in the 
daughter DNA strand, but DNA repair mechanisms exist in the 
nucleus. Lajtha (1979a) has proposed that a long GG state allows 
'genetic housekeeping' so that errors in the stem cell ancestral 
DNA can be repaired. The development of abnormal stem cells (ie 
transformed) is therefore prevented, (Lajtha 1981). 
1.1.2.5 Heterogeneity of CFU-S 
Some evidence suggests that the CFU-S are not a homogeneous 
population of cells, (Rosendaal et al 1979); (Schofield et al 
1979). A CFU-S both self replicates and differentiates during the 
formation of a spleen colony. Retransplantation of a spleen colony 
into a second group of lethally irradiated mice is used as an assay 
of the self replicative capacity of the CFU-S which formed the 
colony in the primary recipient. Schofield and Lajtha (1973) 
demonstrated two main populatoins of CFU-S in normal bone marrow. 
About 70% produced colonies containing a large number of CFU-S (ie 
CFU-S with high self replicative capacity). The other 30% produced 
colonies only containing a few CFU-S (ie CFU-S with low self 
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replicative capacity). Worton et al (1969) also separated two 
CFU-S subpopulations with high and low self replicative capacity. 
These were separated according to cell size and density. The CFU-S 
from developing haemopoietic tissues, the yolk sac and fetal liver, 
have a higher self-replicative capacity than those from normal 
adult mouse bone marrow, (Metcalf and Moore 1971); (Rosendaal et al 
1979). This is reflected by the faster doubling time of fetal 
liver CFU-S in lethally irradiated hosts than those from normal 
bone marrow, (Schofield 1970) and the larger spleen colonies which 
they form, (Micklem 1972). Fetal liver CFU-S when serially 
transplanted (see Section 1.1.2.6) can protect the lethally 
irradiated hosts after more passages than those from normal bone 
marrow, (Metcalf and Moore 1971). 
It now appears that there is a complete spectrum of CFU-S with 
different self replicative capacities, (Schofield 1979). Some 
cytotoxic drugs can selectively kill CFU-S from different positions 
in this spectrum. The CFU-S in the bone marrow from mice treated 
with 5-fluorouracil (5-FU) or hydroxyurea (HU), have a much higher 
self replicative capacity than those from normal bone marrow, 
"Rosendaal et al 1979). In contrast the spleen colonies formed by 
the bone marrow from mice treated with isopropyl methane sulphonate 
(IMS) contain virtually no CFU-S. IMS therefore selectively kills 
CFU-S with a high self replicative capacity, (Scholfield and Lajtha 
1973). The self replicative capacity of CFU-S from mice which 
have been exposed to continuous irradiation is much lower than 
those from normal bone marrow, (Rosendaal et al 1979). From these 
observations (Rosendaal et al 1979) proposed that each time a stem 
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cell generates two daughter stem cells they are 'older' than the 
parent and therefore have a lower self replicative capacity 
consequently as the stem cells divide the probability of them 
differentiating increases. Patt el al (1980) and Hagan and 
MavcVitte (1981) have studied CFU-S kinetics in vivo using a 
continuous bromodeoxyuridine (BrdUrd) infusion. When cells 
synthesize DNA they incorporate BrdUrd. These cells are killed if 
they are exposed to near ultraviolet (UV) radiation in vitro. The 
proportion of CFU-S which had entered DNA synthesis at various 
times after the BrdUrd infusion was started could therefore be 
determined. The proportion of CFU-S killed by the near UV 
radiation increased exponentially with time. This occurred with 
both normal and post HU bone marrow. Patt et al (1980) concluded 
tht fewer than 10% of the CFU-S remain in the Go phase for 
prolonged periods. This is apparently in contrast to other 
descriptions of the CFU-S compartment, (Rosendaal et al 1979), 
(Schofield 1979). 
1.1.2.6 CFU-S decline 
CFU-S can be serially transferred through irradiated hosts to 
measure their functional lifespan, (Micklem and Loutit 1966). 
Haemopoietic cells are injected into primary lethally irradiated 
recipients. The CFU-S proliferate and differentiate to repopulate 
their haemopietic tissues. Haemopoietic cells from these mice are 
then injected into a second group of irradiated mice and the 
procedure repeated ad infinitum, (Micklem and Loutit 1966). A 
'decline' in the ability of CFU-S to repopulate the haemopoietic 
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tissues of irradiated hosts, with successive transfers, was 
ohserved, (Siminovitch et al 1964); (Lajtha and Schofield 1971). 
Schofield (1979) has demonstrated that the CFU-S per colony, 
an indication of the probability of CFU-S self renewal, decreases 
during serial transfer of bone marrow. After a variable number of 
transfers depending on the time between then, and the initial 
source of haemopoietic cells, no repopulation of the irradiated 
hosts haemopoietic tissues occurred, (Micklem and Ogden 1976). 
Repeated exposure of mice to irradiation also produced a decline in 
the ability of CFU-S to produce haemopoietic repopulation, (Hendry 
and Lajtha 1972); (Hendry et al 1974). It therefore appeared 
that by forcing the CFU-S population to proliferate it had become 
older, with a reduced self replicative capacity, (Lord 1976); 
(Rosendaal et al 1979); (Schofield 1979). 
The number of divisions which the CFU-S must undergo in the 
life time of a mouse exceeds those in the serial transfer 
experiments, (Schofield 1978). From these observations it would be 
predicted that in old mice the CFU-S would be reduced both 
quantitatively and qualitatively. But the number of CFU-S, (Metcalf 
and Moore 1971), and their self replicative capacity in young and 
old mice are not significantly different, (Lajtha and Schofield 
1971); (Harrison 1973). 
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1.1.2.7 The relationship between the CFU-S and the 
haemopoietic stem cell 
Schofield (1978) has tried to explain the apparently 
contradictory observations of CFU-S decline in serial transfer 
experiments and the consistency of CFU-S self replicative capacity 
and numbers throughout the lifetime of a mouse. He proposed that 
the CFU-S is not the ultimate haemopoietic stem cell, it has an age 
structure. The true haemopoietic stem cell is maintained in an 
immortal state by its association with other fixed tissue cells, 
maybe stromal cells, in a 'niche'. When this niche stem cell 
divides one of its daughter cells leaves the niche. If it does not 
find another niche, it undergoes a form of maturation. At each 
division its capacity for further self replication is reduced and 
eventually it differentiates to form a committed progenitor cell. 
This corresponds with the generation age hypothesis proposed by 
Rosendaal et al (1979). The haemopoietic stem cells not in niches 
would be the transplantable CFU-S. Only the cells removed from the 
niche cell by a few divisions would be able to fill empty niches, 
ie early in the maturation sequence. The niche and the niche stem 
cell would not be transplantable. 
Schofield (1978) suggested the following mechanism using the 
stem cell niche hypothesis to explain the decline of repopulating 
ability of serially transferred haemopoietic cells. In a lethally 
irradiated bone marrow grafted mouse (primary recipient), some of 
the niches would be filled by stem cells with very high self 
replicative potential. The stem cells produced by these cells 
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would undergo more divisions than normal to help repopulate the 
haemopoietic tissues. The proportion of stem cells with lower self 
replicative capacity would therefore be increased. When the bone 
marrow from these mice was transferred into a second group of 
irradiated mice, less stem cells capable of filling vacant niches 
would be present. The stem cells produced by the few niche cells 
would have to undergo even more divisions to repopulate the 
haemopoietic tissues. Their self-replicative capacity would be 
even further reduced. Eventually after several transfers 
insufficient niche stem cells would be transferred to repopulate 
the haemopietic tissues. Schofield (1978) speculated that the stem 
cell niches might be located near or in the bone. This was based 
on the observations that haemopoietic recovery after irradiation 
and in femurs from which the bone marrow had been removed initially 
occurred in close apposition to the bone, (Maloney and Patt 1969); 
(Patt 1970); (Patt and Maloney 1976). 
The cellular composition of the niche is not established. 
Dexter et al (1973), Dexter and Lajtha (1974), and Allen and Dexter 
1976a) have produced an 'environment' in vitro which supports 
CFU-S proliferation and differentiation for several months. This 
'environment' consists of an adherent layer of giant fat cells, 
endothelial cells and reticular cells. Without these cells no 
haemopoiesis occurs, (Allen and Dexter 1976). The CFU-S 
concentration in the femur is highest next to the bone surface, 
(Lord et al 1972 , 1975). But the CFU-S with the highest 
repopulating ability are located in the centre of the femur, 
'Schofield 1980). The location of these proposed stem cell niches 
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therefore remains an open question. 
The niche cell may also be important in the maintenance of 
error free DNA. Such errors occurring in stem cells could lead to 
the emergence of malignant clones, (Lajtha 1979). When the niche 
stem cell divides the stem cell containing the new daughter DNA 
strand may be preferentially excluded from the niche. Consequently 
errors accumulating during DNA replication would not be retained in 
the niche cell, but passed to the maturing stem cell (CFU-S), 
(Cairns 1975); (Schofield 1978). This may occur when epithelial 
stem cells replicate, (Potten et al 1978). The chances of errors 
occurring in DNA are greater in rapidly proliferating cells, than 
those in a Gn state, (Lajtha 1978). The maintenance of the niche 
cells in a prolonged Go state would augment the DNA repair 
mechanisms and therefore maintain the DNA of the ultimate 
haemopoietic stem cell free from errors. 
1.1.2.8 The morphological identity of the pluripotential 
haemopoietic stem cell 
The morphological identity of the haemopoietic stem cell has 
not been definitely established. But the numbers of transitional 
lymphocytes in haemopoietic tissues, have been shown to rise and 
fall in parallel with the numbers of CFU-S when the system is 
perturbated, (Cudkowicz 1964); (Yoffey 1973); (Sharp et al 1976); 
(Thomas et al 1977); (Yoffey 1980). It was therefore suggested 
that the transitional lymphocyte population contained the 
haemopoietic stem cells, (Van Bekkum et al 1971); (Thomas 1977); 
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'Yoffey 1980). These cells are characterised by: a high nuclear 
cytoplasmic ratio; leptochromatic chromatin; pale blue cytoplasm 
when stained with Jenner-Giemsa; and a diameter of 9 to 11pm, 
'Thomas 1977); (Yoffey 1980). But there are many more 
transitional cells than CFU-S in haemopoietic tissues. The 
committed precursor cells are probably also contained in the 
transitional cell population, (Yoffey 1973); (Thomas et al 1977); 
(Van Bekkum et al 1979). 
Cytotoxic drug treatment of mice and density separation of 
bone marrow suspensions, have been used to produce enriched 
populations of CFU-S to aid morphological identification, (Sharp et 
al 1974); (Van Bekkum 1977). These techniques produced some 
enrichment of CFU-S in the bone marrow. Antibodies to CFU-S 
specific antigens have provided the most successful means for 
isolating them, (Miller and Price 1979); (Ziegler 1980). 
One of the first haemopoietic stem cell specific antigens 
demonstrated was shown to be common with an antigen expressed by 
mouse brain tissue. Rabbit anti-mouse brain serum was selectively 
cytotoxic for CFU-S, (Monette et al 1977); (Filippi et al (1978); 
(Van den Engh et al 1978). Monoclonal antibodies to haemopoietic 
cells have been developed, (Milstein et al 1979); (Ziegler et al 
1980). A range of these antibodies with different specificities 
for haemopoietic stem cells and progenitor cells has been produced. 
These antibodies are conjugated with fluorescein. Haemopoietic 
cell suspensions are incubated with a particular fluorescein 
conjugated antibody. The cells bind the antibody and fluoresce 
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when exposed to ultraviolet light in proportion to the quantity of 
the corresponding antigen on their surface. Haemopoietic cells 
with specific cell surface antigens can then be separated using a 
fluorescence activated cell sorter (FACS). This machine will also 
separate cells on the basis of their light scattering properties, 
(Fulwyler 1980), (Goldschneider et al 1980), (Ziegler et al 1980). 
Goldschneider et al (1980) separated haemopoietic cells using a 
FACS on the basis of fluorescence produced by the binding of 
fluorescein conjugated anti Thy-1 antibody and their relative light 
scattering. They produced a cell suspension of which 80% of the 
cells were CF! -S. The morphology of these cells corresponded to 
that described by Van Bekkum et al (1979) of an undifferentiated 
mononucleur, transitional lymphocyte type cell. The 
granulocyte-macrophage progenitor cells had a similar morphology to 
the CFU-S but were separable from them on the basis of their 
relative light scattering properties. 
1.1.2.9 Multipotential haemopoietic colony formation in vitro 
(CFL'-mix) 
Murine fetal liver cells, in the presence of pokeweed 
mitogen-stimulated spleen conditioned medium (PWMSCM) produce large 
erythroid colonies. Half of these colonies also contain variable 
numbers of neutrophils macrophages, megakaryocytes and eosinophils, 
(Johnson and Metcalf 1977); (Metcalf and Johnson 1978 , 1979). 
The demonstration that micromanipulated single fetal liver cells 
could form these colonies indicated that they were clones, (Johnson 
and Metcalf 1977). 
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These mixed colonies contained both committed progenitor cells 
and haemopoietic stem cells, (Metcalf and Johnson 1978). This 
suggests that the cell forming these colonies may be the CFU-S. 
These mixed colonies were also produced by adult bone marrow cells, 
'Johnson and Metcalf 1980). These adult multipotential cells had 
different properties from those in fetal liver. A small proportion 
of them were synthesizing DNA compared with a large proportion of 
those from fetal liver. The multipotential cells from adult bone 
marrow were also smaller than those from fetal liver, (Johnson and 
Metcalf 1980). The frequency and kinetic and physical properties 
of the cells which form mixed haemopoietic colonies in vitro are 
similar to the CFTJ-S from the corresponding source, (Becker et al 
1965); (Metcalf and Moore 1971). Hara and Ogawa (1978) have also 
demonstrated a cell in normal murine bone marrow forming mixed 
haemopoietic colonies (CFU-mix) which has similar properties to 
that described by(Johnson and Metcalf 1980). 
Fausner and Messner (1979a) have produced mixed haemopoietic 
colonies from human bone marrow. In cultures of male and female 
bone marrow, x, y chromosome analysis indicated that these colonies 
were clones. The cells forming these mixed colonies were 
predominantly non-cycling, (Fausner and Messner 1979b). Fausner et 
al 1981) and Messner et al (1981) cultured human bone marrow in 
the presence of T-cell growth promoting medium in addition to 
phytohaemaglutinin stimulated leukocyte conditioned medium. In 
these cultures mixed haemopoietic colonies containing T-lymphocytes 
in addition to granulocytes, erythroblasts, megakarocytes and 
macrophages were formed. Assuming these colonies are also clones 
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this is further evidence that the colonies are formed by a 
multipotential haemopoietic cell. The properties of these human 
cells forming mixed haemopoietic colonies are similar to those 
demonstrated by Johnson and Metcalf (1980). It has not been 
established whether the human cell forming these mixed haemopoietic 
colonies is a stem cell. To do this an extensive capacity for self 
replication would have to be demonstrated. 
The cells forming mixed colonies in culture may therefore be 
equivalent to part of the haemopoietic stem cell population. This 
assay has provided some indications of the mechanisms which control 
the differentiation of the haemopoietic stem cell into the 
different committed progenitors, (Metcalf et al 1980); (Johnson 
1981) (see Section 1.1.3.3.2). 
1.1.3 The Committed Progenitor Cells 
The committed progenitor cells are produced by the 
differentiation of the pluripotential haemopoietic stem cell. 
These cells have restricted differentiation capacities. Some are 
unipotential and are thus committed to a single line of 
differentiation while others are bipotential, (Lajtha 1979b). 
Committed progenitors exist for all of the lines of haemopoietic 
differentiation (Figure 1.3). They can be assayed by virtue of 
their ability to form clones of their more differentiated progeny 
(ie recognisable precursors) in vitro cultures, (Metcalf 1977). 
The growth of these cultures is absolutely dependent on the 
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FIGURE 1.3 
The relationship between the haemopoietic stem cells and the 
committed progenitors. The differentiation pathway between these 
two compartments has not been established. There may be a cell 
population interposed between these two compartments which 
progressively loses the potential to form the different 
progenitors, 'Johnson 1981). The derivation of the lymphoid cells 
from the haemopoietic stem cell or a separate stem cell is also not 
clear. 
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presence of specific stimulating factors, 
(Metcalf 1977); (Burgess 
and Metcalf 1980); (Metcalf 1981). 
Recloning of the progeny of erythroid and 
granulocyte/macrophage progenitor cells has demonstrated that they 
are only capable of producing terminally differentiated cells, 
; Metcalf and Johnson 1979). This indicates that the committed 
progenitors have only limited self replicative ability. 
Substantial evidence indicates that the colonies formed by the 
committed progenitors are clones, (Metcalf 1977). Micromanipulated 
single cells from bone marrow can give rise to colonies composed of 
granulocytes and/or macrophages, (Moore et al 1972). In some 
disease states cells from fractionated haemopoietic cell 
suspensions can produce colonies with a plating efficiency of 
almost 100%, (Metcalf 1977). Cells isolated by plastic rings in 
the culture plate, have formed granulocytic and macrophage 
colonies, (Pluznick and Sachs 1965). 
A consistent description of the cells which form in vitro 
colonies and the factors which stimulate them, has not been 
forthcoming, ', Lajtha 1979b). The following key descriptions and 
definitions will be used herein: - 
CFC - colony forming cell. A colony consists of more than 
50 cells. 
CLFC - cluster forming cell. A cluster consists of less than 
50 cells. 
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CSF - colony stimulating factor. This refers to a factor of 
a defined molecular weight. 
CSA - colony stimulating activity. This refers to 
preparations of reduced purity 
including heterogenous soups 
stimulate colony formation. 
The committed progenitors unlike the CFU-S are virtually all 
in cycle in most haemopoietic tissues, (Metcalf 1977). A large 
number of observations including their different kinetic properties 
suggest that the CFU-S and the GM-CFC (and other progenitors) are 
not the same cells detected by different assay systems. 
The following examples are differences between the GM-CFC and 
CFU-S, similar differences between the other progenitors and the 
CFU-S have been demonstrated, (Metcalf 1977). They indicate that 
the progenitors and CFU-S are two distinct cell populations. 
1. The radiation sensitivities of the two cell populations are 
significantly different, (Testa et al 1973). 
2. CFU-S are more slowly sedimenting cells than GM-CFC, (Worton et 
al 1969). 
3. In irradiated bone marrow the CFU-S and GM-CFC have different 
density distribution properties, (Moore and Williams 1973a). 
4. Isoproterenol stimulates CFU-S but not GM-CFC proliferation; 
GM-CSF has the converse effect, (Moore and Williams 1973a). 
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1.1.3.1 The granulocyte/macrophage progenitor cell 
Cells producing colonies of granulocytes and/or macrophages in 
vitro were first demonstrated by Pluznik and Sachs (1965) and 
Bradley and Metcalf (1966). The growth of these colonies is 
dependent on the presence of a specific stimulatory factor GM-CSF, 
(Metcalf 1970). The GM-CFC are a heterogenous population of cells 
with different proliferation and differentiation potentials, 
(Metcalf 1977); (Jacobsen et al 1979); (Francis et al 1981). 
Three principal forms of CSF have been isolated, GM-CSF, G-CSF and 
M-CSF which stimulate the formation of colonies composed of cells 
with corresponding morphologies, (Burgess and Metcalf 1980). The 
granulocyte-macrophage progenitor cells form a spectrum of cells of 
increasing maturity interposed between the haemopoietic stem cell 
population and the recognizable myeloid and monocyte precursors 
(Figure 1.3). 
Unlike the CFU-S the majority of the GM-CFC are normally in 
cycle in virtually all haemopoietic tissues (35-45% in S-phase), 
(Metcalf 1977). A few exceptions have been demonstrated, (Moore and 
Williams 1973a). Only one of these was in a normal tissue, the 
liver from human fetuses of between 11 and 14 weeks gestational 
age, 'Moore and Williams 1973b). The GM-CFC and the mechanisms 
which control their proliferation and differentiation are discussed 
in Section 4.1. 
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1.1.3.2 The erythroid committed progenitors 
The erythroid committed precursors were initially demonstrated 
in vivo, (Gurney et al 1962); 
(Lajtha et al 1971). Erythropoietin 
causes the second step differentiation of cells from the erythroid 
committed progenitor (ECP) compartment into the recognizable 
erythroid compartment (REC), (Gurney et al 1962); (Gordon 1971). 
The cells which differentiate are the erythropoietin responsive 
cells (ERC) which are quantified in the polycythaemic mouse assay, 
(Gurney et al 1962). On the basis of spleen colony growth 
kinetics, the ECP was divided into the pre-ERC and the ERC, (Lajtha 
et al 1971). Reissmann and Samorapoompicht (1970) have shown that 
erythropoietin can also increase the number of amplification 
divisions within the pre-ERC. The ERC are also rapidly 
proliferating in polycythaemic mice, (Lajtha et al 1969); 
(Wengenheim et al 1977). There is no demand for ERC 
differentiation in these mice, and their fate is not known, (Testa 
1979). 
Two erythroid colony forming cells have been detected using in 
vitro assays, (Stephenson et al 1971); (Iscove and Sieber 1975). 
Cells forming small erythroid colonies after 1 to 3 days in 
cultures stimulated by erythropoietin. These have been called 
erythroid colony forming units, (CFU-E), (Stephenson et al 1971; 
(Axelrad et al 1974). They have a limited proliferative capacity 
and are only separated from the erythroblasts synthesizing 
haemoglobin by about two cell divisions, (Cormack 1976). In 
hypertransfused mice there is a 90% decrease in the numbers of 
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CFU-E. In contrast a 2- to 3-fold increase can be produced by an 
erythropoietin injection, 
(Gregory et al 1973). These observations 
suggest that the CFU-E are more differentiated than the ERC, and 
are therefore probably early erythroblasts, 
(Testa 1979). 
An earlier erythroid precursor has also been detected, the 
erythroid burst forming unit (BFU-E), (Iscove and Sieber 1975). 
The clones produced by the BFU-E are very large (up to 10,000 
cells). The BFU-E are a heterogenous population, two main forms 
have been identified, those forming bursts detected after 3 days in 
culture and others after 8 days, (Gregory and Eaves 1978). 
Erythropoietin is not necessary for the initiation of burst 
formation but is necessary for their full in vitro development, 
(Iscove 1977). The numbers of BFU-E do not change in polycythaemic 
mice and are only slightly altered in bled mice, 
(Wagemaker et al 
1978); (Testa 1979). 
The proliferation of the BFU-E is enhanced by various factors, 
the burst promoting activities (BPA), (Meytes et al 1979). 
Leukocyte conditioned medium increases the number of bursts formed 
in the presence of erythropoietin but it does not enhance CFU-E 
growth, (Gregory and Eaves 1978). Some of these factors are 
released by T-lymphocytes, 
(Meytes et al 1979). BPA may be 
essential for the initiation of burst formation, and its levels are 
increased in mice with a haemolytic anaemia, (Wagemaker 1978); 
(Testa 1979). 
The BFU-E have similar physical characteristics to the CFU-S, 
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; Testa 1979). Some bursts also contain megakaryocytes which are 
part of the clone, (McLeod et al 1980). This suggests that some 
BFU-E may be bipotential and supports the observations of Johnson 
(1981). The Day 8 BFU-E is probably situated between the CFU-S and 
the pre-ERC, the Day 3 BFU-E probably overlapping with the pre-ERC, 
Testa 1979). The erythroid progenitor cells are therefore also a 
heterogenous population forming a spectrum of cells between the 
haemopoietic stem cell and the early erythroblasts (Figure 1.3). 
1.1.3.3 Eosinophil and megakaryocyte progenitor cells 
The megakaryocyte and eosinophil progenitor cell compartments 
have not been characterised as extensively as the erythroid and GM- 
progenitors, (Metcalf 1977). Eosinophil colony formation is 
stimulated by lymphocyte conditioned medium. This may be 
correlated with the dependence of eosinophil production in vivo on 
a factor from activated lymphocytes, (Baston and Beeson 1970). In 
parasite infected mice with an eosinophilia the production of 
E0-CSF is dependent on a factor produced by activated T 
lymphocytes, (Metcalf 1979). This E0-CSF is biochemically distinct 
from GM-CSF, (Metcalf et al 1974). 
Megakaryocyte colony forming cells MEG-CFC form colonies of 
megakaryocytes when stimulated by factors from activated 
T-lymphocytes, MEG-CSF, (Metcalf et al 1975a). In thrombocytopenic 
mice, increases in the numbers of MEG-CFC precede the increase of 
megakaryoblasts, (Nakeff 1977). MEG-CFC are therefore probably 
intermediate between the CFU-S and megakaryoblasts. 
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Thrombopoietin is a serum factor, the levels of which are 
raised in bled mice. Injection of thrombopoietin in vivo 
stimulates megakaryocyte formation and increases the numbers of 
platelets in the blood. Nakeff et al 
'1977) produced a two-fold 
increase in the number of megakaryocyte colonies by adding 
thrombopoletin to the cultures, but other workers did not observe 
this, Metcalf 1977). MEG-CSF and thrombopoietin are probably not 
the same factor. The proportion of MEG-CFC synthesizing DNA 
determined using in vivo and in vitro suicide methods have been 
inconsistent, eg, 0 and 55% respectively, (Williams and Jackson 
1978). These discrepancies may be due to in vivo inhibition or 
artifacts produced by the in vitro system, (Ebbe 1979). 
1.1.3.4 The T and B-colony forming cells 
Both B-lymphocyte, (Metcalf et al 1975b) and T-lymphocyte 
colonies Metcalf 1977), ! Spitzer et al 1980), have been produced 
from normal murine and human bone marrow. The cells forming these 
colonies are probably more mature than the committed progenitor 
cells, 'Metcalf 1977). The colonies are produced using either 
2-mercaptoethanol in the culture medium or by stimulating the 
lymphocytes with mitogens such as phytohaemagglutinin prior to 
culturing, 'Metcalf 1977). The colonies consist of large numbers 
of lymphoblasts and the B-lymphocyte colonies contain the 
differentiated plasma cells producing immunoglobulins. The cells 
forming B-lymphocyte colonies, BL-CFC also produce immunoglobulins, 
! Poulsen and Claesson 1980). This indicates that the BL-CFC are 
probably more differentiated than the B-lymphocyte progenitor 
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cells. 
1.1.4 Differentiation of Haemopoietic Cells 
1.1.4.1 Differentiation: definition 
Differentiation is a change in the patterns of genetic 
expression in a cell. This re-programming of the genome is 
irreversible under normal physiological conditions. The cell 
undergoes qualitative phenotypic changes. This is in 
contra-distinction to determination which is just a genotypic 
change, ýLajtha and Schofield 1974); (Lajtha 1979b). 
1.1.4.2 Haemopoietic differentiation events 
Two differentiation events occur in haemopoiesis. A first 
differentiation step transforms the pluripotential haemopoietic 
stem cell into a uni or bipotential committed progenitor cell. 
These committed progenitors are transformed by a second 
differentation step into the earliest of their respective 
recognisable precursors, (Lajtha and Schofield 1974). 
1.1.4.3 Haemopoietic stem cell differentiation 
Three mechanisms have been proposed to explain the commitment 
of the haemopoietic stem cell to a particular line of 
differentiation: a random process (stochastic); local micromileu 
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control; and long range humoral control, (Till et al 1964); (Wolf 
and Trentin 1968); (Van Zant and Goldwasser 1977); (Frindel et al 
1980); (Schrader 1981). 
1.1.4.3.1 Haemopoietic inductive microenvironments 
Till et al (1964) suggested that CFU-S differentiation was a 
purely random (stochastic) or preprogrammed event. In contrast 
Curry et al (1967) and Wolf and Trentin (1968) demonstrated that 
the colonies on the surface of the spleen were predominantly 
erythroid, while those inside were mainly granulocytic. In the 
spleen the erythroid to granulocyte colony ratio was 3: 1, but in 
the bone marrow it was 1: 1. From these observations, Curry et al 
(1967) suggested that the "haemopoietic inductive microenvironment" 
(HIM) in which a CFU-S was situated determined its line of 
differentiation. Subsequent observations supported this concept. 
For the first 7 days after transplantation, spleen colonies 
consisted predominantly of one line of differentiation, erythroid, 
granulocytic or megakaryocytic, but by day 9 most contained all 
three, (Curry et al 1967). Trentin (1970) proposed that this was 
because the colonies encountered other microenvironments as they 
became larger. In support of this hypothesis, the second line of 
differentiation always appeared at the periphery of a colony, 
(Tavassoli 1975). In hypertransfused mice very small colonies 
containing erythropoietin responsive cells were still present, and 
the number of granulocytic colonies remained constant, (Curry et al 
1967). This suggested that specific 'HIM' in the spleen would 
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only support the growth of erythroid colonies. 
Wolf and Trentin (1968) transplanted pieces of irradiated 
(1000R) bone marrow stroma into the spleens of lethally irradiated 
bone marrow reconstituted mice. Subsequently the irradiated bone 
marrow stroma was put into a trocar with unirradiated splenic 
tissue. This was then inserted into the irradiated recipient's 
spleen. Erythroid and granulocytic colonies were formed in the 
marrow and spleen stroma in the proportions observed in the 
respective whole organ. Some colonies straddled the junction 
between the marrow and spleen stroma. If these were mixed 
colonies, the part in the marrow stroma was granulocytic, and that 
in the spleen stroma erythroid. These observations suggested that 
stromal cells were a major constituent of the HIM, (Trentin 1978); 
(Wolf 1979). 
Mice with genetic anaemias have been used to study the 
regulation of haemopoietic differentiation, (Harrison 1979). Two 
genetic mutants the W/Wv and S1/Sld have been extensively studied, 
(Russell 1979). The defect in the W/Wv mouse is intrinsic to the 
CFU-S. The W/Wv mice can therefore be cured of their anaemia by 
grafting with a normal bone marrow suspension. S1/Sld mice have 
normal CFU-S, which will cure the anaemia of the W/Wv mice. The 
defect in the S1/Sld mice is intrinsic to the stromal cells which 
form the haemopoietic microenvironment, (Bernstein et al 1968); 
(Trentin 1971). The anaemia of the S1/Sld mice cannot be cured by 
injecting cells from a normal hone marrow or spleen cell 
suspension. The grafting of an entire spleen from a normal mouse 
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cures their anaemia, (Harrison 1979). These observations indicate 
that the cells forming the haemopoietic microenvironment cannot be 
transplanted in a cell suspension and/or they cannot migrate via 
the circulation to the haemopoietic tissues. This conclusion was 
supported by Friedenstein et al (1968), (1978) who transplanted 
haemopoietic organs under the kidney capsule. In the grafts donor 
stromal cells remained, but host haemopoietic cells reconstituted 
it. 
Friedenstein et al (1976), (1978) has cloned the haemopoietic 
stromal cells in vitro. The colonies were composed entirely of 
fibroblasts. The cells forming these colonies were therefore 
called fibroblast colony forming cells (FCFC)(Friedenstein et al 
1974); (Castro-Malaspina et al 1980). FCFC from different 
haemopoietic tissues have been transplanted under the kidney 
capsule of rabbits. Some of the FCFC derived from bone marrow and 
spleen formed haemopoietic organs corresponding to their site of 
origin, (Friedenstein 1980). 
The first step differentiation of the CFU-S may be determined 
by a haemopoietic inductive microenvironment. The main component 
of this environment are the stromal cells of the haemopoietic 
tissues. This stromal HIM may be derived from clonogenic cells 
which do not originate from the haemopoietic stem cell, (Tavassoli 
1975); (Trentin 1978); (Friedenstein et al 1978). The influence 
of stromal cells on CFU-S differentiation may be mediated by 
diffusable factors, (Blackburn and Patt 1980). 
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1.1.4.3.2 Humoral control of CFU-S differentiation 
Some evidence suggests that CFU-S differentiation may be 
controlled by humoral factors, although some of the results are 
contradictory and difficult to interpret. Van Zant and Goldwasser 
(1977), (1979) incubated bone marrow suspensions with erythropoietin 
or GM-CSF. Erythropoietin depressed the number of GM-CFC colonies 
formed. In contrast, GM-CSF decreased the number of erythroid 
bursts formed and caused decreased haemoglobin synthesis. Bone 
marrow incubated with erythropoietin also produced an increased 
erythroid/granulocytic spleen colony ratio, (Van Zant and Goldwasser 
1979). They suggested that this supported the concept of 
competition between erythroid and myeloid CFU-S differentiation, 
(Kubaneck et al 1973). Receptors for erythropoietin and GM-CSF on 
the CFTJ-S were proposed to account for this competitive effect. 
In contra-distinction Johnson (1981) added erythropoietin to 
PWMSCM stimulated bone marrow cultures, this did not alter the 
proportions of mixed erythroid and non-erythroid colonies. While 
GM-CSF could initiate the formation of mixed erythroid colonies in 
serum free cultures. Thus erythropoietin and GM-CSF rather than 
acting competitively were acting in cooperation, (Metcalf and 
Johnson 1979). Van Zant and Goldwasser (1979) also found that 
although GM-CSF inhibited the actions of erythropoietin at high 
concentrations, when used at low concentrations it augmented the 
effect of erythropoietin, stimulating burst associated haemoglobin 
synthesis. In PWMSCM stimulated fetal liver cultures 
multipotential colonies always contained erythroid cells, (Johnson 
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and Metcalf 1977 , 1978a). 
Colonies composed of granulocytes 
and/or macrophages, megakaryocytes, and eosinophils were also 
formed. These cultures were dispersed and recultured with PWMSCM 
(Metcalf et al 1979). The mixed erythroid colonies produced 
secondary colonies of all the haemopoietic lineages. In contrast, 
reculturing of granulocyte and/or macrophage colonies, produced 
colonies containing only cells of these two lineages. Recultured 
pure erythroid or megakaryocyte colonies did not produce secondary 
colonies. 
From these observations, Johnson (1981) proposed that a 
multipotential haemopoietic cell exists which eventually forms 
committed erythroid progenitors. When these cells differentiate 
they sequentially lose differentiation potential (eosinophil, then 
neutrophil/macrophge then megakaryocyte), but the potential to form 
erythroid progenitors is retained. Frindel et al (1980) suggested 
that in mice treated with Ara-C, CFU-S differentiate preferentially 
towards erythropoiesis; in contrast, in irradiated mice increased 
differentiation to granulopoiesis occurs. This deduction was made 
from corresponding changes in the BFU-E and GM-CFC concentration in 
the bone marrow of these mice. The erythroid/granulocytic spleen 
colony ratio which these sources of bone marrow produced when 
injected into lethally irradiated recipients was also altered 
accordingly. They demonstrated that the marrow from these drug and 
irradiation treated mice released humoral factors which stimulated 
changes in normal bone marrow, similar to those in the treated 
marrow. From these observations it was suggested that CFU-S 
differentiation was regulated by humoral factors. These did not 
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appear to be erythropoietin or GM-CSF. 
The first differentiation step which the haemopoietic stem 
cell undergoes may be regulated both locally, (Trentin 1978) and 
humorally, (Frindel et al 1980); (Johnson 1981). These two 
mechanisms may act together in different circumstances. The 
importance of the microenvironment is emphasised by the cellular 
relationships which are necessary for the establishment of long 
term marrow cultures, (Dexter et al 1976); (Dexter 1979). Humoral 
control may be important when the haemopoietic system is stressed. 
The observations of Metcalf and Johnson (1979) and Johnson 
(1981) suggest that the differentiation of the haemopoietic stem 
cell to the different committed progenitors may be via a common 
cell (ie, the cell forming mixed erythroid colonies in PWMSCM 
stimulated cultures). This cell might then sequentially loose 
differentiation potential. The gap between the haemopoietic stem 
cell population and the committed progenitors in Figure 1.3 
indicates that the extract mechanism of this differentiation step 
is not known. 
1.1.4.4 Second step haemopoietic differentiation 
A second differentiation step transforms the committed 
progenitor cells into their respective recognisable precursors, 
(Lajtha and Schofield 1974). Only in the erythroid lineage has the 
regulation of this process been definitely established. 
Erythropoietin stimulates the differentiation of the ERC into the 
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early recognisable erythroid precursors (ie proerythroblasts), 
(Lajtha et al 1971); (Gurney et al . 
1962). 
No equivalent granulopoietin has been demonstrated. This is 
principally because granulopoiesis cannot be suppressed, in vivo, 
(cf erythropoiesis in polycythaemic mice), nor is there a 
granulocyte label equivalent to haemoglobin, (Lajtha and Schofield 
1974). The granulocyte-macrophage progenitors (GM-CFC) form 
colonies of their recognisable precursors in vitro, in the presence 
of specific stimulatory factors (GM-CSF), (Metcalf 1977); (Burgess 
and Metcalf 1980) (see Section 4.1). GM-CSF stimulates the 
proliferation of the GM-CFC and the recognisable myeloid precursors 
in vitro, (Metcalf 1977). GM-CSF has not been shown to be the 
factor stimulating differentiation of the granulocytic macrophage 
progenitors into the recognisable precursors, (Lajtha and Schofield 
1974); (Burgess and Metcalf 1980). 
1.1.5 The Regulation of Haemopoiesis 
The number of functional cells in the peripheral blood is 
normally constant. Their numbers can be increased in response to 
various perturbations such as hypoxia, infection and bleeding, 
(Thompson 1977). Figure 1.1 illustrates the structure of the 
haemopoietic tissues. Each haemopoietic cell population is 
dependent upon an input from its precursor cell compartment. The 
output of functional cells from the bone marrow to the peripheral 
blood is normally related to the animal's requirements. There must 
therefore be control mechanisms acting on the stem cell, progenitor 
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cell and recognizable precursor compartments. These controls 
maintain the compartments in equilibrium with each other and ensure 
their output is appropriate for the animals requirements. 
Proliferation control can occur at each of the compartment 
boundaries (Figure 1.1), to increase or decrease the output of 
cells from that compartment. In addition controls may act on the 
cells within a compartment to shorten or lengthen their cell cycle 
time. This mechanism increases and decreases respectively the 
amplification divisions and therefore cell production within a 
compartment. Lengthening of the compartment maturation time will 
also increase the production of cells. If concomitant reductions 
of the cell cycle and compartment maturation time occur the cell 
output will not be changed, (Lord and Lajtha 1974). 
1.1.5.1 Positive and negative feedback control of 
haemopoiesis 
Haemopoiesis appears to be regulated by a balance between 
positive and negative factors. These form integrated feedback 
loops which match the production of blood cells with the needs of 
the animal, (Lord 1979a). Positive factors selectively increase 
the production of usually one type of functional blood cell. The 
best characterised positive factor is erythropoietin. Many workers 
have postulated that factors released by the mature cells of a 
tissue can specifically inhibit the proliferation of their 
precursors and so regulate their own production, (Houck 1976). As 
the number of mature cells rises the concentration of the inhibitor 
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increases and consequently the proliferation of the precursor 
population decreases. Bullough (1962) has called these substances 
"chalones". He defined them as "antimitotic phase specific 
substances which are synthesized within the same tissue on which 
they act, which are not species specific and act rapidly and 
reversibly to inhibit the proliferation of the tissue in which they 
are produced. " 
The characterization of positive and negative feedback control 
mechanisms has been easiest to elucidate in the erythron. This is 
because of the presence of haemoglobin synthesis as a specific 
marker for erythropoiesis. This can be quantified and cells traced 
using the incorporation of radioactive iron, (Lord 1979b). 
Erythropoiesis, unlike granulopiesis, can also be suppressed in 
vivo by hypertransfusion, (Gurney et al 1962). 
1.1.5.2 The Regulation of erythropoiesis 
Erythrogenin is released by the kidney and combines with a 
plasma factor to form erythropoietin, (Gordon 1971). Erythrogenin 
is released if an animal is bled or exposed to a decreased 
atmospheric oxygen pressure. Hypoxia may therefore be the stimulus 
for its release. Miller et al (1976) have proposed that it is not 
the hypoxia per se but the resulting changes in acid base balance 
(ie respiratory alkalosis) which stimulate erythrogenin release. 
The principal action of erythropoietin is to initiate the 
second step differentiation of the late committed erythroid 
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progenitors (ERC) into the haemoglobin synthesizing recognisable 
erythroid precursors (REP), (Gurney et al 1962). Erythropoietin 
also increases the number of amplification divisions within the 
early erythroid progenitors (pre-ERC), (Reissmann and 
Samorapoompichit 1970). It may also have the same effect on the 
recognisable erythroid precursors (REP), (Hanna et al 1969). The 
result of these actions of erythropoietin is to increase the output 
of erythrocytes into the peripheral blood from the REP compartment. 
This abrogates the hypoxia which the kidney detects, consequently 
the erythropoietin level returns to normal. 
Burst promoting activity (BPA) stimulates the proliferation of 
the BFU-E in vitro, (Meytes et al 1979). The BFU-E probably 
correspond to a very early committed erythroid progenitor, 
(Testa 
1979). The levels of BPA are raised in mice with a haemolytic 
anaemia, (Wagemaker 1978). BPA may therefore be another positive 
stimulator of erythropoiesis in vivo. 
Inhibitors of red blood cell production have been demonstrated 
in plasma, (Krzymowski and Kryzmowska 1962), urine, 
(Lindemann 
1971), and erythrocyte conditioned medium, (Kivilaakso and Rytomaa 
1971), (Bateman 1974). Kivilaakso and Rytomaa (1971) incubated 
red blood cells in saline and obtained cell free supernatants by 
centrifugation. This red cell extract (RCE) and a granulocyte cell 
extract (GCE) were assayed in a short term bone marrow culture on a 
coverslip. The incorporation of tritiated thymidine into the 
erythroblasts and myeloid precursors was used as an index of cell 
proliferation. The RCE and GCE selectively reduced the labelling 
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index of their respective recognisable precursors. This RCE was 
therefore called an erythrocyte chalone because it had apparently 
selectively inhibited the proliferation of its own precursors. 
This erythrocyte chalone was contained in a 2000-4000 dalton gel 
filtration fraction. The same fraction from a GCE contained the 
granulocyte chalone, (Rytomaa and Kiviniemi 1968a). 
The effect of the RCE reported by Kivilaakso and Rytomaa 
(1971) may be artifactual. The culture system which they used 
permits the maintenance of myeloid precursors, but erythroblasts 
are difficult to culture, (Lord et al 1974b). Maurer et al (1976) 
demonstrated that bone marrow cells do not divide in the short term 
bone marrow cultures used to assay the RCE and GCE. Proliferation 
of the assay cells is an obvious prerequisite for the testing of 
cell proliferation inhibitors. Many cell extracts purported to be 
chalones have been shown to contain thymidine, (Lenfant et al 
1973). This would dilute the tritiated thymidine and consequently 
reduce the labelling index of the assay cells. 
Lord et al (1974b) overcame these problems by measuring the 
structuredness of the cytoplasmic matrix (SCM) using the 
fluorescence polarization technique. As cells progress from the 
resting Go or G, phase into the S-phase the SCM decreases. SCM 
measurements of a cell suspension can therefore be used to 
determine the proportion of cells in cycle. Erythroblast and 
myeloblast cell suspensions were incubated with either an RCE or a 
GCE. These extracts only increased the SCM (ie proliferation 
inhibition) of their respective recognizable precursors. If the 
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cells were then washed in fresh medium this effect was reversed, 
(Lord et al 1974c). This technique demonstrated that an RCE and 
GCE could specifically and reversibly inhibit the proliferation of 
their own recongizable precursors. The RCE and GCE were prepared 
from rat cells, while the test cells were of murine origin. The 
action of these extracts was therefore species non-specific, 
another property of a chalone, as defined by(Bullough 1962). 
1.1.5.3 Regulators of erythropoiesis: mechanisms of action 
Lord et al (1977a) investigated the effect of the RCE 
(erythrocyte chalone) in vivo. Lethally irradiated bone marrow 
reconstituted mice were injected with either an RCE, a GCE or a 
lymph node extract (LNE). The GCE and LNE had no significant 
effect on any aspect of erythropoiesis. Repeated injections of the 
RCE into the irradiated bone marrow reconsitituted mice reduced the 
cellularity of the developing erythroid colonies by 50%. Repeated 
labelling with tritiated thymidine indicated that the RCE slowed 
the flow of cells into DNA synthesis, but the length of the S-phase 
was only marginally increased. Changes in the strathmokinetic 
index after an RCE injection showed no increase in the length of 
the G2 phase of the cell cycle. The incorporation of 
59Fe into the 
red blood cells of polycythaemic mice given erythropoietin was 
unaffected by the RCE. The RCE therefore had no effect on the 
differentiation of cells from the ERC into the REP compartment. 
The RCE also had no effect on the release of erythrocytes into the 
peripheral blood until 24 hours after its injection. This 
indicated that the RCE had no effect on the more mature cells in 
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the REP compartment (ie late polychromatic and orthochromatic 
erythroblasts). In contrast two days after the injection of the 
RCE there was a significant reduction in the number of 
erythroblasts released into the circulation. From these 
observations Lord et al (1977a) concluded that the RCE selectively 
and reversibly prolonged the GI phase of the cell cycle of the pro, 
basophilic and early polychromatic erythroblasts. Thus the number 
of amplification divisions within the REP would be reduced and 
consequently less erythrocytes produced. 
The labelling index of erythroblasts returned to normal 5 
hours after the injection of 200pg of the RCE. This suggests that 
it has a short half life in vivo. The RCE did not stop 
erythropoiesis but rather slowed the production of erythrocytes. 
This demonstration of the specific in vivo role of the RCE 
suggested that it may have a physiological role. The levels of a 
physiological inhibitor of erythropoiesis would predictably be high 
in polycythaemia and low in anaemia. Kivilaakso and Rytmoaa (1971) 
demonstrated higher levels of an inhibitor of erythropoiesis in 
serum from polycythaemic mice than in normal mouse serum. 
Fractionation of the serum by gel filtration demonstrated that the 
inhibitory activity was contained in a 2000-4000 dalton fraction. 
The RCE inhibitory activity was contained in the same fraction. 
Hanna et al (1969) used the fraction of labelled mitosis 
technique to determine the length of the cell cycle and its 
constituent phases for the REP in normal and anaemic rats. They 
showed that there was a large reduction in the duration of both the 
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S and G1 phases of the REP cell cycle in response to anaemia. This 
is the opposite kinetic response to that reported after an RCE 
injection by Lord et al (1977a). The decrease in the cell cycle 
time of the REP will only allow extra divisions within the 
compartment if there is no concomitant reduction of the compartment 
maturation times, (Lord and Lajtha 1974). Hanna (1968) 
demonstrated that at the time of bleeding the maturation time of 
the REP compartment was normal. In contrast, Tarbutt (1969) showed 
that in response to a protracted anaemia both the maturation time 
and cell cycle time of the REP were decreased. The number of 
divisions within the REP was therefore not increased. The 
increased production of erythrocytes in these mice was achieved by 
an increased differentiation of cells from the ERC to the REP 
compartment. 
The response to an acute anaemia is an increase in the number 
of divisions in the REP compartment, Hanna et al (1969). This 
rapid response may be mediated by a decreased RCE concentration as 
a result of the recent loss of circulating erythrocytes. The short 
half-life of the RCE, (Lord et al 1977a), would support this. In 
contrast, the response to chronic anaemia, (Tarbutt 1969), is 
predominantly controlled by erythropoietin. This increases the 
flow of cells from the ERC into the REP. Blackett (1968) 
demonstrated that in mice exposed to continuous irradiation the 
number of circulating erythrocytes was normal but the flow of cells 
from the ERC to REP was reduced. This was compensated for by an 
increase in the number of amplification divisions within the REP 
compartment. This was produced by a shortening of the cell cycle 
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time and lengthening of the maturation time of the REP. This 
response is probably stimulated by erythropoietin. 
These observations indicate the flexibility of the 
haemopoietic system. The erythron can respond to many 
perturbations to maintain normal numbers of circulating 
erythrocytes. Bleeding produces a rapid fall in the concentration 
of the RCE because of its short half life. The RCE can therefore 
exert a rapid control of erythrocyte production. Erythropoietin is 
probably responsible for the long term response to anaemia. 
Erythropoietin can increase the number of amplification divisions 
in both the pre-ERC and REP compartments, it also stimulates the 
differentiation of cells from the ERC to REP compartment. These 
multiple actions confer a flexibility to respond to different 
insults to the erythopoietic tissues. 
1.1.5.4 The regulation of cell production in other 
haemopoietic lineages 
Cell production in the other haemopoietic lineages appears to 
be regulated in a similar manner to the erythron, (Metcalf 1977), 
'Lord 1979a), (Burgess and Metcalf 1980). Factors mediating 
positive and negative feedback loops within the other lineages have 
been demonstrated. The characterization of these mechanisms has 
not been as extensive as in the erythron. This is because unlike 
erythropoiesis the other haemopoietic lineages do not have specific 
markers (ie unlike haemoglobin) nor can they be suppressed in vivo. 
The regulation of granulocyte and macrophage production is 
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discussed in Chapter Four. This also appears to be regulated by 
positive and negative feedback loops. The many factors 
demonstrated which control the production of these cells mean that 
the system is very flexible and can respond rapidly and 
specifically to different demands made upon it (see Section 4.1). 
Granulocyte and macrophage production are also linked to the immune 
response by interactions with different lymphocyte subpopulations, 
'Metcalf 1979), (Verma et al 1981). 
Thrombopoietin is a serum factor, its levels are raised in 
mice which have been bled. When thrombopoietin is injected into 
mice megakaryocyte production is stimulated and the numbers of 
platelets in the blood are increased, , Metcalf 1977). A 
megakaryocyte colony stimulating factor (MEG-CSF) has also been 
demonstrated, (Nakeff 1977). MEG-CSF does not appear to be the 
same factor as thrombopoietin. An inhibitor of platelet production 
has also been demonstrated. This was contained in a platelet 
homogenate, (Krizsa et al 1977). This homogenate when injected 
into mice produced a dose dependent thrombocytopenia and reduced 
the number of megakaryocytes in the bone marrow. 
A plethora of factors and pathways regulating lymphocyte 
production have been demonstrated, (Golub 1977), (Cohen et al 
1979). The two arms of the immune response T and B lymphocytes 
interact with each other and cells from the macrophage complex to 
control their own production. Factors released by lymphocytes and 
macrophages (lymphokines) in response to antigenic challenges 
control the production of cytotoxic, helper and suppressor T-cells, 
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(Ruscetti and Gallo 1981). 
Mitogens such as phytohaemagglutinin (PHA) stimulate 
T-lymphocyte proliferation in vitro, (Jannosy and Geaves 1972). A 
factor has been extracted from lymph nodes containing non-cycling 
lymphocytes (LNE) which inhibits the proliferation of PHA 
stimulated T-lymphocytes, (Houck 1971), (Lord et al 1974b). Allen 
and Smith (1979) demonstrated that the lymphocyte chalone which 
they extracted from lymph nodes was a polyamine, complex. The 
polyamine, spermine probably interacted with an amine oxidase in 
the fetal calf serum used in the lymphocyte cultures to produce an 
inhibitory factor. This observation illustrates that it is easy to 
inhibit cell proliferation, but it is difficult to demonstrate the 
physiological significance of an inhibitor. 
1.1.6 The Regulation of Haemopoietic Stem Cell Proliferation 
In the normal steady state the haemopoietic stem cells (CFU-S) 
are in a predominantly non-cycling state (<10% synthesizing DNA), 
(Becker et al (1965). This is because of the extensive 
amplification divisions which can occur in the committed progenitor 
and recognizable precursor compartments, (Lord and Lajtha 1974). 
In contrast, in the developing rapidly expanding haemopoietic 
tissues, ie the yolk sac, fetal liver, bone marrow and spleen, a 
large proportion of the CFU-S are in cycle (>40% synthesizing DNA), 
! Metcalf and Moore 1971), (Moore and Williams 1973b). 
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The CFU-S are also triggered into cycle following exposure to 
irradiation, (Guzman and Lajtha 1970), and cytotoxic drugs such as 
hydroxyurea, (Vassort et al 1973), (Necas and Neuwirt 1977). These 
agents kill a large proportion of the committed progenitors 
recognisable precursors and some of the CFU-S. The CFU-S are less 
sensitive to these agents because they are in a predominantly 
non-cycling state, (Tubiana et al 1974). After cytotoxic drug 
treatment the rate of CFU-S differentiation into the committed 
progenitor compartment increases, (Millard et al 1973), (Blackett 
and Millard 1976). This will cause a depletion of the CFU-S 
compartment. This depletion may cause a triggering of the 
non-cycling CFU-S into cycle, (Blackett 1976). 
The contrasting results obtained by Vassort et al (1973) and 
Necas and Neuwirt (1977) indicate that the mechanisms which 
trigger the entry of quiescent (GO) CFU-S into cycle are not 
established. Vassort et al (1973) injected mice, in which 
virtually all the CFU-S were non-cycling with hydroxyurea or high 
specific activity tritiated thymidine. These drugs selectively 
kill cells which are synthesizing DNA. Four hours after either of 
these drugs the number of CFU-S in the bone marrow startd to fall. 
Six hours later 40% of the CFU-S were synthesizing DNA. It was 
proposed that these drugs killed a large proportion of the 
committed progenitors and recognizable precursors, but not the 
CFU-S because they were predominantly non-cycling. This resulted 
in an increased differentiation of the CFU-S into the committed 
progenitors. Consequently the number of CFU-S fell and they were 
triggered into cycle to compensate for this loss. 
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Necas and Neuwirt (1977) injected mice with either hydroxyurea 
or vinblastine. These drugs kill cells synthesizing DNA and arrest 
those in mitosis respectively. After hydroxyurea the CFU-S 
synchronously entered DNA synthesis, to reach a peak 12 hours after 
hydroxyurea, as reported by Vassort et al (1973). Virtually no 
CFU-S entered DNA synthesis after the administration of 
vinblastine. At the doses used the damage to the CFU-S and 
recognisable precursors was similar. Necas and Neuwirt (1977) 
suggested that CFU-S in S-phase inhibit the entry of non-cycling 
CFU-S into cycle. Selective killing of CFU-S in S-phase by 
hydroxyurea releases this inhibition. This hypothesis is in 
contrast to the suggestion of Vassort et al (1973) that killing of 
the recognizable precursors is the initial event which causes the 
triggering of CFU-S into cycle. 
1.1.6.1 Evidence for local control of CFU-S proliferation 
The mechanisms which trigger CFU-S entry into cycle are not 
established, but a lot of evidence suggests it may be controlled 
locally by a concentration dependent mechanism. Gidali and Lajtha 
(1972) shielded one leg of a mouse, while exposing the rest of it 
to 300 rads. In the shielded tibia there was an initial fall in 
the number of CFU-S and an increased proportion synthesizing DNA. 
This was probably due to an increased differentiation of CFU-S, to 
compensate for the loss of haemopoietic cells in the irradiated 
tissues. 72 hours after the irradiation, the number and proportion 
of CFU-S synthesizing DNA was back to normal in the shielded tibia. 
In contrast, in the rest of the mouse the numbers of CFU-S were 
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reduced to less than 10% of normal and a large proportion were 
synthesizing DNA. Thus the concentration and proportion of CFU-S 
synthesizing DNA returned to control values in the shielded tibia 
uninfluenced by the severe depletion of CFU-S in the rest of the 
mouse. Croizat et al (1970) made similar observations. 
Rencricca et al (1970) injected mice with phenylhydrazine 
(PHZ), which induced a severe haemolytic anaemia. Subsequently the 
CFU-S content of the femur decreased to 50% of the normal, while 
the number of CFU-S in the spleen increased fourfold. This was 
caused by a migration of CFU-S from the femur to the spleen, 
because there was no change in the kinetic state of the CFU-S 
during this time. Thereafter the proportion of CFU-S synthesizing 
DNA in the bone marrow but not the spleen increased significantly. 
Thus in phenylhydrazine treated mice (6 days post PHZ) the CFU-S in 
the spleen and femur are in two distinct kinetic states. This 
suggests that CFU-S proliferation is regulated locally by a 
concentration dependent mechanism. 
Patt and Maloney (1970) removed a small plug of marrow from a 
mouse femur. This plug was too small to cause any change in the 
numbers of peripheral blood cells. Within 4 weeks the bone marrow 
cellularity in this region had returned to normal. If the 
depopulated area of the femur was irradiated (800 rads) no recovery 
of the local bone marrow cellularity occurred. After irradiation 
of all but this depopulated area (1000 rads), total recovery of the 
depopulated area occurred. These observations indicated that the 
CFU-S responsible for the repopulation were derived locally. 
Blackett et al (1976) have also demonstrated that a depletion 
of the CFU-S rather than the recognizable precursors is the main 
trigger for increased CFU-S proliferation. They injected mice with 
busulphan which causes a severe depletion of the CFU-S and followed 
their recovery. The rate of recovery of the number of CFU-S was 
markedly increased if the mice were given vinblastine but not if 
they were given methotrexate. Blackett et al (1976) suggested that 
this occurred because vinblastine and methotrexate selectively kill 
the CFU-S and recognizable precursors respectively. 
These observations suggested that CFU-S proliferation was 
controlled by a local concentration dependent mechanism. A search 
was therefore made for factors which might mediate this control, 
(Lord et al 1976 , 1977b). 
1.1.6.2 Regulation of CFU-S proliferation by a specific 
inhibitor and stimulator 
Lord et al (1976), (1977b) looked for regulators of CFU-S 
proliferation in saline conditioned by haemopoietic cells. These 
were suspended in saline at 5-10x106 cells/ml and incubated at 37°C 
for 2 hours. The cells were removed by centrifugation and the cell 
free supernatant retained. This was fractionated using Amicon 
Diaflo ultrafiltration membranes. This is a crude sieving process, 
in which molecules in solution are concentrated above a membrane 
which excludes molecules above a certain molecular weight. The 
filtrate from the first filter is applied to a filter with a lower 
molecular weight cut off. Material excluded by this filter 
54 
therefore has a molecular weight between the cut-off points of the 
two filters. The procedure can be repeated with different filters 
to produce several fractions. This is a crude process the 
molecular weight ranges are only approximate, (Lord et al 1974b). 
This procedure was used to produce five molecular weight 
fractions from saline conditioned by haemopoietic cells, 500-10,000 
daltons (Fraction I); 10,000-30,000 daltons (Fraction II); 
30-50,000 daltons (Fraction III); 50-100,000 daltons (Fraction 
IV); and >100,000 daltons (Fraction V). The haemopoietic tissues 
used either contained slowly proliferating CFU-S (eg normal bone 
marrow and post phenylhydrazine spleen) or rapidly proliferating 
CFU-S (eg post irradiation bone marrow; murine fetal liver; post 
phenylhydrazine bone marrow). 
Populations of either slowly or rapidly proliferating CFU-S 
(eg normal and post irradiation bone marrow respectively) were 
incubated with either an Amicon fraction or medium as a control for 
5 hours. The proportion of CFU-S in S-phase was determined during 
both the first and last hour of this incubation using the Suicide 
technique, (Becker et al 1965), (Lord et al 1974a , 
1976). Two 
principal observations were made from these experiments: 
I: A 50-100,0000 daltons molecular weight Amicon fraction from 
saline conditioned by haemopoietic cells in which a small 
proportion of the CFU-S were synthesizing DNA (eg normal bone 
marrow and post phenylhydrazine spleen), inhibited the 
prolifereation of rapidly cycling CFU-S (eg post irradiation or 
Di 
phenylhydrazine bone marrow), (Lord et al 1976), (Wright et al 
1979). A 50-100,000 daltons fraction from saline conditioned by 
haemopoietic cells containing rapidly proliferating CFU-S did not 
have this effect. The 50-100,000 daltons fraction from normal bone 
marrow did not inhibit GM-CFC proliferation. This fraction also 
had no effect of the average cytoplasmic structuredness of a normal 
bone marrow suspension, (Lord et al 1976). This indicated that 
this fraction specifically inhibited CFU-S proliferation, not 
affecting the committed progenitors or recognizable precursors. 
II: A 30-50,000 daltons molecular weight fraction from saline 
conditioned by haemopoietic cells in which the CFU-S were rapidly 
proliferating (eg post irradiation and post phenylhydrazine bone 
marrow) stimulated the proliferation of slowly proliferating normal 
bone marrow CFU-S. The same fraction from saline conditioned by 
normal bone marrow did not have this effect, (Lord et al 1977b), 
(Wright et al 1979). All the progenitor cells are rapidly 
proliferating in normal haemopoietic tissues, (Metcalf 1977). It 
was therefore not possible to demonstrate the specificity of this 
CFU-S proliferation stimulator, although it did appear to be source 
specific. A 30-50,000 daltons molecular weight fraction from 
granulocyte or erythrocyte conditioned saline did not stimulate 
CFU-S proliferation. 
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1.1.6.3 The production of haemopoietic stem cell 
proliferation stimulators and inhibitors by haemopoietic cell 
suspensions 
Wright and Lord (1977) injected mice with phenylhydrazine 
(PHZ) using the same regime as Rencricca et al (1970). They 
confirmed that after PHZ the CFU-S were rapidly and slowly 
proliferating in the bone marrow and spleen respectively. This 
provided an ideal opportunity to investigate the mechanisms which 
control CFU-S proliferation, by mixing haemopoietic cell 
suspensions containing CFU-S in different kinetic states. 
One haemopoietic cell suspension was irradiated in vitro (900 
rads) these "modifier" cells were mixed with a suspension of 
unirradiated "assay" cells. The changes in the kinetic state of 
the CFU-S in the assay cell suspension were determined using the 
suicide assay. The modifier cells were irradiated so they did not 
contribute to the CFi? -S in the assay population. 
Bone marrow cells from PHZ treated mice were incubated with 
irradiated spleen cells from the same mice. This caused a marked 
reduction in the proportion of bone marrow CFU-S synthesizing DNA. 
In contrast if the reciprocal experiment was performed, spleen 
cells incubated with irradiated bone marrow cells, the spleen CFU-S 
were rapidly triggered into cycle. These effects were not unique 
to post PHZ treated hemopoietic tissues. Other sources of rapidly 
proliferating CFU-S such as fetal liver and post irradiation bone 
marrow, stimulated the proliferation of slowly proliferating CFU-S 
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from normal bone marrow. Conversely, normal bone marrow cells 
inhibited the proliferation of CFU-S from fetal liver and post 
irradiation bone marrow. As the ratio of modifier cells to assay 
cells was increased above 1: 1 the kinetics of the CFU-S in the 
assay cells changed more rapidly. A standard modifier: assay 
(test: responder) cell ratio of 2: 1 was therefore used. If the 
irradiated modifier cells were washed in medium their effect on the 
assay cells was abrogated, but the activity was retained in the 
medium, (Wright and Lord 1978). 
The results of these cell mixing experiments, (Wright and Lord 
1977), were analogous with the effects of haemopoietic cell 
extracts, (Lord et al 1976 , 1977b). For example, an irradiated 
normal bone marrow suspension, medium conditioned by these cells 
and a 50-100,000 daltons molecular weight fraction from this cell 
conditioned medium all inhibited rapidly proliferating CFU-S. This 
suggested that the CFU-S prolifertion inhibitor and stimulator 
found in saline conditioned by haemopoietic cells might be 
responsible for the physiological control of CFU-S proliferation. 
If washed post PHZ bone marrow cells were incubated at 37°C in 
fresh medium the CFU-S proliferation stimulatory activity returned 
within 3 hours. Reincubation of the washed post PHZ spleen cells 
resulted in the transitory production of CFU-S proliferation 
stimulatory activity after 3 hours. This was overridden by the 
return of CFU-S proliferation inhibitory activity after 5 hours, 
(Wright and Lord 1978). This production of both CFU-S 
proliferation inhibitory and stimulatory activity was inhibited by 
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cyclohexamide, (Lord and Wright 1980). It was therefore probably 
dependent on protein synthesis. 
Thus both the CFU-S proliferation stimulator and inhibitor 
were produced by the same haemopoietic cell suspension. This 
suggests that the kinetic state of the CFU-S is determined by the 
relative concentration of these two factors. The demonstration 
that CFU-S which had been stimulated by the regenerating bone 
marrow extract (RBME) 30-50,000 daltons fraction, could be 
inhibited if they were reincubated with an excess of the 50-100,000 
daltons fraction from a normal bone marrow extract (NBME) supports 
this, (Lord et al 1977). 
1.1.6.4 Characteristics of cells producing the CFU-S 
proliferation inhibitor and stimulator 
Wright and Lord (1979) used bovine serum albumin (BSA) density 
gradients to separate cells with different densities from 
haeopoietic cell suspensions. Conditioned media was prepared from 
the cells of each density fraction. The conditioned media were 
assayed for the presence of CFU-S proliferation inhibitory and 
stimulatory activity. Dose response studies were performed to 
determine the concentration of these factors. The conditioned 
media was also fractionated and the presence of the proliferation 
regulators in each fraction assayed. The CFU-S proliferation 
inhibitory activity was produced by cells with a density of 
1.052-1.062 gm/cm3 and stimulatory activity by cells with a density 
of 1.064-1.072 gm/cm3. The inhibitor and stimulator were both 
59 
produced by haemopoietic tissues irrespective of whether they 
contained rapidly or minimally proliferating CFU-S. Dose response 
studies indicated that in normal bone marrow and post PHZ spleen 
(small proportion of CFU-S synthesizing DNA) there was an 
enrichment of the inhibitory activity. In contrast in post PHZ 
bone marrow (large proportion of CFU-S synthesizing DNA) there was 
an enrichment of the stimulatory activity. The inhibitory and 
stimulatory activity were contained in the 50-100,000 daltons and 
30-50,000 daltons molecular weight fractions respectively. These 
observations therefore provided further support to the hypothesis 
that CFU-S proliferation is regulated by a balance between the 
concentration of a specific proliferation inhibitor and stimulator. 
The BSA density fractions containing the inhibitor and 
stimulator producing cells contained a small proportion of the 
CFU-S. There was also a lack of correlation between the numbers of 
CFU-S in a cell suspension and its CFU-S proliferation modifying 
activity. These observations suggested that the CFU-S was not the 
source of its own proliferation regulators. Wright et al (1980a) 
looked at the characteristics of cells producing the CFU-S 
proliferation inhibitor. These cells were removed by adherence to 
plastic and ingested carbonyl iron and could be removed with a 
magnet. In vivo exposure of mice to 1000 rads 48 hours previously 
did not reduce the production of inhibitory activity by their bone 
marrow cells. Cells with the Thy 1.2 receptor were removed by 
lysis using a specific antiserum and complement; this did not 
reduce the production of inhibitory activity. In contrast removal 
of cells with receptors for the FC portion of IgG, (FC +ve cells) 
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abrogated the production of inhibitory activity. The CFU-S 
proliferation inhibitor is therefore produced by a population of 
low density, adherent, phagocytic, radioresistant, Thy 1.2 -ve, FC 
+ve cells. The CFU-S proliferation stimulator producing cells are 
also adherent, phagocytic, Thy 1.2 -ve and FC +ve, but have a 
higher density than the inhibitor producing cells, (Lord and Wright 
1980), (Wright 1981). The source of the CFU-S proliferation 
inhibitor and stimulator appears to be cells from the macrophage 
complex. Macrophages have been implicated in the regulation of 
many aspects of haemopoiesis, granulopoiesis, (Kurland 1978), 
(Section 4.1.6.4); erythropoiesis, (Kurland et al 1980); 
megakaryopoiesis, (Moore 1978); and lymphopoiesis, (Nelson (1976). 
As cells with multiple roles in the regulation of haemopoiesis the 
macrophage complex may constitute a critical part of the 
haemopoietic inductive microenvironment, (Wolf 1979), (Section 
1.1.4.3.1). 
1.1.6.5 Haemopoietic stem cell proliferation regulators: 
mechanisms of action 
Lord et al (1979) investigated the mechanism of action of the 
50-100K dalton molecular weight CFU-S proliferation inhibitor. 
They demonstrated that a minimum concentration of this factor was 
necessary to inhibit CFU-S proliferation. This varied inversely 
with the time the CFU-S were exposed to the inhibitor, ie, the 
longer the CFU-S were exposed to the inhibitor, the lower the 
minimum concentration necessary to inhibit their proliferation. 
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The proportion of CFU-S synthesizing DNA was reduced more quickly 
if they were exposed to a higher concentration of the inhibitor. 
Lord et al (1979) proposed two models to explain these 
observations. They suggested that the inhibitor acted early in 
either the G1 or G2 phase of the cell cycle (see Figure 1.2). In 
the first model, as the concentration of the inhibitor is increased 
it affects cells throughout the G2 phase to the G1-S boundary. 
Thus at high concentrations the inhibition is almost immediate. In 
the second model low concentrations of the inhibitor act early in 
the G2 phase, which is much longer than the G1 phase. Higher 
concentrations of the inhibitor affect CFU-S later in G2. This 
also produces an early reduction of the proportion of CFU-S in 
S-phase. Washing the cells in fresh medium after incubation with 
the inhibitor did not reverse its effect. Lord et al (1979) 
proposed that the CFU-S are held in Go and prevented from entering 
the G1 phase. They can be triggered from GD into G1 if they are 
exposed to the CFU-S proliferation stimulator, (Lord et al 1977). 
In normal murine bone marrow most of the CFU-S are in a 
resting GO phase, (Becker et al 1965), (Lajtha 1979a). Agents 
which kill CFU-S such as irradiation, (Lahiri and Van Putten 1972), 
and cytotoxic drugs, (Necas and Neuwirt 1977), cause a rapid 
triggering of CFU-S into cycle. This is probably mediated by the 
actions of the 30-50K daltons CFU-S proliferation stimulator. This 
triggers quiescent normal bone marrow CFU-S into cycle within 30 
minutes, ( Lord et al 1977). Various chemicals such as E type 
prostaglandins, testosterone and isoproterenol also cause a rapid 
entry of CFU-S into cycle, (Feher and Gidali 1974), (Byron 
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1972 , 1975). Byron (1973) suggested that these chemicals acted 
via specific receptors on the haemopoietic stem cell. But if the 
stimulator producing cells were removed from a suspension of normal 
bone marrow cells, the subsequent addition of testosterone did not 
stimulate CFU-S proliferation, (Wright 1981). These results 
suggest that these chemicals may cause the release of the CFU-S 
proliferation stimulator rather than acting directly on the CFU-S. 
Lord (1981) has investigated the location of the Go phase in 
the CFU-S cell cycle. Byron (1972) and Lahiri and Van Putten 
(1972) suggested that Gp was situated close to the end of the GI 
phase (see Figure 1.2). This location explained the rapid 
triggering of CFU-S into the S-phase. Lord (1981) used different 
combinations of the CFU-S proliferation inhibitor as a Go block; 
vinblastine as a mitotic block and the CFU-S proliferation 
stimulator to investigate this problem. From these experiments 
Lord (1981) concluded that Gn was located either towards the end of 
the G1 phase or intercalated between the G, and S-phase. 
1.1.6.6 A CFU-S proliferation inhibitor and stimulator 
demonstrated by the French group 
Frindel and Guigon (1977) homogenized fetal calf bone marrow 
which had previously been frozen. The cellular debris was removed 
by centrifugation and the supernatant was dialysed for 12 hours at 
4°C. The dialysate was lyophilized and the protein concentration 
determined. Mice were exposed to 150 rads total body irradiation. 
24 hours later the CFU-S were rapidly proliferating. Some of the 
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mice were injected with 2mg of the BME protein at 22 and 23 hours 
after the irradiation. One hour later these mice were sacrificed 
and the proportion of CFU-S synthesizing DNA determined. In 
contrast to the irradiated controls, a small proportion of the 
CFU-S were in cycle in the bone marrow of the BME treated mice. 
Extracts prepared from thymus and liver did not have this effect. 
Cytotoxic drugs such as hydroxyurea, (Vassort et al 1971), and 
irradiation, (Croizat et al 1970), cause a rapid recruitment of 
CFU-S into DNA synthesis. Frindel et al (1976) took plugs of bone 
marrow from the femurs of mice which had previously been injected 
with hydroxyurea and placed them on millipore filters. A normal 
bone marrow suspension was put into petri dishes and the cells were 
allowed to settle. Millipore filters with either hydroxyurea 
treated bone marrow or normal bone marrow on them were floated on 
the medium. After a 24 hour incubation at 37°C the normal bone 
marrow "responder" cells on the bottom of the petri dish were 
harvested. The proportion of CFU-S synthesizing DNA was then 
determined. If normal bone marrow was put on the millipore filters 
no triggering of the responder CFU-S into cycle occurred. In 
contrast, when bone marrow from mice treated with hydroxyurea was 
put on the millipore filters the responder CFU-S were triggered 
into cycle. Bone marrow from mice exposed to 500 rads 15 minutes 
prior to sacrifice also triggered normal bone marrow CFU-S into 
cycle. 
Guigon and Frindel (1980) injected mice with cytosine 
arabinoside (Ara-C). This treatment triggered their CFU-S into 
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cycle. These bone marrow cells were put onto millipore filters and 
floated on a normal bone marrow suspension. This also triggered 
the CFU-S in the normal bone marrow suspension into cycle. If the 
CFU-S proliferation inhibitor from a fetal calf bone marrow 
extract, (Frindel and Guigon 1977), was added to the cell 
supsension no triggering of the CFU-S into cycle occurred. 
The properties of the CFU-S proliferation inhibitors 
demonstrated by Frindel and Guigon (1977) and Lord et al (1976) are 
not consistent. The inhibitor isolated by Frindel and Guigon 
(1980) was contained in a dialyzate of a fetal calf bone marrow 
suspension. Gel filtration of this material indicated that it had 
a molecular weight of less than 700 daltons, 
(Guigon et al 1980). 
In contrast, the inhibitor isolated by Lord et al (1976) was 
contained in a 50-100K dalton molecular weight fraction. 
The bone marrow used by Frindel and Guigon (1977) had been 
previously frozen, the cells would therefore be dead. Autolytic 
enzymes such as proteases would be released from these cells. 
Dialysis produces optimal PH conditions for the action of 
proteases, ( Fracassini 1979). A low molecular weight moiety may be 
cleaved off a larger carrier molecule by proteases. Frindel and 
Guigon (1977) could have detected such a low molecular weight 
biologically active moiety. Lord et al (1976) used freshly 
aspirated normal murine bone marrow. The extract was produced by 
washing the cells in physiological saline. This system would 
contain much lower concentrations of proteases. They may have 
extracted the active moiety demonstrated by Frindel and Guigon 
65 
(1977) attached to a larger carrier protein. All murine fetal 
haemopoietic stem cells are rapidly proliferating. The same 
situation would be predicted in fetal calf bone marrow. It is 
therefore strange that Frindel and Guigon (1977) were able to 
extract a CFU-S proliferation inhibitor from this bone marrow. 
The CFU-S proliferation stimulators released by cytotoxic drug 
treated, (Frindel et al 1976), and irradiated bone marrow, (Croizat 
and Frindel (1980), were not biochemically characterised. 
Consequently no comparison of the specific activities or molecular 
weights of these stimulatory activities and those reported by Lord 
et al (1977) and All (1981), can be made. Croizat and Frindel 
(1980) demonstrated CFU-S proliferation stimulatory activity in the 
bone marrow of mice irradiated (500 rads) 15 minutes previously. 
No stimulatory activity was detected if the bone marrow was removed 
4 hours after the irradiation. All (1981) extracted a 30-50K 
daltons molecular weight CFU-S proliferation stimulator from 
irradiated bone marrow. This had similar properties to the 
stimulator demonstrated by Lord et al (1977) in post irradiation 
bone marrow. All (1981) found that the CFU-S proliferation 
stimulator was not released until 6 hours after the irradiation 
(450 rads). High levels of this stimulator were still present 7 
days after the irradiation. 
1.1.6.7 In vivo action of the CFU-S proliferation inhibitor 
Marrow aplasia occurs in patients being treated with 
fractionated doses of cytotoxic drugs, (Geary 1979). This limits 
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the dose of these drugs which can be administered and therefore the 
efficacy of tumour cell killing, (Clarysse et al 1976). In normal 
murine and presumably human bone marrow, a small proportion of the 
haemopoietic stem cells are in cycle, (Becker et al 1965). A 
single dose of an S-phase specific cytotoxic drug will therefore 
kill only a small proportion of the haemopoietic stem cells. But 
CFU-S are triggered rapidly into cycle after cytotoxic drug 
treatment, (Vassort et al 1971). S-phase specific cytotoxic drugs 
(eg hydroxyurea) cause a greater proportion of the CFU-S to start 
cycling than mitotic arrest agents (eg vinblastine), (Necas and 
Neuwirt 1977). Consequently when the second dose of an S-phase 
specific cytotoxic drug is administered a much larger proportion of 
the CFU-S are killed (ie, 30-40% of the remaining CFU-S). Thus, 
after several doses of the drug the number of CFU-S remaining is 
not sufficient to repopulate the animal's haemopoietic tissues. A 
fatal aplastic anaemia is the consequence. In practice, this 
complication is overcome by decreasing the doses of the cytotoxic 
drugs and increasing the time between each dose, (Calman et al 
1980). This protocol allows recovery of the haemopoietic tissues, 
but the malignant clone can also expand during this time. A 
substance which could selectively switch the haemopoietic stem cell 
out of cycle while not affecting tumour clonogenic cells would help 
solve this problem. 
The 50-100K daltons fraction from a normal murine bone marrow 
extract (NBME) inhibits CFU-S proliferation in vitro, (Lord et al 
1976). Lord and Wright (1980) therefore investigated the actions 
of this factor in vivo. Mice were pretreated with phenylhydrazine, 
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an intravenous injection of cytosine arabinoside (Ara-C) killed 24% 
of their femoral CFU-S. If the NBME 50-100K daltons fraction was 
injected 4 hours before the Ara-C, the killing of CFU-S was 
insignificant. In a second experiment mice were injected with 
hydroxyurea (Hu) at 0 and 7 hours. This treatment killed a large 
proportion of the CFU-S. If the mice were given an injection of 
the NBME 50-100K daltons fraction intercalated between the two Hu 
injections, the killing of CFU-S by the Hu was reduced. The 
protection afforded by this CFU-S proliferation inhibitor was not 
total. Lord and Wright (1980) suggested that this was due to the 
impurity of the factor used and suboptimal timing of its injection 
into the mice. 
1.1.7 Long-term Bone Marrow Cultures 
A method for the long-term maintenance of bone marrow cells in 
vitro has been developed, (Dexter et al 1973 , 
1977a). The 
maintenance of haemopoiesis depends on the establishment of an 
adherent layer of bone marrow cells. This layer consists of bone 
marrow stromal cells. The main cell types being flattened 
epithelial cells, macrophages, and giant fat cells, 
(Allen 1978). 
This adherent layer is innoculated with more bone marrow cells 
after 2-3 weeks in culture. The cultures are then fed weekly by 
removing half the growth medium and suspended cells; this is 
replaced with fresh medium, (Dexter et al 1977a). The CFU-S 
self-replicate and differentiate in these cultures for several 
months. The CFU-S produced are normal, and are capable of forming 
erythroid, granulocytic and megakaryocytic colonies in lethally 
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irradiated mice. The CFU-S differentiate to produce the committed 
progenitor cells. The erythroid (BFU-E), (Testa and Dexter 1977), 
the granulocyte-macrophage (GM-CFC), (Dexter et al 1978), and the 
megakaryocyte (MEG-CFC)(Williams et al 1978), progenitors are also 
maintained for several months. 
The CFU-S are produced within the adherent layer of bone 
marrow cells and are subsequently released into the growth medium. 
When the cultures are fed half of these suspended CFU-S are 
removed. The concentration of CFU-S in the growth medium is 
therefore highest just prior to feeding the cultures. At this time 
a small proportion of the CFU-S in the adherent layer and in 
suspension are synthesizing DNA (<10%). In contrast 24 hours after 
feeding the cultures >40% of the CFU-S are synthesizing DNA. The 
proportion in cycle then decreases to reach a minimum just prior to 
the next feeding, (Dexter et al 1977b). In contrast the GM-CFC 
remain in a rapidly cycling state throughout the culture period. 
This suggests that changes in the proportion of CFU-S in cycle are 
not due to nutritional deficiencies. 
The proportion of CFU-S in cycle in these cultures therefore 
appeared to be related to their concentration. This is analogous 
to the control of CFU-S proliferation in vivo, 'Rencricca et al 
1970), (Gidali and Lajtha 1972). Toksoz et al (1980) investigated 
the mechanisms controlling CFU-S proliferation in these cultures. 
The medium from these cultures was assayed every day for the 
presence of the CFU-S proliferation inhibitor and stimulator. 24 
hours after feeding the cultures a high concentration of the 30-50K 
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daltons CFU-S proliferation stimulator was detected. This 
decreased over the next 6 days so that just prior to re-feeding the 
concentration of the CFU-S proliferation stimulator was very low. 
In contrast just prior to re-feeding the concentration of the 
50-100K daltons CFU-S proliferation inhibitor was very high. 
Exogenous CFU-S proliferation inhibitor was added to some 
cultures 24 hours after feeding. This abrogated the effect of the 
endogenous stimulator. The CFU-S remained in a slowly 
proliferating state for the next 3 days. Exogenous CFU-S 
proliferation stimulator was added to some cultures just prior to 
feeding. This treatment reversed the effect of the endogenous 
inhibitor. The CFU-S in these cultures remained in a rapidly 
proliferating state for the next 5 days. These observations 
suggested that the proportion of CFU-S in cycle is regulated in 
vitro as in vivo, by. a balance between the concentration of the 
CFU-S proliferation inhibitor and stimulator. 
The establishment of an adherent layer of bone marrow stromal 
cells is essential for the maintenance of haemopoiesis in these 
cultures, (Dexter 1979). This adherent layer may form an inductive 
microenvironment for the haemopoietic cells. This would be 
analogous to the in vivo stromal haemopoietic inductive 
microenvironment proposed by Trentin (1970), (see Section 1.1.4.3). 
Allen and Dexter (1976ä), (1976b) studied the interrelationships of 
cells in these cultures using scanning and transmission electron 
microscopes. Numerous granulocytes were aggregated on top of the 
adherent layer, especially around the giant fat cells. Embedded 
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within the adherent layer immature granulocyte precursors were 
surrounded by epithelial cells and macrophages. Gap junctions and 
numerous pinocytic vesicles were seen between the granulocyte 
precursors and the epithelial cells. These structures are 
indicative of intercellular communication and therefore provide a 
route through which stromal cells could influence haemopoiesis. 
The culture of bone marrow from two anaemic mutant mice (W/Wv 
and SI/Sld) supports the crucial role of stromal cells in the 
maintenance of haemopoiesis, (Dexter and Moore 1977). The Sl/Sld 
mice have an intrinsic stromal cell defect but normal CFU-S. The 
W/Wv mice have normal stromal cells, but no normal CFU-S, (Harrison 
1979). Adherent layers established from the bone marrow of Sl/Sld 
mice would not support the production of CFU-S by Sl/Sld, W/Wv or 
normal bone marrow. If the adherent layer was derived from W/Wv 
bone marrow it supported the production of CFU-S from Sl/Sld and 
normal but not W/Wv bone marrow. 
The long term bone marrow culture system therefore provides an 
excellent system to investigate the interactions between stromal 
and haemopoietic cells. The mechanisms which control normal 
haemopoietic stem cell and progenitor cell proliferation and 
differentiation. This is therefore an ideal system with which to 
investigate leukaemic transformation. Dexter et al (1977c) 
infected normal bone marrow cultures with friend leukaemic virus. 
This caused increased CFU-S proliferation, with decreased erythroid 
but increased granulocytic differentiation. The in vitro 
transformed cells were also able to cause leukaemia in vivo. 
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1.2 MATERIALS AND METHODS 
1.2.1 Mice and Housing 
SPF female CD1 mice weighing 20-25g were supplied by Charles 
River, and CBA mice of both sexes weighing 20-25g were supplied by 
the Centre for Laboraotry Animals, The Bush, Penicuik. The mice 
were housed five to a cage and fed on R and M No-1 pellets (BP, 
Witham, Essex) and water containing l5ppm chlorine free ions 
(Kirbychlor, Mildenhall, Suffolk) ad libitum. Cages and bottles 
were sterilized and changed frequently and access to the mice 
restricted. 
Wistar rats were bred in our own animal house. Albino guinea 
pigs were supplied by David Hall, Barley Hall, Newchurch, 
Burton-on-Trent, Staffordshire. 
All animal experiments were performed under Home Office 
Licence number ED, 4344. 
1.2.2 Medium and Serum 
All media were obtained from Gibco Biocult Ltd. RPMI medium 
was supplemented with 0.05% w/v NaHC03; 50mg streptomycin/ml; 50 
IU penicillin/ml and 2mM glutamine/ml which was buffered to PH 7.4 
with 10-2M Hepes (N-2-hydroxyethylpiperazine-NI-2-ethane sulphonic 
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acid). RPMI medium supplemented as above was used for all the 
GM-CFC cultures. Fischer's medium supplemented with 50mg strepto- 
mucin/ml; 50 IU penicillin/ml, and 2mM glutomine/ml, was buffered 
with 0.11% w/v NaHC03 to PH 7.4. Fishers medium supplemented as 
above was used for all washing and incubation of haemopoietic 
cells. 
Medium supplemented as above will be referred to as RPMI and 
Fischer's medium respectively. Glutamine, streptomycin, penicillin 
and Hepes were supplied by Flow Laboratories Ltd. 
Horse and fetal calf sera were obtained from Flow Laboratories 
Ltd. 
1.2.3 Human Fetal Tissues 
19 human fetuses of crown rump lengths 76-156mm were obtained 
from therapeutic prostaglardin inductions. Fetal gestational age 
was determined from crown rump length measurements, Kelemen et al 
(1979) and clinical data (Table 1.1). The fetal liver, bone 
marrrow, spleen and thymus were removed within 1-6 hours of 
delivery. Smears, touch preparations and histological sections 
were made from each organ to check tissue preservation. 
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TABLE 1.1 Fetal Crown Rump Lengths and Equivalent 
Gestational Ages 
Fetus Number Crown Rump Length cm Fetus Age - Weeks 
1 13.2 16.0 
2 9.2 
3 7.6 
4 8.5 
1.5.0 
12.0 
12.5 
5 11.2 14.5 
6 9.7 
7 12.0 
8 14.5 
9 7.6 
10 9.5 
11 11.8 
12 14.9 
13 15.6 
14 11.4 
15 10.8 
16 10.6 
17 11.9 
18 7.2 
19 12.0 
1 : 5.4 
15.0 
16.9 
11.8 
13.1 
14.9 
17.1 
17.6 
14.6 
14.1 
14.0 
15.0 
11.5 
15.0 
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1.2.4 Preparation of Haemopoietic Cell Suspensions 
1.2.4.1 Murine and rat bone marrow 
The ends of the femur were removed with a scalpel and the bone 
marrow flushed out with ice cold Fischer's medium. The cells were 
aspirated repeatedly through a 23 gauge needle to produce a single 
cell suspension. 
1.2.4.2 Human rib bone marrow 
The rib was cut into 0.5cm sections with bone forceps. The 
bone marrow was squeezed from them into ice cold Fischer's medium 
with pliers and an adjustable spanner. The cells were repeatedly 
aspirated through a 23 gauge needle to produce a single cell 
suspension. 
1.2.4.3 Human fetal bone marrow 
Human fetal bone marrow was either flushed from the femur as 
per murine bone marrow (1.2.4.1), or squeezed from the femur with 
two pairs of artery clamps and aspirated as above (1.2.4.1). 
1.2.4.4 Human and murine fetal liver, spleen and thymus 
These tissues were teased into small pieces with a scalpel and 
forceps in Fischer's medium. They were then repeatedly aspirated 
into a lml syringe with no needle, and subsequently through 
75 
increasing gauge needles to produce a single cell suspension. 
1.2.5 Cell Counts 
Nucleated haemopoietic cells were counted by diluting an 
appropriate aliquot of the cell suspension in 20mis of Isoton 
(Coulter Electronics Ltd. ). Red blood cells were lysed with 3 
drops of Zaponin (Coulter Electronics Ltd. ). The cells were 
counted in a Coulter electronic particle counter, model ZBI 
(Biological). The Coulter counter was calibrated for murine bone 
marrow cells using the half count method, (Coulter Manual 1973) and 
the following settings were found to be optimal when using a 100pm 
aperture. 
Amplification 1 
2 
Aperture current 1 
4 
Lower threshold 20 
Upper threshold out 
This calibration was checked by counting the same cell 
suspension in an improved Neubauer haemocytometer. 
76 
1.2.6 Preparation of Haemopoietic Cell Conditioned Media 
1.2.6.1 General description 
A haemopoietic cell suspension normally of 15 x 106 cells/ml 
in Fischer's medium with 10% horse serum was incubated at 37°C in a 
shaker water bath (Grant Instruments Ltd) at speed 40 for 2 hours. 
The cell suspension was then spun down at 1,000rpm (168g) in a 
chilspin centrifuge (Fisons Ltd) for 10 minutes. The cell free 
supernatant was removed as 'Supernatant one. The cells were 
resuspended in Fischer's medium with 10% horse serum at 15 x 106 
cells/ml and incubated for another 5 hours at 37°C. The cells were 
spun down and a second supernatant 'Supernatant two' was removed 
(Figure 1.4). In some experiments the cells were resuspended and 
incubated for a further 12 hours to produce a third supernatant. 
All supernatants were centrifuged at 4,000rpm for 30 minutes 
in a chilspin to remove debris and sterilized by passing through a 
22um filter (millipore). This step was crucial if supernatants 
from human fetal liver were to be fractionated using Amicon 
filters. In some experiments the concentration at which cells were 
incubated was varied (5 to 30 x 106 cells/ml). The supernatants 
were stored at -20°C until use. 
1.2.6.2 Plastic adherent cell separation of human fetal liver 
cells: production of conditioned media 
Human fetal liver cells were suspended in Fischer's medium 
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Haemopoietic Tissue 
Cell Suspension 
"" 
" 
"" 
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" 
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a Incubate for 2 hours 37°C 
Spin Down Cells 
Cells Resuspended 
5 hour Incubation 
i 
a Remove Cell Free 
'Supernatant One 
Cells Spun Down 
Remove 
Supernatant Two 
i 
Assay for CFU-S and GM-CFC 
Proliferation Regulators 
FIGURE 1.4 
The preparation of conditioned medium from haemopoietic cell 
suspensions. A single cell suspension is prepared from the 
haemopoietic tissue in supplemented Fischer's medium or 
physiological saline if the supernatant is to be fractionated. The 
cells are incubated for 2 hours at 37°C. The cells are then 
removed by centrifugation and the supernatant (One) retained. The 
cells are resuspended in fresh medium or saline and incubated for a 
further 5 hours. The cells are removed by centrifugation and this 
second supernatant retained. Both the supernatants are centrifuged 
at 4000 rpm for 30 minutes and passed through a 22um filter prior 
to testing or fractionation. 
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with 15% horse serum at 5x 106 cells/ml in 90mm plastic petrie 
dishes (Nunclon Intermed). Cells were allowed to adhere for 2 
hours at 37°C in an atmosphere of 10% C02 in air. The non-adherent 
cells were washed from the petrie dish with warm medium (37°C). 
The adherent cells were removed by gentle scraping with a rubber 
policeman. Adherent and non-adherent cells were washed, 
resuspended separately in Fischer's medium with 15% horse serum at 
15 x 106 cells/ml and incubated for a further 5 hours. Cell free 
supernatants were then obtained from the 2 'cell populations 
following centrifugation (as in Section 1.2.6.1). 
1.2.6.3 Fractionation of haemopoietic cell conditioned media 
The haemopoietic cell conditioned medium was fractionated by 
ultrafiltration, using Amicon Diaflo membranes (Diaflo 
Ultrafilters, Lexington, Massachusetts), (Lord et al 1976). The 
haemopoietic cells were incubated in physiological saline (0.9% 
w/v), rather than Fischer's medium if the conditioned media was to 
be lyophilised after fractionation. 
In a standard haemopoietic cell supernatant fractionation 
procedure, 3 molecular weight fractions were produced, 50-100K, 
30-50K and 10-30K daltons. These were produced by applying the 
supernatants successively to filters which allowed the passage of 
only molecules below a certain size. The crude supernatant was 
initially applied to a filter (XM100A) which only allowed 
molcecules of <100K daltons to pass through it (Figure 1.5). It 
was pushed through this filter with 100mis of distilled water. 
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Haemopoietic Cell Supernatant 
Amicori Filter 
Molecular Weight 
Cut Off (Daltons) 
Fractions MW (Daltons) 
100,000 0 L___ý J 
'ý' 
Fraction One 
>100,000 
Fraction Two 
50-100,000 
50,000 
30,000 n ----- 
a 
10,000 
FIGURE 1.5 
<10,000 
Fraction Three 
30-50,000 
Fraction Four 
10-30,000 
The Amicon Diaflo ultrafiltration procedure. The molecular weight 
cut off of each filter indicates -the approximate weight of 
molecules which will not pass through the filter. (See Section 
1.2.6.3) 
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This filtrate was applied to a second filter (XM50A) with a 50K 
daltons molecular weight cut off, and was concentrated to 5mls 
above it. 100mis of distilled water was added, and it was again 
concentrated to 5mls. This was removed as a 50-100K daltons 
fraction. The filtrate from the second filter (Figure 1.5) was 
applied to a third filter (PM30) which only allowed the passage of 
molecules of less than 30K daltons. It was concentrated to 5mls 
(as above), 100mis of distilled water was added and concentrated to 
5mis again. This was removed as the 30-50K daltons fraction. The 
filtrate from filter three was applied to a fourth filter (PM1d) 
with a 10K daltons molecular weight cut off. It was concentrated 
above this filter (as above) to produce a 10-30K daltons fraction. 
These fractions were lyophilised and stored at -209C until use.. 
The fractions were dissolved in medium at between 1 and 100ug/ml 
when assaying their effect on CFU-S and GM-CFC proliferation. The 
dissolved Amicon fractions were passed through a 22Vm millipore 
filter prior to use. 
1.2.7 Culture of Human Fetal Liver and Bone Marrow 
The fetal liver was cut into small pieces and aspirated 
through a iml syringe with no needle on it (in 70-100mis of 
Fischer's medium depending on the size of the liver). 0.5mis of 
this suspension was put into a 2.5cm2 tissue culture flask 
(Sterling) containing 9.5mls of Fischer's medium supplemented with 
25% horse serum and 0.362ug/ml (10-6 Moles) of hydrocortisone 
(Sigmar H-4001). 36.211g of hydrocortisone in O. lmis of aristar 
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alcohol was added to a 100ml bottle of medium. This concentration 
of alcohol had no adverse effect on the growth of the cultures. 
Fetal bone marrow cultures were set up in a similar manner to the 
fetal liver. The bone was cut into about 20 fragments with a 
scalpel and this was added to a tissue culture flask as for the 
liver. 
The flasks with loose caps were incubated at 37°C in a fully 
humidified atmosphere of 10% C02 in air. After 3 days all the 
culture medium was removed, the cultures were washed with 5mls of 
medium and 10mis of Fischer's medium supplemented as above was 
added. The medium removed from the cultures was centrifuged and 
filtered as in Section 1.2.6.1. This was retained as a 'Culture 
Supernatant One. Subsequently half the culture medium was removed 
every four days and replaced with fresh supplemented medium (vide 
supra). Supernatants were also prepared from the culture medium 
removed at each of these feedings. 
1.2.8 Irradiation and Spleen Colony Assay 
Groups of 10 mice were exposed to 820 Rads (8.2Gy) of whole 
body X-irradiation using a Siemens Stabiliplan X-ray set (250Kvp, 
14ma, 0.5cm copper filtration, and dose rate 79 Rads per minute 
(0.79Gy/min)), in the radially disposed compartments of a perspex 
cage. At this dose of irradiation no endogenous spleen colonies 
were formed, (Cork 1979). In the standard spleen colony assay the 
cell suspension to be assayed was diluted with Fischer's medium to 
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105 nucleated cells per ml. 0.5mis of this suspension was injected 
into each mouse intravenously (ie 5x104 nucleated cells). The mice 
were sacrificed 9 days later, the spleens removed, fixed in bouins 
for 24 hours and then transferred to 70% alcohol. Colonies were 
counted through a x3 magnification lens after Till and McCulloch 
(1961). 
1.2.9 Cytotoxic Drug Treatment of Murine Bone Marrow 
Mice were treated with cytotoxic drugs to produce populations 
of CFU-S, a large proportion of which were synthesizing DNA. Two 
regimens were employed: - 
1. Mice were injected IV with 250mg/kg of cytosine arabinoside 
(Ara-C) (Cytosar, Upjohn Ltd, Crawley, Sussex), dissolved in 0.9% 
NaCl. 24 hours later the mice were sacrificed and the bone marrow 
removed from both femurs. This source of bone marrow is 
subsequently referred to as '24 hour Ara-C bone marrow'. It should 
not be confused with the use of Ara-C as a CFU-S suicide agent 
(Section 1.2.10.1). 
2. Mice were injected IV with 5mg/kg of nitrogen mustard (HN 2) 
(mustine hydrochloride, Boots Pure Drug Company, Nottingham, 
England) in 0.9% NaCl. 4 days later the mice were sacrificed by 
cervical dislocation and the bone marrow removed from both femurs. 
This source of bone marrow is subsequently referred to as 'Day 4 
HN2 bone marrow'. 
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The pooled femoral bone marrow from at least 8 cytotoxic drug 
treated mice were used in each experiment. 
1.2.10 The GM-CFC Assay 
1.2.10.1 Endotoxin serum GM-CSA 
Endotoxin serum GM-CSA at a final concentration of 2.5% was 
used for all GM-CFC cultures. Mice were injected IV with 25pg of 
S-typhimurium endotoxin (Sigma L5130). 3 hours later they were 
bled retro-orbitally with non-heparinized glass microhaematocrit 
tubes (John Poulter Ltd, Barking, Essex). The blood was left to 
coagulate at 4°C for 12 hours and then spun down at 4000rpm in a 
chilspin centrifuge (Fisons). The serum was removed and diluted, 1 
part serum plus 3 parts RPMI medium. This was stored at -20°C 
until use. O. lml of the diluted endotoxin serum was added to each 
GM-CFC culture plate. 
1.2.10.2 GM-CFC agar colonies plating procedure 
All medium and bone marrow suspensions were kept at 37°C in a 
water bath until just prior to plating. A 6% agar solution (w/v in 
double distilled water), (Bactoagar, Difco Laboratories, Detroit) 
was sterilized by boiling for 30 minutes, and kept at 100°C until 
use. 0.5mls of a suspension of 1.4 x 106 murine bone marrow 
cells/ml in RPMI medium was added to 9.5mls of RPMI medium 
supplemented with 25% Fetal Calf Serum (Figure 1.6). To this 
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GM-CFC Agar Colonies Plating Procedure 
\ý 
1 
Bone Marrow 
Suspension 
1.4 x 106cells/ml 
00 
00 
00 
6% Molten Agar 
0.5mIs \/0.5m1s 
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+25% FCS 9.5mIs 
O. 1mis GM_CSA 1. Omis per plate 
i-I 
i 
)Cultured in 10% CO2 in Air 
(Humidified Atmosphere) 
Agar Allowed to Gel at 20°C 
I' 
I 
Colonies Counted Day 7 
FIGURE 1.6 
The procedure used to culture granulocyte macrophage colonies from 
murine bone marrow. (See Section 1.2.10.2) 
85 
mixture 0.5mis of the 6% agar solution was added with a heated 
glass pipette. This mixture was inverted 3 times and 1. Oml 
aliquots placed into 9, lux 35mm tissue culture plates, into which 
O. lml of endotoxin serum GM-CSA had been previously placed. 
Cultures were incubated at 37°C in a 10% C02 in air, fully 
humidified atmosphere (Hot Pack Corporation C02 Incubator, 
Philadelphia). The colonies were counted on day seven, using a 
Kyowa dissecting microscope x45 magnification with indirect 
illumination. 
A differential count was performed on each plate. Loose 
macrophage colonies, tight granulocytic colonies and colonies 
consisting of a tight granulocytic centre with a loose macrophage 
periphery were scored. Some colonies were stained to confirm the 
cell morphology deduced from the colonies' gross appearance. 
1.2.10.3 Procedure for fixing and staining GM-CFC colonies 
The entire semisolid agar culture was fixed by adding 1.0ml of 
0.3% Glutaraldehyde, (BDH Chemicals Ltd) in 0.9% NaCl to it for 20 
minutes. The plastic culture dish containing the agar was held in 
a water bath at 37°C for 20 seconds. It was then removed and 
inverted over a slide (7.5 x 3.8cm). The agar was dried by placing 
an acetate (millipore) membrane onto it, this was left for 24 hours 
at 25°C. A few drops of water were placed onto the acetate 
membrane to facilitate its removal. The GM-CFC colonies were 
stained with Mayers haematoxylin and eosin, (Culling 1963), but the 
staining times were lengthened to allow penetration of the agar by 
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the stain as follows: - 
1. Rinse in acid alcohol - 30 seconds 
2. Rinse in distilled water - 30 seconds 
3. Stain with Mayer's Haematoxylin - 15 minutes 
4. Rinse and blue with running tap water -6 minutes 
5. Stain with Eosin -1 minute 
6. Rinse with distilled water - 30 seconds 
7. Dry at 2500 for 24 hours 
8. Conventional mounting in styrene. 
1.2.11 The Suicide Technique 
The proportion of CFU-S synthesizing DNA was determined by 
incubating aliquots of murine bone marrow or fetal liver cells at a 
concentration of 5- 15x106 cells/ml with a suicide agent or medium 
as a control. The standard suicide experiment consisted of two 
tubes, both containing 1.0ml of a haemopoietic cell suspension and 
0.25m]s of horse serum (ie 20% horse serum). To one tube in each 
pair a suicide agent was added, to the other an equal volume of 
Fischer's medium. 
Two suicide agents were used, either 20ug/ml of Ara-C (Cytosar 
Upjohn Ltd) (0.125mis of a 200ug/ml solution of Ara-C in Fischer's 
medium) or 200pci/ml of 3H-thymidine (20Ci/mMole Amersham) in 
0.2mis of medium. The 20Ci/mMole 3H-thymidine was diluted to 
15Ci/mMole with cold thymidine (Sigma) and made isotonic with ten 
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times Fischer's medium prior to use. The tubes were incubated at 
37°C in a shaker water bath for 60 minutes, Ara-C suicide or 30 
minutes for the 
3H-Thymidine 
suicide. 
3H-thymidine 
was only used 
as a suicide agent with day 4 HN2 bone marrow: Ara-C was used for 
all other experiments. 
The proportion of CFU-S and GM-CFC surviving in a haemopoietic 
cell suspension after incubation with a suicide agent or medium as 
a control were determined by their respective clonal assays, 
Sections 1.2.8 and 1.2.10 respectively. For the spleen colony 
assay the cells were just diluted in Fischer's medium and 5x104 
cells injected into groups of lethally irradiated mice (Section 
1.2.8). But for the GM-CFC assay the cells were spun down at 1000 
rpm (168G) in a chilspin centrifuge (Fisons), resuspended in fresh 
medium, spun down again at 1000 rpm and resuspended again before 
plating. This was to ensure that all Ara-C was removed before 
culturing the cells. The proportion of CFU-S or GM-CFC 
synthesizing DNA was then determined as follows: 
A-BX 100 % killed by suicide agent 
A1 
% synthesizing DNA 
where B is the number of colonies produced by 105 haemopoietic 
cells incubated with a suicide agent 
and A is the number of colonies produced by 105 haemopoietic cells 
incubated with medium, (Becker et al 1965). 
The Standard error (SE) of the percentage of CFU-S killed by the 
suicide agent is calculated as follows: 
SE 
Kill = 
JSE. 
A2 + SE. B2 
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1.2.12 The Assay of CFU-S and GM-CFC Proliferation 
Regulators 
1.2.12.1 Inhibitors and stimulators: general principles, 
The principle of this assay is that haemopoietic cells, eg 
normal murine bone marrow, are incubated with either Fischer's 
medium as a control, or medium which has been conditioned by 
incubation with other haemopoietic cells (ie a haemopoietic cell 
supernatant, see Section 1.2.6.1). The supernatant removed from a 
population of haemopoietic cells is called a test supernatant 
(Figure 1.7), and the haemopoietic cells that are incubated with 
it, responder cells. These experiments were designed to determine 
if test supernatants from different haemopoietic cell populations 
contained factors which could increase or decrease the proportion 
of CFU-S and/or GM-CFC that were symthesizing DNA in the responder 
cell population. 
The concentration of test cells from which the test 
supernatant was removed was compared with the concentration of 
responder cells, to produce a "test responder cell ratio" (Figure 
1.7), (Wright and Lord 1978). A test responder ratio of 3: 1 was 
normally used but this was sometimes varied to determine the 
concentration of CFU-S or GM-CFC proliferation regulators in a 
haemopoietic cell supernatant. 
Instead of incubating responder cells with a haemopoietic cell 
conditioned supernatant, they were also incubated with a solution 
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Assay of CFU-S and GM-CFC 
Proliferation Inhibitors and Stimulators 
0.5m1 
1.0m1 
1.0m 
Horse Serum 
Responder Cells 
5x 106cells/ml 
Test Supernatant 
Conditioned by 
15x 106CeIIs/ml 
Test Responder Cell Ratio = 15: 5-3: 1 
FIGIRE 1.7 
The test responder cell ratio compares the concentration of test 
cells used to produce conditioned medium, with the concentration of 
responder murine bone marrow cells. 
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of a lyophilized Amicon fraction from it (see Section 1.2.6.3). 
1.2.12.2 Standard experimental design 
The standard experiment to assay a test supernatant or Amicon 
fraction for the presence of CFU-S and/or GM-CFC proliferation 
inhibitors and stimulators, consisted of 4 tubes. In all 4 tubes 
there was 1. Oml of a responder bone marrow suspension and 0.5mis of 
horse serum. To two tubes in each pair (the controls) 1. Oml of 
Fischer's medium was added. To the other pair, 1. Oml of the test 
supernatant or a dissolved Amicon fraction from it was added. The 
four tubes were incubated at 37°C for 4 hours in a shaker water 
bath. Then to one tube in each pair a suicide agent was added, 
normally Ara-C (20ug/ml, ie 50Vg). To the other pair an equal 
volume of medium was added. The tubes were incubated for a further 
hour at 37°C. They were then stood on ice and the number of CFU-S 
and/or GM-CFC per 105 cells in each tube assayed (ie total 
incubation time 5 hours). 
This standard experimental design was modified to assay for 
both CFU-S and GM-CFC proliferation stimulators and inhibitors. 
The CFU-S or GM-CFC proliferation regulators were incubated with a 
bone marrow suspension which contained CFU-S or GM-CFC in an 
opposite kinetic state to that which they would induce; eg, normal 
murine bone marrow - small proportion CFU-S synthesizing DNA - 
incubated with CFU-S proliferation stimulator. This allowed the 
maximum change in the proportion of CFU-S synthesizing DNA, and 
therefore less mice per group were needed to produce statistical 
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significance. 
1.2.12.3 Assay of CFU-S proliferation inhibitor 
Sources of the CFU-S proliferation inhibitor eg NBME, were 
incubated with haemopoietic cell suspensions in which a large 
proportion of the CFU-S were synthesizing DNA, eg 24 hour Ara-C 
bone marrow, day 4 HN2 bone marrow or day 15 gestational age murine 
fetal liver. This allowed a greater potential reduction in the 
proportion of CFU-S synthesizing DNA than if normal bone marrow had 
been used (Figure 1.8). 
1.2.12.4 Assay of CFU-S proliferation stimulator 
Sources of the CFU-S proliferation stimulators were incubated 
with haemopoietic cell suspensions in which a small proportion of 
the CFU-S were synthesizing DNA, eg normal bone marrow. This 
allowed the greatest potential increase in the proportion of CFU-S 
synthesizing DNA, ie the converse to Section 1.2.12.3 (Figure 1.9). 
1.2.12.5 Assay of GM-CFC proliferation inhibitor 
A large proportion of GM-CFC in almost all haemopoietic 
tissues are synthesizing DNA. GM-CFC proliferation inibitors were 
therefore assayed by incubating them with normal bone marrow. The 
experiments were set up as for a CFU-S proliferation regulator 
assay, with four tubes containing l. Oml of normal bone marrow cells 
and 0.5ml of horse serum. To each tube in one pair, 1. Oml of 
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Assay of CFU-S Proliferation Inhibitor 
Incubate for 1 hour 
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Assay 
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Technique for assaying cell conditioned medium for the presence of 
a CFU-S proliferation inhibitor. The top tube represents a pair of 
tubes containing 1. Oml of responder cells (eg 24 hour Ara-C bone 
marrow) and 1. Oml of a supernatant or Amicon fraction solution to 
be assayed for CFU-S inhibitory activity. The bottom tube 
represents the pair of control tubes containing 1. Oml of the 
responder cells and 1.0ml of medium. 0.5mis of horse serum was 
also added to each tube. The four tubes were incubated at 37°C for 
5 hours. For the last hour 20Pg/ml (ie 50ug) of Ara-C was added to 
one tube in each pair. An equivalent volume of medium was added to 
the other tube. The cells were then stood on ice, diluted with 
fresh medium and assayed for CFU-S. 
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Assay of CFU-S Proliferation Stimulator 
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FIGURE 1.9 
Technique for assaying cell conditioned medium for the presence of 
a CFU-S proliferation stimulator. The procedure was as for the 
assay of a CFU-S proliferation inhibitor, but using normal bone 
marrow as the responder cells. 
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medium was added. To the other 2 tubes l. Oml of a potential GM-CFC 
proliferation inhibitor was added. The tubes were incubated for 4 
hours, then to one tube in each pair Ara-C was added and to the 
other an equal volume of medium. The incubation was continued for 
1 hour, the cells were then washed twice in fresh RPMI medium and 
assayed for GM-CFC (see Sections 1.2.11,1.2.12.2 and 4.2.3.1). 
1.2.12.6 Assay of GM-CFC proliferation stimulators 
See Section 4.2.3.2 for detailed experimental design. 
1.2.13 The 125I-iododeoxyuridine'Assay 
1.2.13.1 Dose response studies 
Lethally irradiated mice (820 rads) were injected IV with 
between 2 and 20 x 105 normal bone marrow; 24 hour Ara-C bone 
marrow; or day 15 gestational age murine fetal liver cells. 3 or 
5 days later the mice were injected IV with 1 or 2 UCis of 
125I-lododeoxyuridine (5Ci/mg Amersham). 2 or 24 hours later the 
mice were sacrificed and the spleens and femurs removed. These 
were fixed in Bouins for 24 hours and then transferred to 70% 
alcohol. The alcohol was changed daily for 4 days. No activity 
could be detected in the alcohol on day 4. The spleen and femur 
were placed in separate plastic tubes (1.0 x 7.5cm) with 70% 
alcohol and counted in an intertechnique gamma counter. 
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Subsequently the 125IUdR technique was standardised as 
follows: 
lethally irradiated mice (820 rads) were grafted with 
haemopoietic cells, 5 days later they were injected IV with 2PCi of 
125IUdR and sacrificed 2 hours later. 
1.2.13.2 Trichloro-acetic acid precipitation of DNA 
Lethally irradiated (820 rads) mice were grafted with 
different numbers of normal bone marrow cells. 5 days later they 
were injected with 2UCi of 125IUdR, and sacrificed 2 hours later. 
The spleens were removed, cut in half, and one half weighed. One 
half was fixed in Bouins. The other half was homogenized in l. Oml 
of ice cold 5% trichloro-acetic acid, BDH) w/v in double distilled 
water. The homogenate was left for 24 hours at 4°C and then 
centrifuged at 1000g for 10 minutes. The supernatant was removed 
and the pellet resuspended in l. Oml of fresh 5% trichloro-acetic 
acid (TCA). This was centrifuged at 1000g for 10 minutes and the 
supernatant removed and added to the first. 
The uptake of 
125IUdR into the TCA precipitate, supernatant 
and the half spleen fixed in Bouins were counted. These values 
were divided by the weight in mgs of the spleen tissue from which 
they were derived, fBonting and Jones 1957). 
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1.2.13.3 CFU-S suicide and assay of CFU-S proliferation 
stimulators and inhibitors using the 125IUdR assay 
The incubation of haemopoietic cells with CFU-S proliferation 
inhibitors and stimulators was carried out-as for the spleen colony 
assay (see Sections 1.2.12 and 2.2). Ara-C was used as a suicide 
agent in all experiments (see Sections 1.2.11 and 2.2). 
1.2.14 Histological and Cytological Preparations for Light 
Microscopy 
Smears and touch preparations of human fetal liver and bone 
marrow were air dried; fixed in methanol for 20 minutes and 
stained using an improved Jenner-Giemsa technique, (Thomas 1971). 
7pm sections were prepared from human fetal liver, thymus and 
femoral bones by standard histological techniques, (Culling 1963). 
All sections were stained with Mayers haematoxylin and eosin, 
(Culling 1963). 
1.2.15 Preparation and Staining of Tissues for Electron 
Microscopy 
2 to 5 mm diameter blocks of human fetal liver, were fixed in 
Karmovsky's fixative - (4% paraformaldehyde - 5% glutaraldehyde in 
0.08m sodium cacodylate buffer PH 7.3) for 4 hours. After washing 
in buffer the tissue was post fixed in 1% osmium tetroxide in 0.08m 
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sodium cacodylate buffer. The blocks were then washed in buffer 
dehydrated in upgrading alcohols (50%, 75%, 96% Absolute), and 
placed into 50% epoxy propane 50% absolute alcohol. From this the 
blocks were soaked in 3 changes of epoxy propane for a total of 45 
minutes. The blocks were embedded in araldite which was cured at 
600C for 48 hours. Thin sections were cut on a Reichardt OMU2 
ultramicrotome and stained with Toluidine blue to determine 
orientation of the blocks. Ultrathin silver-grey sections were cut 
on a Reichardt OMU2 ultramicrotome using glass knives. These were 
collected on water and mounted on copper grids, (Hayat 1970). 
The sections were stained for 20 minutes with 2% uranyl. 
acetate in 50% ethanol. The sections were subsequently washed in 
distilled water and stained for 5 minutes with 4% lead citrate in 
O. lml sodium hydroxide, (Hayat 1970). All reagents apart from 
Araldite epoxy resin, were supplied by BDH, Poole, England; 
Araldite epoxy resin was supplied by Graticules Ltd., E. F. Fullam 
Inc., New York. 
Sections were examined with a Zeiss EM95 electron microscope 
and photographs taken on Ilford EM film. This was developed in D19 
fine grain developer (Kodak). 
1.2.16 Other Materials Used 
20um nylon mesh, used for filtering cell suspensions (Section 
2.2.7) was supplied by Begg Cousland Ltd. 
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1.3 EXPERIMENTAL DESIGN 
1.3.1 Proportion of CFU-S Synthesizing DNA in Different 
Haemopoietic Tissues 
The Ara-C suicide technique was used to determine the 
proportion of CFU-S synthesizing DNA in normal bone marrow; 24 
hour Ara-C bone marrow; day 4 HN2 bone marrow and day 15 
gestational age murine fetal liver. The number of CFU-S per 105 
nucleated cells and the proportion synthesizing DNA, were compared 
in normal and 24 hour Ara-C bone marrow from CD1 and CBA mice (see 
Section 1.2.11). 
1.3.2 The Effects of Normal Bone Marrow and Thymus Extracts on 
CFU-S Proliferation 
24 hour Ara-C bone marrow was incubated with a 50-100K daltons 
fraction from normal rat, guinea pig or pig bone marrow for 4 
hours. Ara-C was used as a suicide agent for the last hour. 24 
hour Ara-C bone marrow was also incubated for 5 hours, with a 
30-50K daltons fraction from normal rat bone marrow and with a 
50-100K daltons fraction from a rat thymus extract. All these 
fractions were assayed at a final concentration of 50pg/ml (see 
Section 1.2.12). Incubation time 5 hours, last hour with suicide 
agent. 
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Day 4 HN2 bone marrow was incubated with the 50-100K daltons 
fraction from 
. 
a. rat NBME. High specific activity 3H-thymidine was 
used as a suicide agent. The fraction was assayed at different 
concentrations, 1,12.5,25,50 and 100 vg/ml (see Section 1.2.12). 
1.3.3 The Effect of a 50-100K Daltons Rat NBME Fraction on the 
Proportion of NMBM GM-CFC Synthesizing DNA 
Normal nurine bone marrow was incubated with 50pg/ml of a 
50-100K daltons rat NBME fraction, or medium as a control. Ara-C 
was used as a suicide agent. The proportion of GM-CFC synthesizing 
DNA in the two groups was compared (see Sections 1.2.11 and 
1.2.12.5). 
1.3.4 The Effects of Medium Conditioned by Day 15 Gestational Age 
Murine Fetal Liver Cells on CFU-S Proliferation 
Normal murine bone marrow was incubated with a supernatant 
from day 15 gestational age murine fetal liver cells for 5 hours at 
a 3: 1 test responder cell ratio. Ara-C was used as a suicide agent 
for the last hour of incubation This was a number one supernatant, 
ie, conditioned by freshly aspirated cells for two hours (see 
Section 1.2.12). 
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1.4 RESULTS 
1.4.1 The Proportion of CFU-S Synthesizing DNA in Different 
Haemopoietic Tissues 
The proportion of CFU-S synthesizing DNA in different 
haemopoietic tissues was compared using the Ara-C suicide 
technique. In normal bone marrow <21% of the CFU-S were killed 
during a1 hour incubation with Ara-C. In contrast, in 24 hour 
Ara-C bone marrow, day 4 HN2 bone marrow and day 15 gestational age 
murine fetal liver >38% of the CFU-S were killed by incubating with 
Ara-C (Table 1.2). There was no significant difference between the 
CFU-S suicide of normal bone marrow obtained from CD1 or CBA mice. 
Likewise, the CFU-S suicide of 24 hour Ara-C bone marrow was also 
similar in the two species (Table 1.3). 
1.4.2 The Effect of Normal Bone Marrow and Thymus Extracts on the 
Proportion of CFU-S Synthesizing DNA in 24 Hour Ara-C Bone Marrow 
Incubation of 24 hour Ara-C bone marrow in which a large 
proportion of the CFU-S were synthesizing' DNA (>38%), with a 
10OUg/ml of a 50-100K daltons fraction from a normal rat, guinea 
pig or pig bone marrow extract, reduced the proportion of CFU-S 
synthesizing DNA to <12% (Figure 1.10, Tables 1.4 and 1.5). 
Incubation of 24 hour Ara-C bone marrow with a l00ug/ml of a 
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T able 1.2 The proportion of CFU-S killed by Ara-C and 
therefore synthesizing DNA, in normal and cytotoxic 
drug treated bone marrow and murine fetal liver 
(Mean ± SE) CFU-S per 105 cells injected from 
Ara-C treated cells (top value in each pair) and from 
medium treated control 
N= number of CDI mice per group 
Haemopoietic Tissue 
CFU-S per 105 cells 
injected ± SE 
Suicide %± SE 
Normal bone marrow 
N=45 
23.7 ± 1.1 
29.7 ± 1.4 
24 hour Ara-C bone 16.0 ± 1.4 
marrow 
N=22 29.4±1.8 
Day 15 gestional age 9.4 
± 0.9 
murine fetal liver 
N= 16 15.5 ± 1.0 
Day 4 HN2 bone 21.7 ± 2.8 
marrow 
N=14 38.0±3.6 
20.2 + 6.6 
45.3 ± 10.8 
39.5 ± 12.1 
43.0 ± 13.0 
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Table 1.3 The proportion of CFU-S killed by Ara-C andtherefore 
synthesizing DNA in normal and 24 hour Ara-G bone 
marrow from CDI and CBA mice. CFU- S per 105 cells 
injected from Ara- treated cells (top value in each pair) 
and from medium treated control (Mean ± SE) 
N= number of mice per group 
Haemopoietic Tissue 
CFU-S per 105 cells 
injected ± SE 
Suicide To ± SE 
+Ara- C 23.7+1.1 
Normal CDI 
bone marrow 
N= 45 
+ medium 29.7 
+ 1.4 
+Ara-C 23.8±1.1 
Normal C BA 
bone marrow 
N= 12 
+ medium 28.7 ± 1.6 
+Ara-C 16.0+1.4 
24 hour Ara-C 
CDI bone marrow 
N= 20 
+ medium 29.4 ± 1.8 
+A ra-C 17.8 ± 1.6 
24 hour Ara-C 
CBA bone marrow 
N= 10 
+ medium 29.0 ± 2.3 
20.2 ± 6.6 
17.0 ± 7.3 
45.3 f 10.8 
38.5 f 12.0 
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Table 1.4 The effect of a 50-100 K dalton and 30-50 K dalton 
fraction from a normal rat bone marrow extract; and 
a 50-100K dalton fraction from a normal rat thymus 
extract on the proportion of CFU-S from 24 hour 
Ara-C bone marrow synthesizing DNA. CFU-S 
per 105 cells injected from Ara-C treated cells 
(top value in each pair) and from medium treated 
controls (Mean ± SE) (10 mice per group) 
NMBM treatment during CFU-S per 105 cells 
incubation injected ± SE 
+Ara- C 17.8 ± 1.6 
Control 
+ Ara-C 26.0 ± 2.1 
+ NMBE 
50-100 K dalton 
fraction 
+ medium 25.6 ± 2.5 
+ medium 29.0 + 2.3 
+ Ara-C 15.9 ± 1.7 
+ NMBE 
30-50 K dalton 
fraction 
+ medium 23.9 ± 2.4 
+ Ara-C 19.1 ± 1.9 
+ Thymuus extract 
50-100 K dalton 
fraction 
+ medium 31.7 + 3.2 
Suicide %± SE 
38.5 ± 12.0 
-1.6 
± 12.9 
33.5 ± 15.0 
39.9 ± 14.2 
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Table 1.5 The effect of a 50-100 K dalton fraction from a pig 
and guinea pig normal bone marrow extract, on the 
proportion of CFU-S from 24 hour Ara-C bone marrow 
synthesizing DNA. CFU-S per 105 cells injected 
from Ara-C treated cells (top value in each pair) and 
from medium controls (Mean ± SE) (20 mice per group) 
CFU-S 1l05 cells % suicide of 
(± SE) CFU-S (± SE) 
control + medium 40.4 ± 6.9 
control + Ara-C 25.8 ± 1.7 
PBME (50-100 K) + medium 35.2 ± 1.9 
PBME (50-100 K) + Ara-C 32,9 + 2,2 
GPBME (50-100 K) + medium 37.1 ± 2.5 
GPBME (50-100 K) + Ara-C 36.2 ± 3.4 
PBME :- Pig bone marrow extract 
36.1 ± 11.7 
6.5 ± 8.0 
2.4 ± 11.3 
GPBME :- Guinea pig bone marrow extract 
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FIGURE 1.10 
Bone marrow from mice injected with Ara-C 24 hours previously: 
effect of incubation with 1001'g/ml of a 50-100K daltons fraction 
from a normal rat bone marrow extract on the proportion of CFU-S 
synthesizing DNA. (Suicide %, mean ± SE) 
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FIGURE 1.11 
Bone marrow from mice injected with HN2 4 days previously: effect 
of incubation with between 1 and 100ug/ml of a 50-100K daltons 
fraction from a normal rat bone marrow extract on the proportion of 
CFU-S synthesizing DNA. (Suicide %, mean ± SE) 
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30-50K daltonsfraction from a normal rat bone marrow extract, or a 
10OVg/ml of a 50-100K daltons fraction from a rat thymus extract 
did not affect the proportion of CFU-S synthesizing DNA (Table 
1.4). 
1.4.3 The Effect of a 50-100K Daltons Rat NBME Fraction on NMBM 
GM-CFC Proliferation 
The 50-100K daltons rat NBME fraction, did not alter the 
proportion of NMBM GM-CFC synthesizing DNA (Table 1.6) 
TABLE 1.6: The effect of a 50-100K daltons fraction from a 
normal rat bone marrow extract on the proportion of NMBM GM-CFC 
synthesizing DNA 
% GM-CFC in S-phase 
Normal bone marrow + medium 46.0 + 6.0 
Normal bone marrow + NBME 50-100K 42.0 + 5.0 
1.4.4 50-100K Daltons NBME Fraction Dose Response of Effect on 
CFU-S Proliferation from Day 4 HN2 Bone Marrow 
Incubation of day 4 HN2 bone marrow with lOCpg/ml of a 50-100K 
daltons fraction from a normal rat bone marrow extract reduced the 
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proportion of CFU-S synthesizing DNA from >40% to <10%. If the day 
4 HN2 bone marrow was incubated with the 50-100K daltons NBME 
fraction at 50 or 25 g/ml, the same reduction in the proportion of 
CFU-S synthesizing DNA occurred (Figure 1.11). But incubation with 
10pg/ml of the 50-100K fraction only reduced the proportion of 
CFU-S synthesizing DNA from 40% to 21%. The 50-100K NMBE fraction 
at 1yg/ml had no effect on the proportion of day 4 HN2 bone marrow 
CFU-S synthesizing DNA (Figure 1.11). 
1.4.5 The Effect of Murine Fetal Liver Cell Conditioned Media on 
the Proportion of Normal Bone Marrow CFU-S Synthesizing DNA 
Normal murine bone marrow was incubated with a supernatant 
(Si) from day 15 gestational age murine fetal liver cells at a 3: 1 
test responder ratio. This increased the proportion of CFU-S 
synthesizing DNA, from <11% to >32% (Figure 1.12, Table 1.7). 
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MFLS Stimulation of CFU-S Proliferation 
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Suicide% 10.4 ± 11.7 
MFLS 
38.1 ± 12.3 
FIG''RF l. 1? 
The effect of medium conditioned by 15 day gestational age murine 
fetal liver cells on the proportion of normal bone marrow CFU-S 
synthesizing DNA. (Suicide , mean + SE) 
1.5 nISC? 'SSIO'. v' 
1.5.1 CFC-S Kinetics 
The murine haemopoietic stem cell (CFJJ-S), (Till and McCulloch 
1961), has been shown here and previously, (Tecker et al 1965) to 
exist in two distinct kinetic states. In normal bone marrow a 
small proportion of the CFTT-S are synthesizing DNA. In contrast, 
in hone marrow regenerating after cytotoxic drug treatment or 
irradiation and in developing haemopoietic tissues such as fetal 
liver, a large proportion of the CFU-S are synthesizing DNA. 
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It was demonstrated that these two distinct CFU-S kinetic 
states could be found at different sites in the same mouse, 
(Rencricca et al 1970); (Gidali and Lajtha 1972); (Wright and Lord 
1977). This indicated that the proliferation of the haemopoietic 
stem cell might be controlled locally. 
1.5.2 A CFU-S Proliferation Inhibitor 
Lord et al (1976), (1977) and Wright and Lord (1977), (1978) 
demonstrated that this control of haemopoietic stem cell 
proliferation might be mediated by humoral factors produced locally 
in the haemopoietic tissue. In normal bone marrow a specific CFU-S 
proliferation inhibitor was detected of 50-100K daltons. In 
contrast in regenerating bone marrow a 30-50K daltons stimulator of 
CFU-S proliferation was detected. 
The experiments reported herein confirm the observations of 
Lord et al (1976). A 50-100K daltons inhibitor of CFU-S 
proliferation was extracted from normal rat and guinea pig bone 
marrow. This fraction reduced the proportion of CFU-S in 
regenerating bone marrow that were synthesizing DNA from >38% to 
<12%. But it did not affect the proliferation of normal bone 
marrow GM-CFC, confirming the cell line specificity of this 
inhibitor. The fraction also caused no reduction in the number of 
CFU-S per 105 cells grafted, indicating that it was not cytotoxic. 
The 50-100K daltons fraction from a rat thymus extract did not 
reduce the proportion of CFU-S synthesizing DNA, suggesting a 
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specific production of this inhibitor in haemopoietic tissues. 
Dose response studies (Figure 1.11) indicated that the 50-100K 
NBME fraction maximally inhibited CFU-S proliferation at doses over 
25ug/ml. It therefore appears that this inhibitor has a similar 
specific activity to that reported by Lord et al (1979). 
A CFU-S proliferation inhibitor has also been demonstrated by 
Frindel and Guigon (1977). This was found in a dialysate from 
homogenized frozen fetal calf bone marrow. This dialysate did not 
reduce the number of spleen colonies produced compared to controls, 
nor did it affect GM-CFC proliferation, (Frindel and Guigon 1978). 
But this inhibitor was of a much lower molecular weight than that 
described by Lord et al (1976) and herein. This is possibly due to 
the different methods used to produce the inhibitors. The 50-100K 
daltons NBIE inhibitor was produced by washing the freshly 
aspirated normal bone marrow cells in saline, and not by disrupting 
them in distilled water. In contrast, Frindel and Guigon (1977) 
produced a dialysate from frozen fetal bone marrow homogenized in 
water. 
Homogenization of the frozen bone marrow would release a large 
number of hydrolytic enzymes such as proteases from the cells, and 
dialysis produces optimal PH conditions for their action, 
(Fracassini 1979). Proteases could cleave an active low molecular 
weight moiety from a larger carrier molecule which would be small 
enough to pass into the dialysate. Protease inhibitors added to 
the bone marrow homogenate might prevent (or reduce) the appearance 
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of the CFU-S proliferation inhibitor in the dialysate. Burden et 
al (1979) have shown that protease inhibitors added to supernatants 
containing lymphokines will decrease the breakdown of leucocyte 
inhibition factor and thus increase the sensitivity of the assay. 
The fetal bone marrow used by Frindel and Guigon (1977) would 
probably contain a large proportion of proliferating haemopoietic 
stem cells. The presence of larger quantities of a CFU-S 
proliferation stimulator rather than an inhibitor would therefore 
be expected, (Lajtha and Wright 1978). But the CFU-S proliferation 
inhibitor is also present in regenerating bone marrow, albeit at 
much lower concentrations than the stimulator, (Wright and Lord 
1978). It is possible that the CFU-S proliferation stimulator is 
selectively lost in this system (eg more sensitive to hydrolytic 
enzyme breakdown) leaving only the inhibitor to be detected. 
1.5.3 A CFU-S Proliferation Stimulator 
A stimulator of CFU-S -proliferation was contained in a 
supernatant from murine fetal liver cells (Figure 1.12). This 
supports the observations of Wright and Lord (1977) that medium 
conditioned by haemopoietic tissues in which a large proportion of 
the CFU-S are in cycle, contains a CFU-S proliferation stimulator. 
The properties of a CFU-S proliferation stimulator, produced in 
human fetal liver, are discussed in Chapter 3. 
CHAPTERTW0 
THE 
1251UdR ASSAY 
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CHAPTER TWO : ABSTRACT 
The incorporation of 
1251-iododeoxyuridine (125IUdR) into the 
spleen of lethally irradiated mice reconstituted with haemopoietic 
cell suspensions has been used as an assay of the haemopoietic stem 
cell (CFU-S) content of the suspensions. Lethally irradiated mice 
were injected with different numbers of haemopoietic cells (1-20 x 
105). Five days later the mice were injected with 2pCi of 
125IUdR 
and sacrificed 2 hours later. There was a linear relationship 
between the log 125IUdR uptake into the spleen and femur and the 
log cell dose injected over a limited range. 
Pre-treatment of the haemopoietic cells with an S-phase 
specific cytotoxic drug (ie suicide) resulted in a reduction in the 
incorporation of 
125IUdR into the spleen. The reduction was 
similar to the suicide value obtained using the spleen colony 
technique. This technique was therefore used to investigate the 
kinetic properties of different CFU-S populations and to assay the 
humoral factors which modulate the growth fraction of these cells. 
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CHAPTER TWO 
THE 125IUdR ASSAY 
2.1 INTRODUCTION 
CFU-S proliferation stimulators and inhibitors have been 
assayed using the spleen colony suicide technique, (Becker et al 
1965), (Lord et al 1976), (Wright and Lord 1978) (see Section 
1.1). The seeding of CFU-S into the spleen and the subsequent 
colony formation, is'a random process, (Hendry 1973). When more 
than 15 to 20 colonies form in the spleen they become confluent and 
therefore uncountable. The standard error (SE) of the mean number 
of spleen colonies produced in a group of mice is proportional to 
when n is the total number of colonies and m the number of 
mice, (Blackett 1974). Because the number of colonies per spleen 
is limited, large numbers of mice are needed to achieve statistical 
significance in the suicide assay, (Hazout and Valleron 1977). 
The number of potential sources of CFU-S proliferation 
regulators is large. Biochemical characterisation of any putative 
CFU-S proliferation regulator would require the testing of many 
sub-fractions. An alternative rapid screening assay for the 
detection of these regulators was needed. If larger numbers of 
CFU-S could be detected in the spleen (ie increase 'n') the total 
number of mice needed in a suicide assay would be reduced. 
115 
When a CFU-S forms a spleen colony it both self-replicates and 
differentiates to form committed progenitors which subsequently 
form the recognisable precursors, there is thus a clonal expansion 
from one CFU-S, ( Metcalf and Moore 1971) (Figure 2.1). 
1251-iododeoxyuridine (125IUdR) is selectively incorporated into 
cells which are synthesizing DNA, (Hughes et al 1964). Instead of 
assaying the number of injected CFU-S directly by counting the 
colonies they form in the spleen, the total number of dividing 
cells they produce can be assayed by measuring the uptake of 
1251-iododeoxyuridine into the spleen. 
Hubner et al (1980)(1981) injected increasing numbers of 
nucleated bone marrow cells (0.1-40x106) into groups of lethally 
irradiated mice and measured the proliferative activity in the 
spleen 3 and 5 days later using 
125IUdR incorporation. When 
between 0.1 and 5x106 nucleated bone marrow cells were injected, 
there was a linear relationship between the log 
125IUdR 
uptake into 
the spleen and the log cell dose injected. This linear 
relationship suggested that over a limited range the 
125IUdR 
uptake 
into the spleen could be used as an indication of the number of 
CFU-S injected. Thus bone marrow cells could be exposed to a 
suicide agent and injected (at a dose on the linear part of this 
dose response line) into lethally irradiated mice. Five days later 
the 
125IUdR 
uptake produced by these suicided cells should be less 
than that produced by the untreated control cells. 
This assay would have the advantage that about 5 to 10x105 bone 
marrow cells would be injected as opposed to 5x104 in the spleen 
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THE HAEMOPOIETIC STEM CELL 
HSC 
SELF REPLICATION OF 
HAEMOPOIETIC STEM CELLS 
HAEMOPOIETIC STEM CELLS COMMITTED PRECURSORS RECOGNIZABLE 
PRECURSORS 
DIFFERENTIATED 
END CELLS 
Figure 2.1 
The haemopoietic stem cell can both self-replicate to maintain its 
own numbers, and differentiate to form progenitor cells, which are 
committed to produce cells of one haemopoietic lineage. 
f 
f 
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colony assay. Thus the number of CFU-S seeding to the spleen and 
forming colonies (assuming linearity) would be at least 10 times 
that in the spleen colony assay. It would therefore be expected 
that with equivalent numbers of mice, -the standard errors of the 
percentage CFU-S suicide values obtained using this 
125IUdR 
assay 
would be smaller than with the spleen colony technique. This is 
assuming that the number of proliferating cells that are produced 
in the spleen is directly proportional to the number of CFU-S 
injected 5 days previously. For instance, the clonal expansion per 
CFU-S could be less as the number of CFU-S injected is increased. 
This was demonstrated by Schofield and Lajtha (1969). The size of 
spleen colonies was inversely related to the number of cells 
injected and therefore the number of colonies in the spleen. This 
suggested that when there were less colonies in the spleen, 
increased amplification divisions had taken place in the colonies. 
This could occur by shortening the cell cycle time of the 
recognisable precursors, (Blackett 1968), (Hanna et al 1969). This 
would significantly increase cell production and therefore the size 
of the colony produced, (Lord and Lajtha 1974), (Lord et al 1977a). 
But on day 6 the number of cells per colony was independent of the 
graft size, (Schofield and Lajtha 1969). The uptake of 
125 IUdR 
into the spleen 5 days after grafting would therefore be a better 
reflection of the number of CFU-S injected than the day 9 uptake. 
The following principal investigations were carried out: - 
1. The uptake of 125 IUdR into the spleen and femur of lethally 
irradiated mice grafted with haemopoietic cells 3 or 5 days 
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previously was determined. 
2. Dose response studies were performed, of the 
125IUdR 
uptake 
produced by grafting different numbers of cells from different 
haemopoietic tissues into lethally irradiated mice. The linearity 
of these dose response relationships was assessed. 
3. Haemopoietic cells from different sources were exposed to 
Ara-C (as a suicide agent) or medium (as a control). These cells 
were injected into separate groups of lethally irradiated mice. 
The 125IUdR uptake into the spleen and femur of these mice was 
measured 5 days later. 
4. The CFU-S suicide values obtained using this '125IUdR assay' 
and the spleen colony technique were compared. 
5. The 125IUdR assay was used to detect CFU-S proliferation 
stimulators and inhibitors in a similar manner to the spleen colony 
technique (see Chapter One). 
2.2 EXPERIMENTAL DESIGN 
2.2.1 The 125I-iododeoxyuridine Assay 
Groups of lethally irradiated mice were injected with 
nucleated cells over the range of 1-20x105 cells. 3 or 5 days 
later, the mice were injected with 1 or 21iCi of 
125I-iododeoxyuridine (125IUdR) intravenously. The mice were 
sacrificed 2 or 24 hours later and the spleen and femurs removed. 
These tissues were fixed in Bouins for 24 hours. The tissues were 
washed daily in 70% alcohol and counted 1 or 5 days later (Figure 
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2.2). Mice treated as above but not grafted with haemopoietic 
cells after irradiation, were used as controls. 
Three sources of haemopoietic cells were assayed in this 
manner, normal murine bone marrow, the bone marrow from mice 
injected 24 hours previously with cytosine arabinoside (Ara-C), and 
15 days gestational age murine fetal liver. After these initial 
dose response studies the assay was standardised, mice being 
injected with 21. lCi of 
125IUdR 5 days after grafting with 
haemopoietic cells. 
2.2.2 Determination of the Proportion of 
1251-iododeoxyuridine 
Bound to DNA 
Lethally irradiated mice were grafted with either 3.2,7.3 or 
lOxlO5normal bone marrow cells, and injected with 2PCi of 
125IUdR 5 
days later. The spleens were removed 2 hours later and 
homogenized. The DNA in the spleen homogenate was precipitated 
with trichloro-acetic acid. The uptake of 
125IUdR into the 
precipitate and the medium above it were measured. 
2.2.3 The Removal of 125IUdR not Bound to DNA by Washing in 70% 
Alcohol 
Two hours after mice had been injected with 125IUdR the 
spleens were removed and fixed in Bouins. 24 hours later the 
125IUdR 
uptake per spleen was counted. The spleens were 
X-irradiation plus Haenatopoiatic cells 
Day "0 
125 lododeoxyuridine Model 
ý 
00 spleen femur 
removed and counted 
Figure 2.2 The 125IUdR Assay 
2 hours later 
Lethally irradiated mice were grafted with haemopoietic cells and 5 
days later injected with 125IUdR intravenously (1 or 2 pCis). The 
mice were sacrificed 2 or 24 hours later and the spleen and femurs 
removed. These were then washed in alcohol daily for 5 days and 
then counted. M "+-du«- 
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Figure 2.3 The 125IUdR Assay Suicide Technique 
Haemopoietic cells incubated for one hour, with Ara-C as a suicide 
agent or medium as a control. Between 5 and 7x105nucleated cells 
injected into lethally irradiated mice (820 rads). 5 days later 
mice injected with 2tCis of 125IUdR. Mice sacrificed 2 hours 
later, spleen and femurs removed, fixed in bouins, washed in 70% 
alcohol, and counted. 
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subsequently washed in 70% alcohol and the 125IUdR incorporated 
counted, every day for 4 days. 
2.2.4 Determination of Haemopoietic Stem Cell Kinetics using the 
125I-iododeoxyuridine Assay 
The proportion of haemopoietic stem cells (CFU-S) which were 
synthesizing DNA in: 
1. normal murine bone marrow, 
2. bone marrow from mice injected 24 hours previously with 
Ara-C, 
3. bone marrow from mice injected 4 days previously with mustine 
hydrochloride (M 2 ), and 
4. day 15 gestational age murine fetal liver, was determined 
using the 
125IUdR 
and spleen colony assays. 
Ara-C was used as a suicide agent to selectively kill CFU-S 
that were synthesizing DNA. After incubation with Ara-C or medium 
as a control between 5 and 7x105nucleated cells were injected into 
separate groups of lethally irradiated mice. The mice were 
injected with 
125IUdR 5 days later and the 2 hour incorporation 
into the spleen and femur determined (Figure 2.3). 
The difference between the incorporation of 
1251UdR into the 
spleens of mice injected with Ara-C or medium treated cells was 
compared. This was used as an indication of the proportion of 
CFU-S synthesizing DNA (Figures 2.3 and 2.4). These results were 
compared with those obtained using the spleen colony technique. 
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Figure 2.4 The 
125IUdR 
Assay Suicide Technique 
125IUdR uptake into the spleen of lethally irradiated mice injected 
with Ara-C (suicided) haemopoietic cells is less than in those 
injected with medium treated cells. This is because less viable 
CFU-S are injected and therefore the total number of proliferating 
cells produced (clonal expansion) is reduced. 
The bone marrow from mice treated 4 days previously with 
nitrogen mustard (HN2): - In the suicide experiments using the 
125 IUdR assay, 3.6x105cells were injected because there was a 
two-fold enrichment of CFU-S in the bone marrow of these mice, Cork 
(1979). In the spleen colony technique measurement of CFU-S 
suicide, with this post HN2 bone marrow high specific activity 
tritiated thymide was used (see Section 1.2.11). 
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2.2.5 The Assay of Haemopoietic Stem Cell Proliferation Regulators 
Using the Ara-C Suicide 125IUdR Assay 
Humoral regulators of CFU-S proliferation were assayed as 
described in Chapter One. Normal bone marrow was used to assay 
potential CFU-S proliferation stimulators, and bone marrow from 
mice treated 24 hours previously with Ara-C to assay potential 
inhibitors. All test cells were incubated with haemopoietic cell 
conditioned medium at a test responder cell ratio of 3: 1. 
Lyophilized Amicon fractions from these conditioned media were 
tested at a concentration of 50ug/ml. After incubation with these 
factors the proportion synthesizing DNA was determined using the 
Ara-C suicide technique. The 2 hour incorporation of 
125IUdR into 
the spleen was measured 5 days later. 
2.2.6 Haemopoietic Stem Cell (CFU-S) Seeding Efficiency Assayed 
using 
1251-iododeoxyuridine 
The 2 hour seeding efficiency of CFU-S from normal bone marrow 
and the marrow of mice injected 24 hours previously with Ara-C was 
compared using a modification of the 
125IUdR 
assay (Figure 2.5). 
Two groups of 3 lethally irradiated mice (primary recipients) were 
injected with 24x106 cells in 0.5mis of medium (supplemented with 
20 units of heparin/ml). Two hours later the mice were sacrificed 
and their spleens removed. These were aspirated into a single cell 
suspension in 7.5mls of medium. The suspension was passed through 
a 22Um nylon filter to remove stromal debris. 0.5mis of this 
suspension, ie, one fifth of a spleen, was injected into members of 
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CFU-S Seeding Efficiency ': 25lUdR Assay 
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Figure 2.5 
The relative seeding efficiency of CFU-S from different 
haemopoietic tissues measured using the 
125IUdR 
assay. See Section 
2.2.7 for explanation. 
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a second group of lethally irradiated mice (secondary recipients). 
Five days later these mice were injected with 2iCis of 125IUdR. 
They were sacrificed 2 hours later and their spleens removed. The 
spleens were fixed, washed in 70% alcohol and the 
125IUdR 
incorporation determined (vide supra) (Figure 2.5). 
In a second experiment day 15 gestational age murine fetal 
liver cells were incubated at 54x106 cells per ml with or without a 
NBME 50-100K daltons Amicon fraction (at 200pg/ml). After a5 hour 
incubation 50x106 cells were injected into separate groups of 
lethally irradiated mice (primary recipients). The seeding 
efficiency of the fetal liver CFU-S was determined as described 
above. 
2.2.7 Analysis of 125IUdR Incorporation Data 
The 2 hour uptake of 
125IUdR into the alcohol washed spleens 
and femurs of lethally irradiated mice grafted with haemopoietic 
cells was corrected to the day 0 for the batch of isotope used for 
each experiment. The machine background was determined from the 
mean counts per minute produced by empty counting chambers and 
subtracted from the uncorrected mean counts per spleen or femur. 
0.01pCi standards were produced from each isotope batch and counted 
at the same time as the spleens and femurs. A 0.079vCi 125, 
equivalent 124, standard was also counted at the same time as 
experimental tissues. 
The gamma counter machine efficiency was calculated by 
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dividing the number of counts the 124I standard produced per minute 
(-background) by the disintegrations that it should produce per 
minute, ie, 0.079 x 3.7 x 10 
4. The O. OluCi 125IUdR standard counts 
per minute were corrected to the day 0 for the particular batch of 
isotope and for the machine background (actual count). The number 
of counts that these standards produced (actual count) were 
compared with the number that they would be expected to produce 
(expected count), ie (O. O1x3.7x104) x machine efficiency. The 
spleen and femur counts were divided by the ratio of these two 
counts, ie actual O. Ol. Ci 125IUdR standard count/expected O. OlpCi 
125IUdR 
standard count. The counts of 
125IUdR 
uptake per spleen or 
femur were thus normalized for variations in the gamma counter 
efficiency and deviations of the supplied 
125IUdR 
activity from the 
supplier's specifications. 
2_3 RESULTS 
2.3.1 Dose response Studies: 1251-iododeoxyuridine Uptake into 
Spleen and Femur/Cell Dose Injected 
Lethally irradiated mice were grafted with between 1 and 20 x 
105normal bone marrow nucleated cells. Between 1 and lOx105cells 
injected there was a linear relationship betwen the log 125IUdR 
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uptake into the spleen 5 days later and the log cell dose injected 
(Figures 2.6 and 2.7). When more than lOxlO5normal bone marrow 
cells were grafted there was no significant increase in the 125IUdR 
incorporation into the spleen 5 days later (Figure 2.6). The log 
uptake of 
125IUdR into the femurs of these mice was linearly 
related to the log cell dose injected between 3 and 56x105 cells 
grafted (Figure 2.7). There was a small uptake of 
125IUdR into the 
spleens and femurs. of mice which had been lethally irradiated 3 or 
5 days previously but not grafted with bone marrow cells (Figure 
2.6, Table 2.1). 
The uptake of 
125IUdR into the spleens of mice grafted 3 days 
previously with between 1 and 56x105 normal bone marrow cells was 
not significantly higher than controls (Figure 2.8, Table 2.1). 
But in mice grafted with 121x105 normal bone marrow cells there was 
a large increase in the IUdR uptake into the spleen 3 days later 
(Figure 2.8). The uptake of 
125IUdR into the femurs of these mice 
was also only significantly greater than controls in those grafted 
with l2lxlO5cells (Figure 2.1A, Table 2.1). Table 2.1A compares 
the uptake of 
125IUdR into the spleens of mice sacrificed 2 or 24 
hours after the injection of lU Ci of 
125 IUdR. The uptake of 
125 IUdR into the spleens of mice sacrificed 2 hours after the 
125IUdR injection was higher for a set cell dose than those 
sacrificed after 24 hours. 
Mice were also grafted with bone marrow from mice which had 
been injected with Ara-C 24 hours previously. There was a linear 
relationship between the log cell dose injected and the log 125IUdR 
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Normal Bone Marrow 
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Figure 2.8 
The uptake of 125I-iododeoxyuridine into the spleen of lethally 
x-irradiated mice transplanted either 3 or 5 days previously with 
normal bone marrow cells. (loci 125IUdR injected) (Mean ± SE) 
(Log/Log plot) 
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uptake into the spleen and femur 5 days later, between 2 and 
10x105 cells injected (Figures 2.2A and 2.9).. In mice grafted with 
day 15 gestational age murine fetal liver cells the linear 
relationship between log cell dose injected and log 125IUdR 
incorporation into the spleen occurred over a wider range of cell 
doses 3 to 20x105(Figure 2.10). 
Approximately 95% of the 125IUdR incorporated into the spleens 
of lethally irradiated mice 5 days after grafting with normal bone 
marrow cells was contained in the trichloroacetic acid DNA 
precipitates (Table 2.2A). The small proportion of 
non-specifically bound IUdR was removed by washing the spleens 
twice in 70% alcohol (Table 2.3A). 
2.3.2 Key Observations from Dose Response Studies: Pertinent to 
the Use of the 
125IUdR Assay to Measure CFU-S Suicide 
1. In lethally irradiated mice grafted with between 1 and 
10x105normal bone marrow cells or bone marrow cells from mice 
injected with Ara-C 24 hours previously, there was a linear 
relationship between the log cell dose injected and the log 125IUdR 
uptake into the spleen 5 days later. 
In the lethally irradiated mice grafted with day 15 
gestational age murine fetal liver cells this linear relationship 
occurred over a wider range, 3 to 20xlG5cells injected. 
2. There was only a small uptake of 125IUdR into the spleens of 
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The uptake of 
1251-iododeoxyuridine into the spleen and femur of 
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bone marrow from mice which had been injected with 5mg of Ara-C 24 
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s: a a. e 8: 1 
Log Coll Dose Injected 
The uptake of 
125I-iododeoxyuridine into the spleen of lethally 
x-irradiated mice transplanted 5 days previollly with day 15 
gestational age murine fetal liver cells. (2pCi 5 IUdR injected) 
(Mean t SE, -- regression line with 95% confidence limits --). (Log/Log plot) 
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mice which had been lethally irradiated 5 days previously but not 
grafted with haemopoietic cells (Table 1). 
3. The uptake of 
125IUdR into the femurs of lethally irradiated 
mice 5 days after grafting haemopoietic cells was significantly 
less than into the spleen (Figures 2.7 and 2.9). There was also a 
linear relationship between the log cell dose injected and the log 
125IUdR 
uptake into the femur. But the gradient of the spleen dose 
response regression line was greater than that of the femur (eg 
Figure 2.7 spleen dose response regression line gradient - 1.09; 
femur - 0.60; and Figure 2.9 spleen = 1.86, femur = 1.09). 
2.3.3 Determination of the Proportion of CFU-S Synthesizing DNA 
(Suicide) in Different Haemopoietic Tissues, using the 
125I-iododeoxyuridine Assay 
In lethally irradiated mice grafted with Ara-C treated 
(suicided) normal bone marrow cells there was a small reduction in 
the 125IUdR incorporation into the spleen 5 days later compared 
with controls (Figure 2.11, Table 2.4A). In contrast there was a 
large reduction in the incorporation of 125IUdR into the spleen of 
mice grafted with Ara-C treated day 15 gestational age murine fetal 
liver cells compared with controls (Figure 2.11, Table 2.5A). 
Ara-C treatment of the marrow from mice treated 4 days 
previously with HN2 and the marrow from mice treated 24 hours 
previously with Ara-C also resulted in a large reduction in the 
125IUdR incorporation into the spleen compared with controls (Table 
125IUdR Assay: Ara-C Suicide 
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Figure 2.11 
125IUdR 
uptake into the spleens lethally irradiated mice grafted 
5 days previously with 7xlonormal bone marrow or day 15 
gestational age murine fetal liver cells. Comparison of mice 
injected with cells incubated with Ara-C or medium (Control). 
(Mean ± SE) 
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2.5A and 2.6A). These results were very reproducible (individual 
experiment data Tables 2.4A, 2.5A, 2.6A). The reduction in the 
125IUdR 
uptake into the femurs of mice grafted with Ara-C treated 
haemopoietic cells compared with controls is shown in Table 2.7A. 
This was not always consistent with that of the spleens. 
2.3.4 Determination of the Proportion of CFU-S Synthesizing DNA in 
Different Haemopoietic Tissues: Comparison of 
1251UdR 
and Spleen 
Colony Assay 
Figures 2.12,2.13,2.14, and 2.15 compare the reduction in 
the number of CFU-S per 105 Ara-C treated cells injected with 
controls. The proportion of CFU-S synthesizing DNA derived from 
this data is indicated. The reduction in the 125IUdR incorporation 
into the spleen of mice grafted 5 days previously with Ara-C or 
medium (control) treated haemopoietic cells is also indicated. 
The percentage reduction of the number of CFU-S and the spleen 
125IUdR incorporation in mice grafted with Ara-C treated cells 
compared with controls was similar for all haemopoietic tissues 
tested. Thus in mice injected with Ara-C treated normal bone. 
marrow cells there was a small reduction in the number of CFU-S and 
spleen 
125IUdR incorporation compared with controls (Figure 2.12). 
In contrast in mice grafted with cells from day 15 gestational 
murine fetal liver, bone marrow from mice treated with Ara-C 24 
hours previously and bone marrow from mice injected with HN2 4 days 
previously, there was a large decrease in the CFU-S and spleen 
125IUdR incorporation in mice injected with Ara-C treated cells 
I-)V 
Figure 2.12 
Z 33 
Q 
cn 
i 
a 
32 
19 
r3ý 
30 
Normal Bone Marrow 
25IUdR Assay Spleen Colony Assay 
Su c de% 15.9±18.0 
Comparison of spleen 
1251-iododeoxyuridine 
uptake and number of 
CFU-S per lo5cells grafted in mice injected with Ara-C or medium 
(Control) treated, normal bone marrow cells. (Mean ± SE) 
Day 15 Murine Fetal Liver 
'a (D 
U 
C7 
3.4 
Figure 2.13 
O 
3.3 
c 
3.2 
CD CL 
m 
3.1 
'o 
0 3.0 J 
Suicide% 
1 ')C 
+Ara-C El +m edium 
Fý 
i 
: 
39.5±12.1 
1 6.0 
C) 
ý c 
ý 
1 2.0 
ý 
0 n 
8.0 m 
fA 
n 
4.0 n 
t. o 
Comparison of pleen "'I-iododeoxyuridine uptake and the number of 
CFU-S per 10'cells grafted in mice injected with Ara-C or medium 
(Control) treated, day 15 gestational age murine fetal liver cells. 
(Mean ± SE) 
IiI 
compared with controls (Figures 2.13,2.14,2.15). 
2.3.5 Calculation of the Proportion of CFU-S Synthesizing DNA from 
the 125IUdR Assay Suicide Results 
The percentage reduction of the spleen 
125IUdR 
incorporation 
and the number of CFU-S per lO5cells injected, in mice grafted with 
Ara-C treated cells compared to controls were similar. But the 
proportion of CFU-S Synthesizing DNA cannot be directly calculated 
from the spleen 
125IUdR incorporation, unless it is directly 
proportional to the number of nucleated cells and therefore CFU-S 
injected. The following observations suggest that it is. 
The proportion of CFU-S synthesizing DNA was calculated by two 
methods for the spleen 
125IUdR incorporation data. 
(1). Directly: - 
% suicide Acpm - Bcpm 
Acpm 
where A is the uptake of 
125IUdR into the spleens of mice injected 
with haemopoietic cells which had been incubated 
with medium (ie control) (normalized counts per 
minute) 
and B is the uptake of 125IUdR into the spleens of mice injected 
with haemopoietic cells which had been incubated 
with Ara-C (normalized counts per minute) 
(2). By extrapolation of the log spleen 125IUdR uptake for the 
24 hour Ara-C Bone Marrow 
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Spleen Colonies 
58.3 F 15.4 
Comparison of spleen 
1251-iododeoxyuridine 
uptake and the number of 
CFU-S per 105cells grafted: in mice injected with the bone marrow 
from mice which had been treated with Ara-C 24 hours previously. 
This bone marrow was incubated with Ara-C or medium (control) prior 
to grafting. (Mean ± SE) 
Day 4 HN2Bone Marrow 
Figure 2.15 Suicitleqb 
tUdR Assay Spleen Colonies 
43 0±130 
Comparison of spleen 
125I-iododeoxyuridine 
uptake and the number of 
CFU-S per 1 cells grafted: in mice injected with bone marrow from 
mice which had been treated with EIN2 4 days previously. This bone 
marrow was incubated with Ara-C or medium (control) prior to 
grafting. (Mean ± SE) 
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Ara-C and control treated groups to the log/log dose response graph 
for the haemopoietic cells used. The antilog of the cellularities 
which these values corresponded to was multiplied by the 
concentration of CFU-S in the haemopoietic tissue, and the % of 
CFU-S synthesizing DNA determined using the equation in Figure 
2.16. 
The CFU-S suicide values calculated form the 125IUdR assay 
data by the two methods (1 and 2) were similar (Table 2.2). 
The log/log dose response graphs (Figures 2.7,2.9 and 2.10) 
were plotted linearly (Figures 2.17,2.18 and 2.19). At each cell 
dose injected the mean 
125IUdR uptakeI per 1Q5cells grafted is 
indicated. In the middle of the linear dose response graphs for 
normal bone marrow, 24 hour Ara-C bone marrow and day 15 murine 
fetal liver these values were very similar (Figures 2.17,2.18 and 
2.19). 
These observations suggested that the 125IUdR uptake into the 
spleen of lethally irradiated mice was directly proportional to the 
number of haemopoietic cells and therefore CFU-S injected 5 days 
previously. The proportion of CFU-S synthesizing DNA was therefore 
calculated directly from the spleen 125IUdR uptake data (Method 1). 
The CFU-S suicide values obtained by this method were not 
significantly different from those obtained using the spleen colony 
assay (p->0.1) (Table 2.3). When similar numbers of mice were used 
the standard errors of the means from the two assays were also 
similar (Table 2.3,2.4a, 2.5a, 2.6a and 2.8a). 
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Table 2.2 Comparison of CFU-S suicide values obtained using 
the spleen colony technique and the 
125IUdR 
assay 
suicide values from the I25IUdR assay calculated 
either directly or by extrapolation from a dose 
response regression line for the haemopoietic tissue 
used (Mean ± SE) 
Haemopoietic 
tissue 
Suicide % ±SE Suicide %± SE 
spleen colony 
125IUdR 
Assay 
technique regression 
line 
method 
Suicide %± SE 
125IUdR 
Assay 
direct count 
method 
Normal bone 
marrow 
24 hour Ara-C 
bone marrow 
15 day murine 
fetal liver 
20.2±6.6 11.9±20.0 
45.33±10.8 37.5 ± 8.0 
39.5 ± 12.0 68.0 ± 23.0 
10.7 ± 19.8 
. 
53.1 17.3 
56.0 + 17.0 
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The uptake of 
125IUdR into the spleens of lethally irradiated mice 
transplanted 5 days previously with normal bone marrow cells. Data 
from Log/Log graph 2.2 plotted linearly. (Mean ± SE -- regression 
line with 95% confidence limits) *125IUdR uptake per 10 cells 
injected. 
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Figure 2.18 
The uptake of 125IUdR into the spleens of lethally irradiated mice 
transplanted 5 days previously with the bone marrow of mice which 
had been injected with Ara-C 24 hours previously. Data from 
Log/Log graph 2.4 plotted liVIgrly. (Mean ± SE -- regression line 
with 95% confidence limits) * IUdR uptake per lO5cells injected. 
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The uptake of 
125IUdR into the spleens of lethally irradiated mice 
transplanted 5 days previously with day 15 gestational age murine 
fetal liver cells. Data from Log/Log graph 2.5 plotted linearly. 
(Mean ± SE -- regression line with 95% confidence limits) *125IUdR 
uptake per 105 cells injected. 
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Table 2.3 Comparison of CFU-S suicide values obtained using 
the spleen colony technique and the 
125IUdR 
assay 
(mean ± SE) 
Haematopoietic 
tissue 
Normal bone 
marrow 
24 hr Ara-C 
bone marrow 
Day 4 HN2 
bone marrow 
15 Day Foetal 
Liver 
Suicide 
Spleen Colonies 
20.2±6.6 
N= 45 
45.33 ± 10.8 
N=22 
40.5 ± 12.0 
N= 14 
39.5 ± 12.0 
N= 16 
% Suicide 
125IUdR 
Uptake 
18.4 ± 13.3 
N= 42 
42.8+14.8 
N= 12 
36.0 ± 17.0 
N=7 
56.0 ± 17.0 
N=8 
N= Number of mice per experimental group 
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The 125IUdR uptake per 105 cells injected over a short range 
was similar for each haemopoietic tissue tested (Figures 2.17,2.18 
and 2.19). But the 
125IUdR 
uptake per murine fetal liver CFU-S 
injected was significantly higher than that from normal or 24 hour 
Ara-C bone marrow (p-<0.01). The 
125IUdR 
uptake per CFU-S from day 
4 HDi2 bone marrow was <20% of that from the other haemopietic 
tissues (Table 2.4) (p-<0.05). 
2.3.6 The Detection of Inhibitors of CFU-S Proliferation Using the 
125IUdR Assay 
The bone marrow from mice injected with Ara-C 24 hours 
previously in which a large proportion of the CFU-S were 
synthesizing DNA (Table 2.6a and 2.8a) was incubated with a rat 
NBME 50-100K daltons fraction. This abrogated the reduction of the 
spleen 125IUdR uptake caused by incubation with Ara-C (ie it 
reduced the Ara-C suicide) to <5% (p=<0.01). Incubation with a 
30-50K daltons rat NBME fraction did not significantly reduce the 
Ara-C suicide (Figure 2.20, Table 2.9a). Incubation with a 50-100K 
daltons rat thymus extract fraction caused a slight reduction of 
the Ara-C suicide. A 50-100K daltons fraction from a pig NBME also 
eliminated the reduction of the spleen 
125 IUdR uptake after 
incubation of the '24 hour Ara-C bone marrow' with Ara-C (Figure 
2.21, Table 2.5). 
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Table 2.4 Comparison of the number of CFU-S and the 
125IUdR 
uptake per 105 cells injected, and the 
125IUdR 
uptake 
per CFU-S, for lethally irradiated mice grafted with, 
either normal bone marrow, 24 hour Ara-C bone marrow, 
day 4 HN2 bone marrow or day 15 murine fetal liver 
-GFU-S per 105 
125IUdR 
uptake per 
125IUdR 
uptake 
Haemopoietic cells injected 105 cells injected per CFU-S 
tissue ± SE cpm t SE cpm ± SE Olo 
Normal bone 
marrow 
24 hour Ara-C 
bone marrow 
Day 15 murine 
fetal liver 
HNZ Day 4 
bone marrow 
29.68 ± 1.4 566.3 ± 70.7 19.1 ± 13.3 
29.0 ± 2.3 505.4 ± 89.7 17.4 ± 19.3 
15.5 ± 1.0 558.1 ± 86.0 36.1 ± 16.7 
38.0 ± 3.6 104 .0{ 13.0 
2.7 + 15.7 
Values of 
125IUdR 
uptake per 105 cells injected calculated 
from same point on each dose response curve (3-4 x 105 cells) 
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The uptake of 
175IUdR into the spleens of lethally irradiated mice 
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The uptake of 
t25IUdR into the spleens of lethally irradiated mice 
transplanted 5 days previously with 24 hour Ara-C bone marrow. The 
bone marrow was incubated with either medium (control) or a 50-100K 
fraction from a pig bone marrow extract prior to suiciding with 
Ara-C or medium control. (Mean ± SE) (Data as in Table 2.9a) 
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Table 2.5 The effect of pig (PBME 50 - 100 K) and guinea pig 
(GPBME 50-100 K) bone marrow extracts on the 
percentage suicide of CFU-S following in vitro 
incubation with Ara-C, of CFU-S obtained from the 
bone marrow of mice treated 24 hours previously 
with Ara-C 
CFU- S/ 105 cells 
(± SE) 
% suicide of CFU- S 
(± SE) 
control + medium 40.4 
± 6.9 36.1 + 11.7 
control + Ara-C 25.8 
± 1.7 
PBME (50-100 K) + medium 35.2 ± 1.9 6.5 +- 8.0 
PBME (50-100 K) + Ara-C 32.9 + 2.2 
GPBME (50-100 K) + medium 37.1 ± 2.5 2.4 + 11.3 
GPBME (50-100 K) +Ara-C 36.2 t 3.4 
PBME :- Pig bone marrow extract 
GPBME :- Guinea pig bone marrow extract 
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2.3.7 Detection of CFU-S Proliferation Inhibitors: Comparison of 
125IUdR 
and Spleen Colony Assay 
The CFU-S suicides calculated from the 
125IUdR 
assay (Figures 
2.20 and 2.21, Tables 2.9a and 2.10a) were similar to those 
obtained using the spleen colony assay (Tables 2.5 and 2.6). 
The bone marrow from mice injected with HN2 four days 
previously, in which a large proportion of the CFU-S were 
synthesizing DNA (Tables 2.5a and 2.8a) was also incubated with the 
50-100K daltons rat NBME fraction. This significantly reduced 
(p-<0.01) the high Ara-C suicide. This was detected with both the 
125IUdR and spleen colony assay (Figure 2.22, Table 2.11a). 
2.3.8 50-100K NBME: Effect on Spleen 
125IUdR Uptake 
In most experiments incubation of a bone marrow suspension in 
which a large proportion of the CFU-S were synthesizing DNA, with a 
50-100K daltons NBME fraction also significantly reduced (Figure 
2.22; p-<0.01) the 
1251UdR 
uptake per 105cells injected, compared 
to controls (Figures 2.20,2.22; Tables 2.8a and 2.10a). This 
treatment did not alter the number of CFU-S per 105 cells injected 
(Tables 2.5,2.6). But the diameter of the spleen colonies in mice 
grafted with bone marrow cells treated with a 50-100K NBME fraction 
were significantly less (p-<0.01) than controls (Figure 2.23). The 
percentage reduction of the spleen colony diameter was similar in 
magnitude to the reduction of the spleen 
125IUdR 
uptake compared to 
controls (Figure 2.23). 
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Table 2.6 The effect ofAmicon fractions from normal 
bone marrow and thymus extracts on the 
proportion of CFU-S synthesizing DNA 
Treatment of CFU-S per 105 
bone marrow cells injected 
during incubation ± SE 
17.8+ 1.6 
Control 
29.0 ± 2.3 
50 - 100 K 
rat NBME 
30 - 50 K 
rat NBME 
50 - 100 K 
rat thymus extract 
26.0 + 2.1 
25.6 ± 2.5 
15.9 ± 1.7 
23.9±2.4 
19.1 + 1.9 
31.7 ± 3.2 
Suicide %± SE 
38.5 ± 12.0 
-1.6 
± 12.9 
33.5 + 15.0 
39.9±14.2 
NBME :- Normal bone marrow extract 
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The uptake of 
125IUdR into the spleens of lethally irradiated mice 
transplanted 5 days previously with day 4 HN2 bone marrow. The 
bone marrow was incubated with medium (control) or a 50-100K 
daltons fraction from a rat bone marrow extract, prior to suiciding 
with Ara-C. This is compared with the spleen colonies produced by 
day 4 HN2 bone marrow treated in the same man but suicided with 
high specific activity tritiated thymidine. ( IUdR data as in 
Table 2.10a) (: dean ± SE) 
26 
C 
2.5 
Q 
m 
m 
2a 
c 
23 
0 
22 
Figure 2.23 
Control NBME Control NBME 
50-100K 50-100K 
+Ara-t 
ý +Metlium Fý 
m 
r 
10.0 ' 
m 
3 
C 
9.0 
O 
N 
n 
0 
80ö 
O 
3 
7.0 m 
3 
ý8.0 
0 
The uptake of 
125IUdR into the spleens of lethally irradiated mice, 
transplanted 5 days previously with day 4 HN2 bone marrow. The 
bone marrow was incubated with medium (control) or a 50-100K 
daltons fraction from a normal rat bone marrow extract, prior to 
suiciding with Ara-C. This is compared with the mean maximum 
diameter of the spleen colonies of mice transplanted with day 4 HN7 
bone marrow, treated in the same manner but suicided with high 
specific activity 
3HTdR. (Mean ± SE) (125IUdR data as in Table 
2.10a). 
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2.3.9 Stimulators of CFU-S Proliferation: Detection Using the 
125IUdR Assay 
There was a small reduction (<16%) of the spleen 125IUdR 
uptake in lethally irradiated mice grafted with Ara-C treated 
normal bone marrow cells compared to controls (Table 2.4a). This 
was increased from <16% to >36% during an incubation with a human 
fetal liver supernatant (HFLS) at a 3: 1 test responder ratio 
(Figure 2.24; Table 2.7). In mice grafted with HFLS treated 
normal bone marow cells the spleen 
125IUdR uptake per 5x105 cells 
injected was significantly higher than controls (Table 2.7). Table 
2.8 summarises the comparison between CFU-S suicide values obtained 
from both the spleen colony and 
125IUdR 
assay. 
2.3.10 The Relative Seeding Efficiency of CFU-S from 
Different Haemopoietic Tissues: Determination Using the 125IUdR 
Assay 
The uptake of 
125IUdR into the spleens of the secondary 
recipients receiving one fifth of a spleen from a primary recipient 
grafted with 24 hour Ara-C bone marrow was half (49.5 + 23.6%) of 
that from those receiving spleen cells from normal bone marrow cell 
grafted primary recipients (Figures 2.25 and 2.6). 
The spleen 125IUdR uptake of secondary recipients receiving 
spleen cells from primary recipients grafted with murine day 15 
gestational age fetal liver cells is indicated in Figure 2.26. 
Incubation of the murine fetal liver cells with a 50-100K dalton 
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The uptake of 
125IUdR into the spleens of lethally irradiated mice 
transplanted with normal bone marrow 5 days previously. The bone 
marrow was incubated with medium (control) or a HFLS at a 3: 1 test 
responder cell ratio prior to suiciding with Ara-C. (Data from 
Table 2.7) (Mean ± SE) 
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Table 2.8 Comparison of spleen colony technique and 
125IUdR 
assay. Different sources of haemopoietic cells effect 
of 50-100 K dalton NBME fraction, and human fetal 
liver supernatant 
Haemopoietic % Suicide Spleen % Suicide 
125 
IUdR 
Tissue Treatment Colonies 
Normal bone 
marrow 
Uptake 
20.2 ± 6.6 18.4 ± 13.3 
N=45 N=42 
Normal bone 
marrow + human 
fetal liver 
supernatant 
24 hour Ara-C 
bone marrow 
24 hour Ara-C 
Bone marrow + 
50-100 K BME 
fraction 
Day 4 HNZ bone 
marrow 
Day 4 HN2 bone 
marrow 
+ 50-100 K BME 
fraction 
15 day murine 
fetal liver 
45.5 ± 13.2 
N=20 
45.33 ± 10.8 
N=22 
11.53 i 8.8 
N=20 
40.5 + 12 
N=14 
-0.7 
± 11.8 
N= 14 
39.5 ± 12.0 
N= 16 
45.5 + 12.5 
N=18 
42.8 ± 14.8 
N= 12 
-0.6 ± 19.3 
N=23 
36.0 + 17 
N=7 
7.1 ± 18.3 
N=? 
56.0 ± 17.0 
N=8 
I55 
CFU-S Seeding Efficiency25IUdR Assay 
. "ý 
ý 
Normal 24 hour Ara-C 
Bone Marrow Bone Marrow 
Figure 2.25 
The uptake of 
125IUdR into the spleens of lethally irradiated mice 
(secondary recipients) which were transplanted 5 days previously 
with one fifth of a spleen from a primary recipient. The spleens 
were removed from the lethally irradiated primary recipients 2 
hours after the grafting of either normal bone marrow or 24 hour 
Ara-C bone marrow cells. (Mean ± SE) 
Figure 2.26 
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The uptake of 
125IUdR into the spleens of lethally irradiated mice 
(secondary recipients) which were transplanted 5 days previously 
with one fifth of a spleen from a primary recipient. The spleens 
were removed from the lethally irradiated primary recipients 2 
hours after the grafting of day 15 gestational age murine fetal 
liver cells. The MFL cells were incubated either with medium 
(control) or a 50-100k daltons fraction from a rat bone marrow 
extract prior to grafting. 
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fraction from a normal bone marrow extract, prior to grafting into 
primary recipients, did not alter the spleen 
125IUdR 
uptake that 
the spleen cells from these mice produced in secondary recipients 
(Figures 2.26 and 2.6). 
2.4 DISCUSSION 
2.4.1 125IUdR Assay: Dose Response Studies 
2.4.1.1 Day 5 125IUdR uptake 
In lethally irradiated mice grafted with normal bone marrow 
cells, there was, over a limited range, a linear relationship 
between the log cell dose injected and the log 
125IUdR 
uptake into 
the spleen 5 days later. This supports the observations of 
Cudkowiez et al (1964) and Hubner et al (1980), (1981). This linear 
relationship also occurred when mice were grafted with 24 hour 
Ara-C bone marrow and day 15 gestational age murine fetal liver 
cells. 
There was also a linear relationship between the log 125IUdR 
uptake into the femur and the log cell dose injected 5 days 
previously. But the 125IUdR uptake per unit number of nucleated 
cells injected was less in the femur than the spleen. The increase 
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in 125IUdR uptake per unit increase in cell dose injected was also 
less in the femur than the spleen (ie gradient of dose response 
line was less). The slower recovery of the haemopoietic tissue in 
the femur of irradiated bone marrow grafted mice compared to the 
spleen has been reported frequently, ('Micklem and Loutit 1966). 
Lahiri and Van Putten (1969) reported an earlier recovery of the 
total cellularity and CFU-S numbers in the spleen compared to the 
femur. This was. attributed to a differential seeding of CFU-S to 
the two organs. Schofield (1970) demonstrated a slower rate of 
CFU-S production in the femur compared to the spleen of lethally 
irradiated bone marrow grafted mice. This would suggest that there 
was not just a quantitative difference in the CFU-S seeding to the 
spleen and femur, but that the CFU-S seeding to the femur were 
qualitatively different from those that seeded to the spleen, 
and/or the microenvironment in the two tissues was different. 
2.4.1.2 Day 3 
. 
spleen 
125IUdR 
uptake 
Much higher doses of cells were needed to produce a 
significant rise in the spleen 
125IUdR 
uptake 3 as opposed to 5 
days after grafting. Hubner et al (1980) also made this 
observation. The 
1251UdR 
uptake into the spleen is a product of 
the clonal expansion produced by each CFU-S injected. This clonal 
expansion is produced by a combination of CFU-S self-replication 
and differentiation to produce the committed progenitors and 
recognisable precursors. The obvious reason for the higher spleen 
125IUdR 
uptake per unit number of cells injected on day 5, is that 
there has been more time to produce a bigger clone. 
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There is a lag time before the CFU-S start to proliferate in 
the irradiated host. Schofield and Lajtha (1969) grafted lethally 
irradiated mice with different doses of bone marrow cells. They 
demonstrated a delay in the onset of CFU-S proliferation, which was 
inversely related to the number of bone marrow cells injected. 
This phenomenon may also be partially repsonsible for the form of 
the day 3 spleen 125IUdR uptake dose response graph. 
2.4.1.3 2-hour and 24-hour incorporation of 125IUdR 
In this study the incorporation of 
125IUdR into the spleens of 
lethally irradiated mice 5 days after bone marrow transplantation 
was higher if they were sacrificed 2 as opposed to 24 hours after 
the 
125IUdR injection. Wangenheim et al (1980) also demonstrated 
this phenomenon. They also showed that more than 90% of the 
125IUdR 
injected 24 hours previously was bound to DNA in the spleen 
cells. From this it was concluded that the loss of 
125IUdR from 
the spleen between 2 and 24 hours was due to the removal of 
125IUdR 
that was not bound to DNA. But in this study more than 90% of the 
125IUdR injected into mice 2 hours previously was also bound to the 
spleen cell DNA. This would suggest that the loss of 
125IUdR from 
the spleen between 2 and 24 hours was not due to the removal of 
unbound 
125 MR. It is also hard to conceive that sufficient cells 
which had incorporated 
125IUdR 
would migrate from the spleen 
between 2 and 24 hours to explain this loss. 
Both IUdR per se and the radioactive emissions from the 125I 
bound to it are toxic to cells, (Dethlefsen 1974), (Commerford et al 
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1980). It is therefore possible that some of the cells that 
incorporated 125IUdR may have been killed by its combined chemical 
and radiotoxicity. The lysis of these cells would be accompanied 
by the loss of 
125IUdR from the spleen. The 125IUdR released by 
dead cells is not normally re-utilized by other dividing cells, 
(Dethlefsen 1970). This could account for the loss of 
125IUdR from 
the spleen between 2 and 24 hours. But the significance of 
125IUdR 
toxicity at the-dose used is debatable, (Myres and Feinendegen 
1976). 
2.4.1.4 Linearity of dose response relationships 
The linear dose response graphs demonstrated that over a 
limited range the 
125IUdR 
uptake into the spleen was directly 
proportional to the number of nucleated cells and therefore CFU-S 
injected. This suggests that over a limited range the total number 
of proliferating cells (ie clonal expansion) produced by each CFU-S 
is independent of the number of CFU-S injected. 
The number of spleen colonies produced by day 9 is directly 
proportional to the cell dose injected, (Till and McCulloch 1961). 
Schofield and Lajtha (1969) demonstrated that the size of the 
spleen colonies formed was independent of the cell dose injected 6 
days previously. That is the number of cells produced by each 
CFU-S (clonal expansion) was independent of the number of colonies 
in the spleen. This supports the observation of a direct 
proportionality of spleen 
125IUdR uptake on day 5 with the cell 
dose injected. But Schofield and Lajtha (1969) demonstrated that 
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by day 9 the size of spleen colonies was inversely related to the 
cell dose injected. Thus by day 9 the colonies produced were 
larger if there were less of them in the spleen. Consequently on 
day 9 the 
125IUdR 
uptake in the spleen would not be directly 
proportional to the cell dose injected. This could be due to 
increased amplification divisions in the committed progenitor and 
recognizable precursor compartments, (Lord and Lajtha 1974). This 
could be brought about by decreasing the cell cycle time of cells 
within these compartments. In addition, the proportion of cells in 
the colonies which continue to proliferate rather than 
differentiate could be increased. The uptake of 125IUdR into the 
spleen of lethally irradiated mice 5 days but not 9 days after 
grafting with haemopoietic cells, was therefore a convenient assay 
of the number of CFU-S injected. 
2.4.2 Determination of Proportion of CFU-S Synthesizing DNA 
(Suicide) in Different Haemopoietic Tissues, Using the 
1251-iodeoxuridine Assay 
2.4.2.1 Principal observations 
The percentage reduction of the day 5 spleen 
125IUdR 
uptake in 
mice grafted with Ara-C treated (suicided) normal bone marrow cells 
compared with controls was small. In contrast the reduction of the 
day 5 spleen 125IUdR uptake in mice grafted with Ara-C treated 
murine fetal liver; day 4 HN2 bone marrow; or 24 hour Ara-C bone 
marrow cells was large compared to controls. 
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The 125IUdR assay could therefore distinguish between a 
haemopoietic tissue in which a small proportion of the CFU-S were 
synthesizing DNA (NMBM) from one in which a large proportion were 
synthesizing DNA (MFL). The reduction in both the number of spleen 
colonies and the day 5 spleen 
125IUdR 
uptake, in lethally 
irradiated mice grafted with Ara-C treated cells compared with 
controls, was similar for all haemopoietic tissues tested. The 
standard errors of the percentage suicide values, calculated from 
the spleen colony technique and the 
125IUdR 
assay were similar when 
equivalent numbers of mice were used (Table 2.3). The 
125IUdR 
assay is therefore an equivalent method to the spleen colony 
technique for determining the proportion of CFU-S synthesizing DNA 
in a haemopoietic tissue. 
2.4.2.2 Femoral 125IUdR uptake: determination of CFU-S 
suicide 
The difference in the 
125IUdR 
uptake into the femurs of mice 
injected with suicided or control treated haemopoietic cells was 
inconsistent. This could not therefore be used as a reliable assay 
of the proportion of CFU-S in S-phase. This observation was 
predictable from the dose response studies. The uptake of 
125IUdR 
per CFU-S and the gradient of the dose response line, were both 
less for the femur than for the spleen. The absolute reduction in 
125 
femoral IUdR uptake produced by injecting less CFU-S was 
therefore smaller than in the spleen. This was probably the main 
reason for the greater variability of CFU-S suicide values 
calculated from femoral as opposed to splenic 
125IUdR 
uptake data. 
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2.4.3 The 125IUdR Assay: Detection of CFU-S Proliferation 
Regulators 
2.4.3.1 CFU-S proliferation inhibitors 
Incubation of a regenerating bone marrow (4 days after HN2 or 
24 hours after Ara-C) with a 50-100K daltons NBME fraction, reduced 
the CFU-S suicide. signifcantly (>35% to <10%). A 30-50K daltons 
NBM fraction, and a 50-100K daltons fraction from a thymus extract 
did not affect the CFU-S suicide. Equivalent results were obtained 
with both the 
125IUdR 
assay and the spleen colony technique. 
In mice injected with bone marrow cells which had been 
incubated with a 50-100K daltons NBME fraction the 
125IUdR 
uptake 
per 1Q5cells injected was significantly less than for controls (in, 
all but one experiment). In contrast, the number of spleen 
colonies produced per 105 cells injected was not reduced by this 
treatment, as reported by Lord et al (1976). This indicates that 
incubation with the 50-100K daltons NBME fraction, reduced the 
clonal expansion and therefore the 
125IUdR 
uptake into the spleen 
per CFU-S injected. In support of this concept, exposure of bone 
marrow to the 50-100K NBME fraction also reduced the size of the 
spleen colonies which it formed. This also suggests that the size 
of the clone produced by each CFU-S had been reduced. It appears 
that exposure of CFU-S to a specific proliferation inhibitor 
subsequently reduces the clonal expansion which they produce. This 
could be due to an increase in the lag phase before they commence 
proliferation in the irradiated host. The irradiated mouse bone 
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marrow contains high levels of a specific CFU-S proliferation 
stimulator, (Lord et al 1977b). The rapid initiation of CFU-S 
proliferation after transplantation would therefore be envisaged. 
But it is plausible that the CFU-S could become saturated with 
inhibitory signals, during the in vitro incubation with the 50-100K 
NBME inhibitor. Subsequently when transplanted into irradiated 
mice a longer exposure to the stimulatory signals would be needed 
before the CFU-S. would start proliferating. Loss of one or two of 
the initial CFU-S divisions would result in a significant reduction 
in the size of the clone produced in 5 days. 
But from Figure 2.23 it can also be seen that bone marrow 
incubated with just high specific activity HTdR formed smaller 
spleen colonies than controls. Lord et al (1974a) demonstrated 
that high specific activity 3HTdR (>24 curies/millimole) kills more 
CFU-S than are in DNA synthesis. This could be prevented if the 
3HTdR 
was followed by a 4000 fold excess of cold thymidine. It 
appears that small quantities of 
3HTdR incorporated into CFU-S 
during interphase can subsequently kill them. 
In these experiments 3HTdR of 15Ci/mMole specific activity was 
used. Lord et al (1974a) demonstrated that this would not kill 
more CFU-S than were in DNA synthesis. But it is plausible that 
the uptake of even small quantities of 
3HTdR by CFU-S in interphase 
could inhibit their subsequent proliferation, inhibition of cell 
proliferation being a much more subtle event than cell killing. 
Although no spleen colony size data is available, from the 
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125IUdR experiments it appears that Ara-C does not affect the 
clonal expansion produced by injected CFU-S. If Ara-C did reduce 
the clone size produced by a CFU-S, higher CFU-S suicide values 
would be obtained with the 
125IUdR 
assay than the spleen colony 
technique. This is because as well as killing CFU-S the Ara-C 
would reduce the clonal expansion produced by the remaining CFU-S. 
Equivalent CFU-S suicides were obtained using the two assays (see 
Section 2.3.3 and 2.4.2). 
2.4.3.2 CFU-S proliferation stimulators 
The 125IUdR assay could also be used to detect stimulators of 
CFU-S proliferation. The proportion of NMBM CFU-S synthesizing DNA 
detected with both the 125IUdR technique (Table 2.7) and the spleen 
colony technique (Table 3.1) was increased significantly during an 
incubation with a human fetal liver supernatant (HFLS) (see Chapter 
Three). Incubation with a HFLS did not increase the number of 
spleen colonies formed per 105 cells injected. In contrast the 
125IUdR 
uptake per 5xl05cells injected was significantly higher if 
they had been incubated with a HFLS. Thus incubation of normal 
bone marrow with a CFU-S proliferation stimulator increases the 
clonal expansion per CFU-S injected. This could be due to the 
opposite mechanism to that discussed in Section 2.4.3.1 for the 
CFU-S proliferation inhibitor. The CFU-S proliferation stimulator 
could decrease the lag phase before the CFU-S start proliferating 
in the irradiated host. The total number of proliferating cells 
produced by each CFU-S in 5 days would therefore be increased. 
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2.4.4 CFU-S Clonal Expansion 
2.4.4.1 CFU-S proliferation stimulator and inhibitor: effect 
on CFU-S clonal expansion 
Exposure of CFU-S to specific proliferation inhibitors and 
stimulators, reduced and increased respectively the clone size 
which they produced. From this it would be expected that CFU-S 
from fetal liver in which the CFU-S are proliferating rapidly would 
produce a larger clonal expansion, than CFU-S from normal bone 
marrow in which they are slowly proliferating. This was 
demonstrated (Table 2.3). The 125IUdR uptake per MFL CFU-S was 
significantly higher than that per NMBM CFU-S. But it is unlikely 
that the kinetic status of the CFU-S is the major reason for this 
difference. It is more likely that the difference between the 
clonal expansion produced by fetal liver and normal bone marrow 
CFU-S is due to a qualitative difference of the CFU-S which they 
contain. 
2.4.4.2 Differences in CFU-S clone size, dependent on source 
of CFU-S 
Schofield (1970) transplanted lethally irradiated mice with 
cells from different haemopoietic tissues and measured the growth 
rate of the transplanted CFU-S. The doubling time of CFU-S from 
fetal liver was two thirds of those derived from normal bone 
marrow. This suggested that fetal liver CFU-S had a greater 
capacity for self renewal than those from normal bone marrow. 
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Metcalf and Moore (1971) transplanted irradiated mice with fetal 
liver or adult bone marrow cells. The spleen colony cells derived 
from these two sources were serially transplanted through 
irradiated hosts. The CFU-S derived from fetal liver could go 
through 6 transfers before CFU-S renewal ceased, while those from 
adult bone marrow only 3. 
Micklem (1972) demonstrated that CFU-S from fetal liver 
produced larger spleen colonies than those from normal bone marrow. 
The 125I'JdR uptake in the fetal liver derived spleen colonies was 
also higher than in those derived from normal bone marrow. It has 
been postulated that the CFU-S from fetal liver represent an 
earlier subpopulation in a CFU-S age structure, (Schofield 1970), 
(Micklem and Ogden 1976). These CFU-S tend to initially self renew 
rather than differentiate and therefore have the potential to form 
larger clones. In support of this hypothesis Rosendaal et al 
(1979) demonstrated that the spleen colonies in mice injected with 
fetal liver cells contained more CFU-S than those produced in 
normal bone marrow grafted mice. 
In contrast to fetal liver, the uptake of 
125IUdR per CFU-S 
produced by day 4 HN2 bone marrow was significantly less than that 
produced by normal bone marrow CFU-S (table 2.4). This suggests 
that the CFU-S in day 4 HN2 bone marrow had a lower 
self-replicative potential than those from normal bone marrow. 
This has been demonstrated for bone marrow CFU-S from mice treated 
with other cytotoxic drugs. Schofield and Lajtha (1973) injected 
mice with isopropyl methyl sulphonate (IMS). Bone marrow from 
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these mice and normal controls was injected into separate groups of 
lethally irradiated mice. The spleen colonies produced were then 
grafted into secondary recipients to determine the number of CFU-S 
they contained. The spleen colonies produced by IMS treated bone 
marrow contained virtually no CFU-S while 70% of those from normal 
bone marrow grafted controls contained CFU-S. 
It was suggested that IMS had killed the CFU-S that were early 
in an age structure. The remaining CFU-S, those late in the age 
structure, produced colonies, but these CFU-S differentiated rather 
than self-replicated. Consequently the spleen colonies which they 
produced contained few CFU-S, (Schofield and Lajtha 1973). 
Consequently the size of the clone (colony) produced by these late 
CFU-S would also probably be smaller than those produced by normal 
bone marrow CFU-S, (Micklem and Ogden 1976). 
The converse situation to that in the bone marrow of IMS 
treated mice, was found in mice injected with 5 fluorouracil (5-FU) 
or hydroxyurea (HU), (Hodgson and Bradley 1979), (Rosendaal et al 
1979). The spleen colonies produced in mice grafted with bone 
marrow from 5-FU or HU treated mice were injected into secondary 
recipients to determine the number of CFU-S they contained. The 
colonies produced by the 5-FU or HU treated bone marrow contained 
more CFU-S than those produced by normal bone marrow. It was 
suggested that 5-FU and HU killed the 'late' CFU-S, ie those with a 
low self-replicative potential. The early CFU-S with a high 
self-replicative potential were thus spared and so were able to 
form colonies. The bone marrow of mice treated 24 hours previously 
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with Ara-C when injected into lethally irradiated mice produced an 
125IUdR 
uptake per CFU-S similar to normal bone marrow (Table 2.4). 
The 125IUdR uptake into the spleen of lethally irradiated mice 
grafted with haemopoietic cells has been assayed. This can be 
expressed as the 
125IUdR 
uptake per CFU-S injected. A higher 
125IUdR 
uptake produced per CFU-S indicates an increase in the 
number of proliferating cells which it has produced. It is most 
likely that this reflects a greater CFU-S self-replication. As 
discussed, the proportions of CFU-S with different self-replicative 
potentials are not constant in different haemopoietic tissues. 
There may also be variations in the delay before the CFU-S start to 
proliferate in the irradiated host (see Section 2.4.3). 
2.4.5 Potentials of the 125IUdR Assay 
2.4.5.1 To determine CFU-S suicide 
The 125IUdR assay can be used in conjunction with Ara-C 
suicide to determine the proportion of CFU-S synthesizing DNA in 
haemopoietic cell suspensions. The results obtained were similar 
to those from the spleen colony technique. But the standard errors 
of the suicide values obtained from the two techniques were in most 
experiments the same for equivalent numbers of mice. In some 
experiments they were higher in the 125IUdR assay (Tables 3.1, 
3.2). 
Twice as many CFU-S were injected in the 125IUdR assay as in 
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the spleen colony technique. On day 5 when the 
125IUdR 
was 
injected, small 'microcolonies' could be seen on the surface of the 
spleen. There were about 150 of these microcolonies per spleen (ie 
10 times the number of colonies which could be counted on day 9). 
But it was not possible to count these microcolonies accurately 
because of their small size and diffuse nature. It is pertinent to 
Section 2.4.4 that the microcolonies produced by fetal liver cells 
appeared to be larger than those produced by normal bone marrow 
cells. If the microcolonies had been countable the standard error 
of the mean count for a group of mice would have been much smaller 
than that obtainable with the conventional spleen colony technique, 
(Blackett 1974), (Hazout and Valleron 1977). 
Higher errors than expected were obtained with the 
125IUdR 
assay because of its extreme sensitivity (illustrated in Section 
2.4.4). This is because the 
125 IUdR assay does not only measure 
the number of colonies (microcolonies) produced by an injected 
inoculum of haemopoietic cells. It also measures the size of all 
the colonies, because it measures the total number of proliferating 
cells produced. In contrast, the spleen colony technique is an all 
or none assay; the size of the colonies not being relevant to the 
colony count. 
The size of the clone produced by a CFU-S will be determined 
by the self-replicative potential of the CFU-S, (Schofield 1970), 
(Micklem and Ogden 1976). The number of divisions within the 
committed progenitor and recognizable precursor compartments will 
also affect the clone size, (Lord and Lajtha 1974), (Metcalf 1977). 
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The number of divisions within these compartments are responsive to 
many stimuli, (Blackett 1968), (Hanna et al 1969), (Lajtha 1975), 
(Lord et al 1977a). An increase or decrease of one or two 
divisions within these compartments will have a significant effect 
on the final size of the clone produced, (Lord and Lajtha 1974). 
Bacterial and viral infections can alter both CFU-S proliferation 
and differentiation, (Lajtha 1975). 
The degree of clonal expansion from each CFU-S is therefore 
responsive to many factors. This is probably responsible for the, 
wide distribution of spleen 
125IUdR 
uptakes in mice from one 
treatment group. Irradiated mice often become infected. Minor 
infections reduce the size of colonies and make them more difficult 
to count. This type of infection would therefore significantly 
125 
affect the spleen IUdft uptake. 
2.4.5.2 Assay of CFU-S proliferation stimulators and 
inhibitors 
It is possible to assay CFU-S proliferation stimulators and 
inhibitors using an Ara-C suicide in conjunction with the 125IUdR 
assay. But this only has significant advantages over the spleen 
colony technique if the mice are completely free from infections. 
Four key observations were made from the testing of CFU-S 
proliferation regulators with the 125IUdR assay: 
1. Incubation of a regenerating bone marrow suspension with a 
171 
CFU-S proliferation inhibitor decreased the 
125IUdR 
uptake per unit 
number of cells injected compared with controls. 
2. In contradistinction, incubation of a normal bone marrow 
suspension with a CFU-S proliferation stimulator increased the 
125IUdR uptake per unit number of cells injected compared with 
controls. 
3. Similar treatment of bone marrow cells as in 1 and 2 did not 
decrease or increase respectively, the number of spleen colonies 
which they produced. 
4. Incubation of bone marrow cells with a CFU-S proliferation 
inhibitor decreased the size of spleen colonies which they formed 
compared with controls. 
A simple method to test cell conditioned medium for the 
presence of CFU-S proliferation regulators is proposed. Sources of 
potential CFU-S proliferation stimulators and inhibitors are 
incubated with normal and regenerating bone marrow respectively for 
4 hours. Control bone marrow suspensions are incubated with 
medium. The cell suspensions are then injected into separate 
groups of lethally irradiated mice. The 
125IUdR 
uptake into the 
spleen is measured 5 days later. This experimental design 
eliminates the necessity to use the suicide technique and therefore 
at least halves the number of mice needed to test one source of 
conditioned medium. This would provide a rapid screening assay for 
CFU-S proliferation regulators. 
The hypothesis that CFU-S proliferation inhibitors and 
stimulators alter the lag time before the CFU-S start proliferating 
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in the irradiated host is testable, eg dose response studies of the 
effect of incubation with these factors on the 
125IUdR 
uptake 
produced by haemopoietic cells. A logical extension of this 
hypothesis is that rapidly cycling CFU-S should produce a higher 
125IUdR 
uptake than those which are not cycling. If this did occur 
the proportion of CFU-S in S-phase calculated from suicide 
experiments using the 
125IUdR 
assay would be higher than those from 
the spleen colony. technique. This did not occur (Table 2.2). The 
effect of CFU-S proliferation regulators on the 
125IUdR 
uptake 
produced by the grafted CFU-S is probably occurring at 
supraphysiological concentrations. 
The 125IUdR uptake in the spleen of lethally irradiated mice 
grafted with different sources of haemopoietic cells has been 
tested. The spleen 
125IUdR 
uptake per unit number of cells 
injected and per CFU-S injected has been analyzed. Two principal 
observations were made: 
1. Incubation of haemopoietic cells with CFU-S proliferation 
stimulators and inhibitors, increased and decreased the spleen 
125IUdR 
uptake respectively (Section 2.4.3). 
2. The 125IUdR uptake per CFU-S injected was dependent on the 
source of haemopoietic cells (Section 2.4.4). 
The clone size is the total number of proliferating cells 
produced per CFU-S and is reflected by the spleen 125IUdR uptake. 
It has been argued that variations in the size of the clone 
produced by each CFU-S are related to the lag time before it 
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commences proliferation and its intrinsic potential for 
self-replication. This is a plausible hypothesis, and correlations 
with results obtained from the spleen colony technique support it, 
eg murine fetal liver CFU-S produce bigger colonies(Micklem 1972), 
have a higher self-replicative potential, 
(Rosendaal et al 1979), 
and produce a higher spleen 
125IUdR 
uptake per CFU-S injected 
(Table 2.4) than those from normal bone marrow. But the size of 
the clone produced by a CFU-S is not only determined by the number 
and rate at which it produces more CFU-S. The committed 
progenitors and recognisable precursors produced by the CFU-S also 
proliferate. The number of amplification divisions within these 
two compartments can be altered, (Hanna et al 1969), 
(Lord and 
Lajtha 1974), (Metcalf 1977). The final clone size produced is 
therefore also a function of cell production within these 
compartments. 
It was considered that the potential amplification divisions 
within the committed progenitor and recognisable precursor 
compartments would increase if less CFU-S were injected. But 
analysis of the dose response graphs (Figures 2.17,2.18,2.19) 
indicated that over a range of cell clones this did not occur. So 
the spleen 
125IUdR 
uptake and hence clone size was directly 
proportional to the number of CFU-S injected. 
2.4.5.3 Experimental analysis of CFU-S clonal expansion 
It has been demonstrated that variations in the CFU-S clonal 
expansion are produced by incubating them with specific 
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proliferation stimulators and inhibitors (section 2.3.6,2.3.7, 
2.4.3). CFU-S obtained from different haemopoietic tissues produce 
different clone sizes (Table 2.4, Section 2.4.4.2). It would be 
interesting to study the kinetics of clone formation by CFU-S from 
different haemopoietic tissues, and from haemopoietic cells treated 
with different factors. From these experiments it could be 
determined whether the CFU-S proliferation regulators alter the lag 
time before the CFU-S start to proliferate in the irradiated host. 
Variations in the CFU-S self-replicative capacity, of CFU-S from 
different haemopoietic tissues could also be analysed. 
The following experimental design is proposed, groups of 
lethally irradiated mice are grafted with an equivalent number of 
CFU-S from one of the following sources of haemopoietic cells. 
1. Normal bone marrow. 
2. Marrow from mice injected with isopropyl methyl sulphonoate 
(IMS), 12 hours previously, (Schofield and Lajtha 1973). 
3. The marrow from mice injected 4 days previously with nitrogen 
mustard, (Sharp and Thomas 1971). 
4. Day 15 gestational age murine fetal liver cells. 
5. The bone marrow from mice injected 4 days previously with 
5-fluorouracil (5-FU), (Hodgson and Bradley 1979). 
6. The bone marrow from mice which had received 5 injections of 
hydroxyurea (HU), (Rosendaal et al 1979). 
7. The spleen from mice which had received 3 injections of 
phenylhydrazine 4 days previously, (Rencricca and Rizzoli 1970), 
(Wright et al 1978). 
175 
8. The bone marrow from mice which had received 3 injections of 
phenylhydrazine 4 days previously. 
9. Regenerating bone marrow incubated with and without a 50-100K 
daltons NBME fraction (CFU-S proliferation inhibitor) for 4 hours. 
This should be carried out with regenerating bone marrow from 
different sources, eg 24 hour Ara-C bone marrow, day 4 HN2 bone 
marrow, and with murine fetal liver. 
10. Normal bone-marrow incubated with a CFU-S proliferation 
inhibitor. 
11. Normal bone marrow incubated with a CFU-S proliferation 
stimulator. 
12. Regenerating bone marrow incubated with a CFU-S proliferation 
stimulator. 
Mice from each group which had been transplanted with the 
different haemopoietic cells on day 0, would be sacrificed every 12 
hours for at least 14 days. The number of the following cells in 
the spleen would then be assayed, CFU-S, CFU-D, day 7 and day 14 
GM-CFC, day 3 and day 8 BFU-C and the total number of nucleated 
cells. A differential count of the spleen cells could also be 
performed. For completeness the proportion of CFU-S synthesizing 
DNA at each time point could be determined using the suicide assay. 
From this information the proportion and kinetics of CFU-S 
self-replication versus differentiation with time could be 
determined for the CFU-S from different haemopoietic tissues. If 
the hypothesis that the CFU-S proliferation inhibitor increases the 
lag time before the CFU-S start to proliferate is correct, it would 
be detected in mice injected with cells from group 9. If the clone 
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size produced is reduced by inhibiting CFU-S proliferation, the lag 
time before . normal 
bone marrow CFU-S (group 1) commence 
proliferation would presumably be longer than that of CFU-S from 
post PHZ bone marrow (group 8). But all of these CFU-S are 
injected into lethally irradiated mice in which there are high 
levels of the CFU-S proliferation stimulator, (Lord et al 1977b), 
(Ali (1981). This would probably stimulate CFU-S proliferation very 
rapidly. the CFU-S exposed to the proliferation inhibitor in vitro 
may be exposed to supra physiological concentrations of this 
factor. This could produce a prolonged inhibition of CFU-S 
proliferation, even when exposed to the stimulatory environment in 
the irradiated mouse. If this is correct, CFU-S from normal bone 
marrow exposed to the CFU-S proliferation inhibitor would also 
produce smaller clones than controls (group 10 cf group 1). Ie, in 
vitro exposure to the CFU-S proliferation inhibitor is more 
inhibitory than the levels of the inhibitor in normal bone marrow. 
The CFU-S proliferation stimulator may increase the clone size 
produced by decreasing the lag time before a CFU-S starts to 
proliferate (group 11). This seems unlikely because of the high 
levels of the CFU-S proliferation stimulator present in the 
irradiated hosts, (Lord et al 1977b). But All (1981) did not 
detect any CFU-S proliferation stimulator in mice until 6 hours 
after lethal irradiation (900 Rads). Normal bone marrow CFU-S 
triggered into cycle during an incubation with the CFU-S 
proliferation stimulator might therefore start proliferating more 
rapidly in the irradiated host. This treatment might also permit 
CFU-S division in vitro. 
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A higher CFU-S production would be expected in mice injected 
with cells from groups 4,5 and 6, than groups 2 and 3. This 
experiment would give an indication of the age distribution of the 
CFU-S from different haemopoietic tissues. 
It has been postulated that variations in CFU-S quality and 
their prior incubation with CFU-S proliferation regulators both 
alter the clonal expansion produced by each CFU-S. CFU-S in 
different kinetic states might therefore be expected to produce 
clones of different sizes. Murine fetal liver CFU-S would 
therefore be expected to- produce a larger clonal expansion than 
CFU-S from normal bone marrow, because of both their higher 
self-replicative capacity, (Rosendaal et al 1979), and faster 
cycling state, (Metcalf and Moore 1971). It is not possible 
therefore to determine directly whether the size of the clone 
produced by each CFU-S is affected by its kinetic state. But if 
rapidly cycling CFU-S produce bigger clones, in a suicide 
experiment the proportion of CFU-S in S-phase calculated from the 
125IUdR 
assay would be higher than that from the spleen colony 
technique. This did not occur (Table 2.2). 
2.4.6 Determination of Relative CFU-S Seeding Efficiency Using the 
125IUdR Assay 
The uptake of 
125IUdR into the spleens of mice (secondary 
recipients) injected with spleen cells from primary recipients 
grafted with marrow cells from different sources was compared. In 
the first experiment the primary recipients were grafted with 24 x 
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10 6 bone marrow cells from either normal mice or mice which had 
been injected with Ara-C 24 hours previously. The number of CFU-S 
per 105normal and 24 hour Ara-C bone marrow cells was the same 
(Table 1.2). The two groups of primary recipients were therefore 
grafted with equal numbers of CFU-S. After 24 hours the spleens 
were removed from the primary recipients and one fifth of a spleen 
was injected into secondary recipients. The IUdR uptake into 
the spleens of these mice was measured 5 days later. The IUdR 
uptake in secondary recipients which received spleen cells from 
primary recipients grafted with 24 hour Ara-C bone marrow was 50% 
of those which received spleen cells from normal bone marrow 
grafted primary recipients. 
The uptake of 
125IUdR into the spleens of mice injected with 
haemopoietic cells is directly proportional to the-number of CFU-S 
injected (Figures 2.17,2.18,2.19). The 125IUdR uptake per CFU-S 
injected was similar for CFU-S from normal and 24 hour Ara-C bone 
marrow (Table 2.4). It therefore appears that the relative seeding 
efficiency of CFU-S from normal bone marrow is twice that of CFU-S 
from 24 hour Ara-C bone marrow. In normal and 24 hour Ara-C bone 
marrow a small and large proportion of the CFU-S are synthesizing 
DNA respectively (Table 1.2). These observations are consistent 
with those of Monette and De Mello (1979). They demonstrated using 
the conventional CFU-S assay that the seeding efficiency of rapidly 
proliferating CFU-S was 50% of those which were slowly 
proliferating. 
If rapidly cycling CFU-S are incubated with a 50-100K daltons 
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Amicon fraction from a NBME the proportion of CFU-S synthesizing 
DNA is reduced, (Lord et al 1976), (Figures 1.10,1.11). Lord et 
al (1976) also demonstrated that this treatment did not alter the 
CFU-S seeding efficiency. This observation was confirmed in a 
second experiment using the 125IUdR assay. Murine fetal liver 
cells were incubated with or without the CFU-S proliferation 
inhibitor. These cells were injected into primary recipients. The 
spleen cells from these mice were grafted into secondary 
recipients. The uptake of 
125IUdR into the spleens of these mice 5 
days later were not significantly different in the two groups. 
From the observations of Monette and De Mello (1979) and Figure 
2.25 it would be predicted that the CFU-S proliferation inhibitor 
would increase the CFU-S seeding efficiency. 
Worton et al (1969) demonstrated that the seeding efficiency of 
large rapidly sedimenting CFU-S was about 50% of smaller slowly 
sedimenting CFU-S. Subsequently. Monette et al (1974) confirmed 
these observations and demonstrated that a large proportion of the 
large rapidly sedimenting CFU-S were in cycle. In contrast only a 
small proportion of the small slowly sedimenting CFU-S were in 
cycle. Monette and De Mello (1979) suggested that the larger CFU-S 
were more likely to be trapped in the pulmonary and renal capillary 
beds. Consequently less CFU-S would be available to seed to the 
haemopoietic tissues. The 50-100K daltons NBME fraction reduces 
the proportion of CFU-S synthesizing DNA in regenerating bone 
marrow during a5 hour incubation. It is probable that the size of 
the CFU-S does not change during this short period. Consequently 
no increase in the CFU-S seeding efficiency would occur. This 
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could be confirmed by analysing the CFU-S velocity sedimentation 
profile before and after exposure to the CFU-S proliferation 
inhibitor. 
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5.2 
Normal Bone Marrow 
Day 3 and 5 Log125IUdR Uptake per Spleenand Femur 
5.6 6.0 6.4 
Log Cell Dose Injected 
6.8 
Figure 2.1A 
The uptake of 125I-iododeoxyuridine. into the spleen and femur of 
lethally irradiated mice transplanted either 3 or 5 days previously 
with normal bone marrow cells. (1uCi125IUdR injected) (Mean ± SE) 
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24 hour Ara-C Bone Marrow: 
+za 
Log Cell Dose Injected / Log IUdR Uptake per Spleen and Femur 
5.1 
Figure 2.2A 
5.3 5.5 5.7 5.9 
Log Cell Dose Injected 
The uptake of 
1251-iododeoxyuridine into the spleen and femur of 
lethally x-irradiated mice transplanted 5 days previously with the 
bone marrow from mice which had been injected with 5mg of Ara-C 24 
rs previously. Abbreviated as 24 hour Ara-C bone marrow (2141 
IUdR injected) (Mean ± SE) 
T able Z. 1A 
cell dose 
injected 
1.12 x 105 
9.47 x 105 
2.56 x 106 
5.59 x 106 
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Dose response of normal bone marrow cells injected 
125 
into lethally irradiated (820R) mice/spleen IUdR 
uptake. Comparison of 1 iCi 2 or 24 hour pulse 
1 ACi 2 hour 
pulse 
125IUdR 
uptake per spleen 
+ SE (cpm) + Log 
cell dose 
injected 
1 4Ci 24 hour 
pulse 
125IUdR 
uptake per spleen 
+ SE (cpm) + Log 
"" uptake 
106.8 ± 25.3 
1.97 ± 0.095 
1714.2 ± 576.4 
3.11 ± 0.133 
2488.6 ± 1337.7 
3.26 + 0.371 
3563.2 + 733.2 
3.50 ± 0.097 
5.14 x 105 
9.9 x 105 
2.58 x 106 
. 
5.15 x 10 
uptake 
135.8 ± 24.7 
2.10 ± 0.085 
251.8+ 19.2 
2.39 ± 0.035 
728.4 + 213.9 
2.81 ± 0.114 
1419.6 ± 117.4 
3.14 ± 0.036 
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Table 2.2A Trichloroacetic acid precipitation of DNA. 
Percentage of 
125IUdR 
incorporated into the spleen cell DNA 
of lethally irradiated mice, injected with normal bone marrow 
5 days previously 
Group Counts per minute To of Activity in / mg of spleen tissue TCA DNA precipitate 
A TCA precipitate 
A supernatant 
A spleen tissue 
B TCA precipitate 
B supernatant 
B spleen tissue 
C TCA precipitate 
C supernatant 
C spleen tissue 
50.83 ± 15.2 
1.78 + 0.2 
73.9 + 22.9 
24.6 ± 8.6 
0.9 ± 0.1 
26.9+ 8.6 
22.7 + 10.3 
1.7 ± 0.2 
23.4 + 8.9 
96.5 
92.0 
97.0 
TCA :- Trichloroacetic acid 
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Table 2.4A Normal bone marrow suicide. Results obtained using 
125IUdR 
assay. Day 5 spleen 
125IUdR 
uptake, 2 hour, 2 JCi 
pulse 
Number of cell dose 
Log 
125IUdR 125IUdR 
uptake 
mice per injected uptake per per spleen 
group spleen±LogSE counts per 
minute ± SE 
13 7.2 x 105 
3.279 ± 0.059 2158.0 ± 321.0 
3.334 ± 0.057 2415.6 ± 315.3 
8 5.1 x 105 
3.364 ± 0.091 2643.3 ± 452.2 
3.420 ± 0.058 2838.9 ± 408.9 
13 5.4 x 105 
2.905 ± 0.095 104 8.0 ± 184.1 
2.895 ± 0.085 973.2 ± 178.2 
5.0 x 105 
2.973±0.057 
9 
2.999 ± 0.071 
10 7.5 x 105 
3.035 f 0.062 
3.062 ± 0.091 
11 5.4 x 10 
10 5.0 x 10 
* 
5 2.814 
± 0.073 
2.890 ± 0.077 
5 3.200-ý'0.083 
3.181 ± 0.054 
1 018.5 ± 175.5 
1102.6 ± 163.1 
1166.5 ± 143.2 
1399.2 ± 255.1 
754.7±134.5 
899.4 ± 147.2 
1582.3 # 337.0 
1518.7 ± 202.0 
Top group in each pair treated with Ara-"C 
Suicide % 
± SE 
10.7 ± 19.8 
6.87 ± 22.3 
-7.1 
± 25.4 
7.6 ?' 22.7 
16.6 ± 22.0 
16.1 ± 13.1 
-4.6 ± 24.8 
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Table 2.5A Day 15 gestational age murine fetal liver and Day 4 
HN2 bone marrow suicide. Measured using 
1251UdR 
assay. 
Day 5, spleen 
125IUdR 
uptake. 2 hour, 2 ACi pulse 
Haemopoietic Log 
125IUdR 
uptake 
125IUdR 
uptake 
tissue and cell per spleen. Suicide % 
dose injected per spleen ±Log SE Counts per + SE 
minute ± SE 
Day 15 
ge stational 
age, murine 
fetal liver 
7.3 x 105 
* 
3.037 +0.052 1156.3±143.4 
55.7 ± 17.0 
Day 4 HN2 
Bone marrow 
5.0 x 105 
3.398 ± 0.053 2640.1 ± 343.1 
2.357 + 0.53 241.1 ± 29.1 
2.558±0.547 376.8±48.7 
36.0 ± 17.0 
Top group in each pair treated with Ara-C 
8 mice per group 
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Table 2.8A Spleen colony technique, normal, 24 hour Ara-C, Day 4 
HN2 bone marrows and day 15 gestational age murine fetal 
liver CFU-S suicide. 
Haemopoietic CFU-S per 105 cell 
tissue injected ± SE 
Normal bone 23.7 ± 1.1 
marrow 
N=45 29.7±1.4 
24 hour Ara-C 
bone marrow 
N=22 
16.0 ± 1.4 
2 9.4 t 1.8 
Day 15 
gestational age 
murine fetal 
liver N= 16 
Suicide %± SE 
20.2 ± 6.6 
45.3 ± 10.8 
9.4 ± 0.9 
15.5 ± 1.0 
Day 4 HN2 21.7 + 2.8 
Bone marrow 
N=14 38.0±3.6 
39.5 + 12.1 
43.0 ± 13.0 
Top group in each pair treated with Ara-C 
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Table 2.9A The effect of extracts from normal rat bone marrow and 
thymus on the suicide of 24 hour Ara-C bone marrow. Measured using 
125IUdR assay. Day 5 spleen 125IUdR uptake. 2 hour 2 ELCi pulse 
IZ5 
Bone marrow Log- IUdR 
treatment during uptake per 
incubation spleen ± Log SE 
Control 
3.052 f 0.065 
3.47 ± 0.076 
+ 50-100 K 3.047 ± 0.065 
dalton rat 
NBME fraction 3.091 ± 0.169 
+ 30-50 K dalton 
rat NBME 
fraction 
2.930 ± 0.067 
3.375 ± 0.076 
+ 50-100 K 
dalton rat 
thymus extract 
fraction 
3.058 ± 0.082 
3.304 ± 0.04 6 
125IUdR 
uptake 
per spleen 
counts per 
minute 
± SE 
1127.0 ± 196.0 
2951.2 ± 470.0 
1222.2+190.6 
1421.0 ± 492.4 
918.2 ± 123.6 
2548.5 ± 465.0 
1302.2 ± 261.2 
2078.7 ± 259.4 
Suicide %±SE 
61.8 ± 23.6 
14.0 ± 37.9 
64.0 + 22.6 
37.3 ± 23.5 
Top group in each pair treated with Ara-C 
7 mice per group. 7x 105 cells injected per mouse 
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CHAPTERTHREE 
THE REGULATION OF HAEMOPOIETIC STEM CELL PROLIFERATION 
IN THE HUMAN FETAL LIVER 
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CHAPTER THREE : ABSTRACT 
Normal murine bone marrow was incubated with medium 
conditioned by liver cells from human fetuses of 11-17 weeks 
gestational age. This treatment increased the proportion of murine 
haemopoietic stem cells (CFU-S) which were synthesising DNA from 
<10% to >33%. The human fetal liver supernatants were fractionated 
using Amicon filters to obtain nominal molecular weight ranges of 
10-30K, 30-50K and 50-100K daltons. The stimulator was only 
present in the 30-50K daltons fraction. 
Human fetal liver cells were separated by adherence to 
plastic. Medium conditioned by the adherent but not the 
non-adherent cells stimulated CFU-S proliferation. This CFU-S 
proliferation stimulator has properties similar to that 
demonstrated in murine fetal liver and regenerating murine bone 
marrow, (Wright et al 1979). Human and murine haemopoietic stem 
cell proliferation may therefore be regulated by similar 
mechanisms. 
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CHAPTER THREE 
THE REGULATION OF HAEMOPOIETIC STEM CELL PROLIFERATION 
IN HUMAN FETAL LIVER 
3.1 INTRODUCTION 
3.1.1 The Ontogeny of the Haemopoietic Tissues 
Haemopoietis occurs sequentially in three sites within the 
fetus, the extra-embryonic mesoderm, the liver and the bone marrow, 
(Wintrobe 1967), (Wickramasinghe 1975), (Kelemen et al 1979). The 
periods of significant haemopoiesis in these three sites overlap 
considerably (Figure 3.1). The sequential development of the 
haemopoietic tissues in the human fetus is discussed in Sections 
3.1.1.1 to 3.1.1.5. 
The experimental determination of the origin of the 
haemopoietic cells, their migration, differentiation and kinetics 
has been carried out principally in murine and avian fetuses. The 
results obtained in these two species have not always been 
consistent, (Moore and Metcalf 1970), (Dieterlen-Lievre et al 
1976), (Le Douarin '1978), (Beaupain et al 1979). This should be 
considered when extrapolating these results to explain human 
haemopoietic development. 
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The Development of Haemopoietic Tissue 
1 2 34567 
Months of Gestation 
8 9 
FIGURE 3.1 
The principal sites of haemopoiesis in the human embryo and fetus. 
Contribution of each tissue to haemopoiesis during gestation, from 
Wintrobe (1967) and Wickramasinghe (1975). 
3.1.1.1 The extra-embryonic mesoderm 
The first blood cells develop in the extra-embryonic mesoderm 
of the yolk sac, (Wickramasinghe 1975). Solid round masses of 
mesenchymal cells form on the surface of the yolk sac. These form 
the blood islands, which enlarge and fuse to form the area 
vasculosa. Blood islands also develop in the mesoderm of the body 
stalk and the chorion by the third week of gestation, (Kelemen et al 
(1979). Communication between the embryonic circulation and the 
blood islands of the body stalk and area vasculosa is established 
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during the fourth week of gestation, (Wickramasinghe 1975). 
Erythropoiesis occurs in the yolk sac from the third to twelfth 
week of gestation, (Gilmour 1941). This erythropoiesis is 
megaloblastic. Primitive nucleated erythrocytes containing 
distinctive embryonic haemoglobins, (Huens et al 1964), are 
produced. There is no significant granulocytopoiesis in the yolk 
sac. 
3.1.1.2 Fetal liver haemopoiesis 
The liver develops in the fourth week of gestation as a 
diverticulum of the foregut. This invaginates into the caudal part 
of the septum transversum, (Snell 1975), (Kelemen et al 1979). 
Hepatocytes develop from the endodermal lining of the diverticulum. 
The hepatic sinusoids develop from the embryonic mesoderm of the 
septum transversum. The first foci of haemopoietic cells appear in 
the sixth week of gestation. The liver is the principal site of 
erythropoiesis from the third to sixth month of gestation, (Gilmour 
1941), (Wickramasinghe 1979). Erythroblasts constitute half of 
the liver cells from the second to the seventh month of gestation, 
(Thomas and Yoffey 1964). These are normal 'definitive' 
erythoblasts and they produce anucleate red blood cells, 
(Wickramasinghe 1975). Fetal haemoglobin is the predominant form 
during hepatic haemopoiesis, (Huens et al 1964). No significant 
granulocytopoiesis occurs in the fetal liver, (Gilmour 1941), 
(Thomas and Yoffey 1962), (Kelemen 1979). 
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3.1.1.3 Fetal bone marrow haemopoiesis 
Prior to the appearance of haemopoietic cells in the bone 
marrow cavity, blood vessels and perichondrial mesenchymal cells 
penetrate the calcified cartilage in the central region of the 
bone. This cartilagenous matrix is then resorbed by osteoclasts 
and a network of blood vessels and connective tissue develops, 
(Metcalf and Moore 1971). Haemopoiesis is initiated in the bone 
marrow between the second and the fourth month of gestation 
depending on the location of the bone. The bone marrow is the 
principal site of haemopoiesis for the last three months of 
gestation, (Wickramasinghe 1975). 
The bone marrow is the principal site of granulocytopoiesis in 
the fetus, (Thomas et al 1960). This explains the paucity of 
granulocytes in the circulation in the first half of gestation and 
the increase in the second half, (Thomas and Yoffey 1962). The 
bone marrow is also the principal site of erythropoiesis during the 
last three months of gestation. The appearance of red blood cells 
containing adult type haemoglobins coincides with the onset of 
haemopoiesis in the bone marrow, (Wickramasinghe 1975). 
3.1.1.4 Haemopoiesis in the fetal spleen 
The spleen develops as a thickening of the dorsal mesogastium 
about the fifth week of gestation. It consists initially of 
aggregates of mesenchymal cells and takes on its characteristic 
form about the third month of gestation, (Snell 1975), (Ham 1981). 
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Haemopoiesis is first detected in the spleen at 12 weeks of 
gestation. It consists of erythroblastic islands and a few 
megakaryocytes. The white pulp containing lymphocytes does not 
form until the fifteenth week of gestation. The spleen produces 
principally erythocytes and granulocytes until the fifth post natal 
day, (Kelemen et al 1979). The spleen is only a minor site of 
haemopoiesis in comparison to the liver and bone marrow (Figure 
3.1), (Wintrobe 
. 
1967). 
3.1.1.5 Haemopoiesis in the fetal thymus 
The lymphoid tissue of the thymus develops in the twelfth week 
of gestation. Although the thymus is principally a lymphoid organ, 
groups of erythroblastic and granulopoietic cells have been 
demonstrated in the loose connective tissue of the trabeculae, 
(Kelemen et al 1979). Taylor and Skinner (1976) demonstrated with 
histochemical and immunohistochemical techniques a large number of 
early myeloid and erythroid precursors in the fetal thymus. The 
number of these cells was very variable but was highest in mid term 
fetuses. The significance of this haemopoiesis in the human fetal 
thymus is not known. But extensive interactions between the thymus 
and haemopoietic cells have been demonstrated in mice, (Lord and 
Schofield 1973), (Zipori and Trainin 1973), (Goodman et al 1978), 
(Sharp et al 1981). 
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3.1.2 The Ontogeny of the Haemopoietic Stem Cells 
The first generation of murine haemopoietic stem cells (CFU-S) 
is detectable in the yolk sac blood islands, (Metcalf and Moore 
1971). Subsequently they are found in the embryonic circulation, 
fetal liver and fetal bone marrow, (Moore and Metcalf 1970). This 
suggested that the haemopoietic stem cells were produced de novo 
from the mesenchymal cells of the blood islands. These cells were 
then released into-the embryonic circulation and some of them 
initiated haemopoiesis in the fetal liver and bone marrow. In 
contrast purely on morphological grounds, Rifkind et al 
(1969) 
suggested that liver mesenchymal cells were transformed into 
haemopoietic cells. 
3.1.3 Origin of Fetal Haemopoietic Stem Cells 
Moore and Metalf (1970) cultured murine embryos with or 
without their yolk sacs, for one to six days in vitro. The number 
of CFU-S and GM-CFC in the yolk sac, embryonic circulation and 
embryonic liver in the different cultures was then assayed. CFU-S 
and GM-CFC were only detected in seven-day embryos if they were 
cultured with an intact yolk sac. The numbers of CFU-S in the 
cultures of yolk sac and embryo reached a peak in the yolk sac and 
then declined as their numbers increased in the embryonic 
ciruclation and liver. These results suggested that the yolk sac 
is the primary source of murine haemopoietic stem cells. These 
CFU-S are released into the embryonic circulation and subsequently 
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initiate haemopoiesis in the liver. 
This theory was supported by the observations of Johnson and 
Moore (1975). They grafted pre-haemopoietic murine fetal liver 
under the kidney capsule of either lethally irradiated mice, 
lethally irradiated bone marrow grafted mice, nude mice (nu/nu), or 
S1/Sld mice. Haemopoiesis was only initiated in the liver grafted 
into S1/Sld or lethally irradiated bone marrow grafted mice. 
Irradiation of the-fetal liver prior to grafting did not alter the 
results obtained. These results demonstrated that pre-haemopoietic 
fetal liver can support haemopoiesis if supplied with haemopoietic 
stem cells. 
In contrast experiments in the chick-quail chimera, suggest 
that the fetal liver and bone marrow are seeded by haemopoietic 
stem cells from intra-embryonic blood islands, (Dieterlen-Lievre 
1975), (Dieterlen-Lievre et al 1976), (Martin et al 1978), (Le 
Douarin 1978). Haemopoietic stem cells are also present in the 
avian yolk sac blood islands. But these are virtually exhausted by 
the time the liver has developed sufficiently to accommodate them, 
(Le Dourain 1978). The reason for the different origins of 
haemopoietic stem cells in mammalian and avian embryos may be 
related to the much shorter period of yolk sac haemopoiesis in 
mammals. It may be significant that yolk sac blood islands in 
birds develop from embryonic mesoderm, (Settle 1958), while in 
mammals they are of extra-embryonic mesodermal origin, 
(Wickramasinghe 1975). 
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3.1.4. Fetal Liver Haemopoietic Stem Cells 
The human fetus increases in weight from lg at 2 months of 
gestation to 3,300g at full term, (Arey 1954). The haemopoietic 
system must therefore undergo an enormous expansion during 
gestation. Studies of =urine fetal haemopoietic stem cells (CFU-S) 
indicate that they differ from those in normal bone marrow in many 
of their properties. In fetal liver a large proportion of the 
CFU-S are synthesizing DNA in contrast to the small proportion in 
normal bone marrow, (Becker et al 1965). The CFU-S from fetal 
liver when transplanted into irradiated hosts had a doubling time 
two thirds of normal bone marrow CFU-S, (Schofield 1970). In 
serial transfer experiments, CFU-S from fetal liver could be 
transferred through six irradiated hosts before CFU-S self renewal 
ceased, while those from normal bone marrow only three, (Metcalf and 
Moore 1971). Spleen colonies produced by fetal liver CFU-S, are 
larger and contain more CFU-S and dividing cells than those 
produced by normal bone marrow CFU-S, (Micklem 1972), (Rosendaal et 
al 1979). The majority of fetal liver CFU-S are in cycle so that 
a maximum output of CFU-S and differentiated progeny to the 
expanding haemopoietic system can be maintained. The high 
probability of fetal liver CFU-S self renewal, (Schofield 1978), 
(Rosendaal et al 1979), is also indicative of their role in a 
rapidly expanding, developing haemopoietic system. 
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3.1.5 Fetal Liver: CFU-S Proliferation Regulation 
Regenerating bone marrow in which a large proportion of the 
CFU-S are synthesizing DNA contains a specific CFU-S proliferation 
stimulator, (Lord et al 1977b), (Wright and Lord 1978). It was 
therefore not surprising that a CFU-S proliferation stimulator was 
also detected in murine fetal liver, (Wright et al 1979). 
The principal objective of this study was to determine if a 
CFU-S proliferation stimulator was present in human fetal liver. 
The presence of CFU-S proliferation regulators in human fetal bone 
marrow and thymus was also investigated. 
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3.2 EXPERIMENTAL DESIGN 
3.2.1 Preparation of Human Fetal Liver Cell Supernatants 
Cell suspensions were prepared from human fetal livers (HFL) 
of different gestational ages and two types of conditioned media 
were produced from them. A supernatant removed from the HFL cells 
after a2 hour incubation, Supernatant one (Si). The HFL cells 
were resuspended in fresh medium, and incubated for a further 5 
hours, a second supernatant (S2) was then removed (see Section 
1.2.6.1). 
Livers which were removed from the fetus within one hour of 
delivery were suspended in medium and allowed to adhere to plastic 
for 2 hours. Two HFL cell populations were then obtained, plastic 
adherent, and plastic non-adherent. These were resuspended in 
fresh medium, incubated for 5 hours and supernatants obtained from 
them (see Section 1.2.6.2). One liver (HFLS7) was suspended in 
0.9% NaCl, and supernatants one and two were obtained from it. 
These were both fractionated by Amicon ultrafiltration to produce 
10-30K, 30-50K and 50-100K daltons fractions (see Section 1.2.6.3). 
3.2.2 The Effect of a HFLS on the Proportion of Normal Bone Marrow 
CFU-S Synthesizing DNA 
Two pairs of tubes containing normal murine bone marrow were 
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incubated, one pair with a HFLS and the other with medium for 4 
hours. Ara-C was then added to one tube in each pair, and medium 
to the other and the incubation continued for a further hour (see 
Section 1.2.12). The number of CFU-S surviving in each tube was 
then assayed by the spleen colony technique (Section 1.2.8) of the 
125IUdR 
assay (Section 1.2.13). Supernatants from human fetal 
liver cell suspensions, and from resuspended, plastic adherent and 
non-adherent HFL cells were tested at a 3: 1 test responder cell 
ratio. The three Amicon fractions from the IIFL supernatants one 
and two were tested at 100ug/ml. The 30-50K daltons fraction from 
the HFL supernatant two was also tested at 1.5 to 50pg/ml. 
Supernatants from the bone marrow, spleen and thymus of human 
fetuses of different gestational ages were tested at a 3: 1 test 
responder cell ratio, using the methods described above. 
3.2.3 The Effect of a HFLS on the Proportion of 24 Hour Ara-C Bone 
Marrow CFU-S Synthesizing DNA 
Two pairs of tubes containing 24 hour Ara-C bone marrow were 
incubated for 4 hours at 37°C, one pair with a HFLS and the other 
with medium. One tube in each pair was then incubated with Ara-C 
for one hour and the other with medium, (see Section 1.2.12). The 
CFU-S surviving in each tube were assayed (see Section 1.2.8). 
This experiment was set up to test for the presence of CFU-S 
proliferation inhibitors in a HFLS. 
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3.2.4 The Effect of a Human Rib Bone Marrow Supernatant on the 
Proportion of 24 Hour Ara-C Bone Marrow CFU-S and Normal Bone 
Marrow GM-CFC Synthesizing DNA 
Bone marrow from mice injected with Ara-C 24 hours previously 
was incubated with a supernatant (Si) from normal human rib bone 
marrow at a 2.5: 1 test responder cell ratio (see Sections 1.2.4.2 
and 1.2.6). The CFU-S suicide in the HB}IS treated and medium 
treated control group were compared. 
Normal murine bone marrow was also incubated with the HEMS. 
Ara-C was used as a suicide agent and the proportion of GM-CFC 
synthesizing DNA in the HBMS treated and medium treated control 
group compared. 
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3.3 RESULTS 
3.3.1 The Effect of Supernatants from Human Fetal Liver Cells on 
the Proportion of NMBM CFU-S Synthesizing DNA 
Livers were obtained from human fetuses of 11.8 to 17.0 weeks 
gestational age. Normal murine bone marrow (NMBM) was incubated 
with a first or second supernatant from these human fetal liver 
cells. This treatment increased the proportion of NMBM CFU-S which 
were synthesizing DNA from <18% to >33%. Similar results were 
obtained with both the spleen colony technique (Figure 3.2, Table 
3.1) and the 
125IUdR 
assay (Table 3.2). 
Incubation of PNMBM with a supernatant from plastic adherent 
HFL cells, but not from the non-adherent HFL cells, increased the 
proportion of CFU-S in S-phase from <17% to >36% (Figure 3.3). 
Similar results were obtained with both the spleen colony technique 
and 125IUdR assay (Table 3.1A). 
3.3.2 HFLS Amicon Fractions: Effect on NMBM CFU-S Proliferation 
The 10-30K daltons fraction from the first supernatant from 
HFL7, increased the proportion of NMBM CFU-S that were synthesizing 
DNA from <10% to >55% (Figure 3.4). The 30-50K and 50-100K daltons 
fractions from this supernatant had no effect on NMBM CFU-S 
proliferation (Figure 3.4). 
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Control HFLS 
Suicide% 17.7 ±13.6 45.0 ± 13.2 
+Ara-C Q+ medium 7 
The effect of a HFL Supernatant (S1) on the proportion of NMBM 
CFU-S synthesizing DNA (suicide % Mean ± SE). Fetus 5: 14.5 weeks 
gestational age. Test responder cell ratio 3: 1. 
3 0ý 
v CD 
U 
C 
200 
0 
'ö 
m CL 
LL 
U 
0 
Control AD. HFLS NA. HFLS 
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The effect of supernatants from plastic adherent and non-adherent 
HFL cells on the proportion of NMBM CFU-S synthesizing DNA (suicide 
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responder cell ratio 3: 1. 
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In contrast incubation of NMBM with the 30-50K but not the 
10-30K or 50-100K daltons fractions, from the second supernatant 
from HFLS7, increased the proportion of CFU-S synthesizing DNA from 
<10% to >52% (Figure 3.5, Table 3.2A). 
3.3.3 HFLS Dose Response 
Normal murine bone marrow was incubated with between 1.56 and 
50ug/ml of the 30-50K daltons fraction, from the second supernatant 
from HFL7 (Figure 3.6). Incubation with above 12ug/ml of this 
fraction increased the proportion of NMBM CFU-S synthesizing DNA 
from <7% to >48%. 6.25ug/m1 of this fraction, increased the 
proportion of CFU-S in S-phase from <7% to >31%. When used. below 
this concentration this fraction did not significantly affect CFU-S 
proliferation (Figure 3.6). 
3.3.4 HFLS: Effect on Regenerating Bone Marrow CFU-S 
In the bone marrow of mice injected with Ara-C 24 hours 
previously, 47% of the CFU-S were in S-phase. Incubation of this 
bone marrow with a HFL supernatant did not affect the proportion of 
CFU-S in S-Phase (Figure 3.7). 
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Dose response effect of a 30-50K daltons fraction from a HFL 
supernatant two, on the proportion of NMBM CFU-S synthesizing DNA 
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3.3.5 Human Fetal Bone marrow, Thymus and Spleen Supernatants: 
Effect on CFU-S Proliferation 
3.3.5.1 Fetal bone marrow 
Bone marrow supernatants from human fetuses of 14.9,16 and 
17.1 weeks gestational age increased the proportion of NMBM CFU-S 
in S-phase from <15% to >24% (Tables 3.3. and 3.4). A supernatant 
from the bone marrow of a 16.9 week gestational age fetus increased 
the proportion of NMBM CFU-S in S-phase to a smaller extent, <13% 
to 20% (Table 3.3). 
3.3.5.2 Fetal thymus and spleen supernatants 
A thymus supernatant from a human fetus of 15 weeks 
gestational age but not from one of 14.9 weeks, increased the 
proportion of NMBM CFU-S synthesizing DNA from <9% to >31% (Tables 
3.3 and 3.4). A spleen supernatant from a fetus of 13.0 weeks 
gestational age also increased the proportion of NMBM CFU-S 
synthesizing DNA from 10.5 to 30% (Table 3.3). 
3.3.6 Normal Human Rib Bone Marrow Supernatant: Effect on CFU-S 
and GM-CFC Proliferation 
Incubation of 24 hour Ara-C bone marrow with a human bone 
marrow supernatant decreased the proportion of CFU-S synthesizing 
DNA from 33% to 1% (Figure 3.8). In contrast, incubation of normal 
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murine bone marrow with the same supernatant, did not affect GM-CFC 
proliferation (Figure 3.9). 
3.3.7 Cytology and Histology of Human Fetal Liver 
The spectrum of cells present in the human fetal livers was 
studied in sections and smear preparations (Plates 3.1,3.2,3.3, 
3.4,3.5). As reported by Gilmour (1941), Thomas and Yoffey 
(1962), and Kelemen et al (1979), no significant granulocytopoiesis 
was seen in any human fetal livers. Most of the haemopoietic cells 
were erythroblasts at different stages of maturation. 
Megakaryoblasts and megakaryocytes were also present in small 
numbers (Plate 3.5). In Plates 3.1 and 3.2 hepatocyte nuclei can 
be seen interspersed with the haemopoietic cells. In the sections 
of liver the hepatocytes can be distinguished from the 
erythroblasts because of their much darker nuclei, (Kelemen et al 
1979), (Plates 3.3 and 3.4). Thomas and Yoffey (1962) 
demonstrated that at least 50% of the cells in livers from human 
fetuses were haemopoietic. The majority of these were 
erythroblasts. 
In the sections of fetal liver the erythroblasts appear to be 
surrounded by the hepatocyte cytoplasm. Kelemen et al (1979) 
suggested that the erythroblasts appeared to be in cytoplasmic 
lacunae inside the hepatocytes, but they were separated by their 
cell membranes. This relationship of erythroblasts and hepatic 
cells is also apparent in Plate 3.5. Thomas and Yoffey (1962) also 
demonstrated clusters of erythroblasts within the hepatic 
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PLATE 3.1 
Smear of liver cells from a 15 weeks gestational age human fetus 
(HF7), stained with Jenner-Giemsa. The different stages of 
erythroblast maturation from pro-erythroblast to orthochromatic 
erythroblast are interspersed with erythrocytes and hepatocyte 
nuclei. Magnification x1250. 
PLATE 3.2 
Smear of liver cells from a 17.1 weeks gestational age human fetus 
(HF12), stained with Jenner-Giemsa. Pro-erythroblast (bottom 
left); basophilic erythroblasts (bottom right); polychromatic 
erythroblast (upper left), and orthochromatic erythroblast (upper 
right). Magnification x3040. 

PLATE 3.3 
Section of the liver of a 12 weeks gestational age human fetus 
(HF3) stained with haematoxylin and eosin. Erythroblasts at 
different stages of maturation interspersed with hepatocytes. The 
erythroblasts have much 
darker nuclei than the hepatocytes. A few 
macrophages can also 
be seen. Kelemen and Janossa (1980) reported 
that these were the first 
differentiated definitive blood cells 
seen in the fetal liver. 
Magnification x1250. 
PLATE 3.4 
A lower power view of the section seen in Plate 
3.3. The sinusoids 
contain mature erythrocytes and 
late nucleated erythroblasts (top 
left). The erythroblasts are clustered and often appear to be 
surrounded by the cytoplasm of 
hepatocytes. Magnification x780. 

PLATE 3.5 
Transmission electron micrograph of a section of liver from a 15 
weeks gestational age human fetus (HF7), stained with osmium 
tetroxide. The hepatic sinusoid contains erythrocytes and an M-2 
type megakaryocyte, Kelemen et al (1979). The golgi apparatus of 
this cell is very prominent and numerous secretory vesicles are 
visible. In the liver parenchyma, polychromatic (bottom left) and 
orthochromatic erythroblasts are surrounded by the cytoplasm of 
hepatocytes. Prominent rough endoplasmic reticulum is seen in the 
hepatocyte cytoplasm. A very early haemopoietic precursor, 
putative haemopoietic stem cell (previously called haemocytobast) 
is also seen (top left). This cell has a very irregular idented 
nucleus containing a few nucleoli, Zamboni (1965). Magnification 
x7800. 
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trabeculum. Macrophages can also be seen in the sections of fetal 
liver (Plates 3.3 and 3.4). Kelemen and Janossa (1980) reported 
that macrophages were the first blood cells to be seen in the fetal 
liver. This may be related to their extensive roles in the 
regulation of haemopoiesis, 
(Kurland 1977), (Kurland et al 1980), 
(Wright et al 1980a). 
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3.4 DISCUSSION 
3.4.1 Murine Fetal Liver CFU-S Proliferation Stimulator 
Fetal liver is a developing haemopoietic tissue, (Metcalf and 
Moore 1971), (Moore and Williams 1973b). The liver is the 
principal site of. haemopoesis in the human fetus from the third to 
sixth month of gestation, (Wickramasinghe 1975), (Kelemen et al 
1979). In murine fetal liver most of the haemopoietic stem cells 
(CFU-S) are proliferating, (Becker et al 1965). Although the human 
haemopoietic stem cell cannot be assayed directly, it is probable 
that a large proportion of them are proliferating in human fetal 
liver. 
Wright and Lord (1977), Wright et al (1979), demonstrated that 
medium conditioned by murine fetal liver cells could increase the 
proportion of NMBM CFU-S that were synthesizing DNA. The CFU-S 
proliferation stimulator was also detectable in the regenerating 
bone marrow of irradiated mice, (Lord et al (1977b) and the bone 
marrow of mice recovering from a phenylhydrazine induced anaemia, 
(Wright and Lord 1977). This CFU-S proliferation stimulator was 
contained in a 30-50K daltons Amicon fraction and was produced by 
adherent Thy-1 negative phagocytic cells, (Lord and Wright 1980). 
3.4.2 A Stimulator of CFU-S Proliferation in Human Fetal Liver 
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A stimulator of CFU-S proliferation was detected in medium 
conditioned by liver cells from human fetuses of all gestational 
ages tested. This CFU-S proliferation stimulator was produced by 
plastic adherent but not plastic non-adherent human fetal liver 
cells. Amicon fractionation of saline conditioned by freshly 
aspirated HFL cells (ie a supernatant one) indicated that the 
stimulator was only present in the 10-30K daltons fraction. In 
contrast a 30-50K daltons fraction from saline conditioned by the 
same resuspended HFL cells (supernatant two) stimulated CFU-S 
proliferation. 
The smaller apparent molecular weight of the CFU-S 
proliferation stimulator in the first supernatant removed from the 
HFL cells was probably due to a partial breakdown of the molecule. 
The molecule could have been partially broken down by hydrolytic 
enzymes, but still retained some of its activity, (Burden et al 
1979) (see Section 1.5.2). The process would occur rapidly in 
liver because of the high level of hydrolytic enzymes in 
hepatocytes, (Lehninger 1975). Washing the cells and resuspending 
them in fresh medium, would remove a lot of these enzymes. Amicon 
filtration is a crude process and an alteration in the tertiary and 
quarternary structure (3 dimensional structure) of a protein could 
alter its retention by these filters, (Lehninger 1975). Subtle 
changes in the 3-dimensional structure of proteins can be induced 
by the action of hydrolytic enzymes. There is therefore probably a 
correlation between the high levels of hydrolytic enzymes and the 
lower molecular weight of the CFU-S proliferation stimulator, in 
the first HFL supernatant. 
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3.4.3 Human and Murine CFU-S Proliferation Stimulators: Comparison 
of Properties 
The human fetal liver CFU-S proliferation stimulator has 
similar properties to that demonstrated in murine haemopoietic 
tissues, (Lord et al 1977b), (Lord and Wright 1980). They are both 
produced by plastic adherent cells and are contained in 30-50K 
daltons Amicon fractions. 
The HFL and regenerating bone marrow, (Wright and Lord 1977), 
CFU-S proliferation stimulators were also both removed from the 
cells by washing in medium, and resynthesized by the washed cells 
within 5 hours (see Section 1.1.6.3). In addition, neither the HFL 
supernatant (Figure 3.7) nor medium conditioned by the bone marrow 
from phenylhydrazine treated mice, (Wright et al 1979), inhibited 
the proliferation of rapidly proliferating CFU-S. This suggests 
that the effect of any CFU-S proliferation inhibitor present was 
over-ridden by an excess of the CFU-S proliferation stimulator. 
The human fetal liver(supernatant two) 30-50K daltons CFU-S 
proliferation stimulator has a similar specific activity to the 
stimulator extracted from post phenylhydrazine bone marrow, (Wright 
1981). Both produced maximal stimulation of CFU-S proliferation 
when used at a concentration of >l0-12ug/ml. 
More than 25ug/ml of the 50-100K daltons NBME fraction was 
needed to produce maximum inhibition of CFU-S proliferation, Lord 
et al 1979) (Figure 1.11). The CFU-S proliferation stimulator 
226 
from human fetal liver and post phenylhydrazine bone marrow appear 
to have a higher specific activity than the NBME CFU-S 
proliferation inhibitor. These are very impure preparations, 
consequently determination of the true specific activity awaits 
biochemical purification of these factors. 
3.4.4 Specificity of the CFU-S Proliferation Stimulator 
Lord et al (1977b) were only able to demonstrate the source 
specificity of their CFU-S proliferation stimulator. It was not 
detectable in a 30-50K. daltons fraction from normal bone marrow, 
lymphocytes or red blood cell conditioned media. It was not 
possible to demonstrate cell line specificity because the immediate 
progeny of the CFU-S, the progenitor cells (eg GM-CFC, BFU-E) are 
all rapidly proliferating, (Iscove et al 1970), (Metcalf 1977). 
In a few situations GM-CFC are in a slowly proliferating 
state, eg early gestational age human fetal liver, (Moore and 
Williams 1973b). This situation was investigated (see Chapter 
Four). An inhibitor of normal murine bone marrow GM-CFC 
proliferation was detected in medium conditioned by early 
gestational age HFL cells. This inhibitor was used to produce a 
population of slowly proliferating NMBM GM-CFC. The HFL CFU-S 
proliferation stimulator did not affect the proliferation of these 
GM-CFC. This demonstrated the cell line specificity of the HFL 
CFU-S proliferation stimulator (see Chapter Four). 
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3.4.5 A Specific CFU-S Proliferation Inhibitor from Human Bone 
Marrow 
Medium conditioned by normal human rib bone marrow inhibited 
the proliferation of CFU-S from regenerating bone marrow. This 
conditioned medium had no effect on the proliferation of GM-CFC 
from normal murine bone marrow. This supports the observations of 
Wright et al (1980), that human bone marrow also contains a 
specific CFU-S proliferation inhibitor. The inhibitors from normal 
human and murine bone marrow were both contained in a 50-100K 
daltons Amicon fraction, (Wright et al 1980), (Lord et al 1976). 
It appears that the CFU-S proliferation inhibitor and 
stimulator are produced in similar murine and human haemopoietic 
tissues and have similar properties. They are all released from 
plastic adherent cells, and are contained in the same Amicon 
fractions. 
3.4.6 A CFU-S Proliferation Stimulator in Human Fetal Bone Marrow 
The bone marrow from fetuses of all gestational ages tested 
(14.9 -17.1 weeks) contained a CFU-S proliferation stimulator. 
This is probably because haemopoiesis develops in the fetal bone 
marrow from about 16 weeks of gestation, (Yoffey and Thomas 1961), 
(Kelemen et al 1979). The increase in the volume of the bone 
marrow is then rapid and it becomes the predominant haemopoietic 
tissue by 8-9 months of gestation, (Wickramasinghe 1975). The 
zzo 
presence of proliferating haemopoietic stem cells before 16 weeks 
of gestation would be a necessary prerequisite for the development 
of the haemopoietic tissue. The fetal bone marrow from about 14 
weeks of gestation is a rapidly expanding haemopoietic tissue. The 
detection of a CFU-S proliferation stimulator in fetal bone marrow 
is therefore synonymous with its presence in fetal liver. Its 
presence is presumably a reflection of the large proportion of 
fetal bone marrow haemopoietic stem cells in cycle. 
3.4.7 CFU-S Proliferation Stimulators in Human Fetal Spleen and 
Thymus 
Media conditioned by a spleen from a fetus of 13 weeks 
gestational age stimulated CFU-S proliferaton. The spleen is a 
developing haemopoietic tissue from about 8 weeks of gestation, 
(Kelemen et al 1979). The detection of a CFU-S proliferation 
stimulator in fetal spleen would therefore be analogous to its 
presence in fetal liver and bone marrow which are rapdily expanding 
haemopoietic tissues. 
Conditioned media from thymus tissue from fetuses of 15 and 
14.4 weeks gestational age stimulated and had no effect on CFU-S 
proliferation respectively. Although the results from the two 
fetuses tested were reproducible a much larger number of thymuses 
from fetuses of different gestational ages need to be tested before 
valid conclusions can be drawn. 
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Taylor and Skinner (1976) demonstrated significant 
erythropoiesis and granulocytopoiesis in human fetal thymus. But 
they reported a large quantitative variability in this haemopoiesis 
within fetuses of the same gestational age. These observations 
could explain the variable presence of a CFU-S proliferation 
stimulator in human fetal thymic tissue. Haemopoietic foci may 
also occur in any connective tissue and lymphoid organ in the human 
f etus, (Gilmour 1941), (Wickramasinghe 1975), (Kelemen et al 1979). 
The demonstration of CFU-S proliferation stimulator, cell 
source specificity in human fetal tissues is therefore difficult. 
But an indication of cell source specificity was obtained by 
comparing the release of CFU-S and GM-CFC proliferation regulators 
from different populations of HFL cells (see Chapter Four). For 
example, liver cells from fetuses of >14 weeks gestational age were 
separated by adherence to plastic. The CFU-S proliferation 
stimulator was only released by adherent HFL cells, and a GM-CFC 
proliferation stimulator was only released by the non-adherent HFL 
cells (see Chapter Four). 
C'iHAPTER THREE 
APPENDIX TABLES 
230 
ý 
ti NO 
... 
ba MMN 
', T 0 
e- +1+1+1 
2 'j a' -d CN 00 wb.. " M\ 14 
ý 
ýa fA 
w 
ý 
ý 
b 
D 
ý Lt 
N 
ý 
ý 
.ý 
M 
ý 
ý 
ý 
H 
`, :a.:., 1M -4 
w ý:: 
n 
w Ln Ln Ln 'r ý 
:3.. " 
aýO M CO CO O OW "4 10 t! 1 C% Oý 
m 
-4 
! -ý ý b0 00 0ý co 
p4 
eV oo . -1 e}1 MM 00 Qý 0 1-4 ! (. Mr .4 . --4 er 
$4 Ci -4 r-1 . -4 -4 -4 N 
CL4 
00 3ý +1 +1 +1 +1 +1 
+1 
-' b L 
4-b z 
obýý 
U iJ) ý 
ay+1 lý M" 
bo r-1 
7 
(y) 'a -4 
4) -}-1 f1 +1 
4-A Oý .a 
O 
O% V4 
ýV 0 
.ýÖMO 
4) a+ 
O 
ýVý G) 
. s: 
vq 
i 
cýd 
ýOy In 
1Oý b0 O 'fl 
^ý N U 04 
0 14 U) 91 
aýi 
ýNO Oý NN . ýý1 
"p 'b ýy Q" ""ý 
(ý "-º ýO .1ý . -ý 
L'i 00 3ý.. a +1 +1 +1+1 +1 O 
ýa O% .ý 
+1 00 
4MM ýO 00 er 'a' 
y 
H ý, ý UVNN r+ NNN ý+ 
N +' 
y 
a 04 W 
.t H to ý" 
UN 
O` 00 
+1 "" 
to Oý MO 
'^ O Id U 
En 93 -4 
+1 +1ý 
p' 
+1ýV tn 
0GUOOý 
ýO OV DS 
to ý 
w a, 4-, -- 
. -. m to N. OOO .dý 4) a0 "--ý yO 
ý 
,z la 
+-' tn N 00 t11 U1 Ln ^ý 
(ý 
ý 
ß".. 
0ý NN rt NNN 
ý f1 +1 +1+1 
+1 +I it 
gp Oý to 
44 
a ýN 
:3 00 -4 +1 ýM c+i oý MN aý 
G7 ao O. -t Uý NMNMMM 
aa m ++ ý+ a+ ö 
ý "O a+ +, ý1;. O 44 'C O 4-A m 
.SÄOH i" ii O 
$I'd 4 b G"i O a-1 
ýw+, D a) 
13 
rf ä+r. ++b;, o ++a+ aý V4 º-+ 04O tiý 
ý 
rW r-4 v' . r. ' E-4 ýýý 
4A :4-! ra ý `d ... ý P4 P4 ýýU 
z 
231 
`'ý ý, """ 
Id 7" O` "ý .r 00 
-}- 1 -E 1 
ý 
ö0 
MM %O 
e.... 
,, 
}"'ýy 
. --i >. 
t11 NN ýN 
tn . -1 `l" ý0 
0 
. 
ýO ti Ný 10 M -4 ý CO 
ý (ý rl NNN "'y N ý+ ^I 
+1 +1 +1 +1 +1 f1 +1 
ý+ 
O 
ý44 ý t11 rl -. 0 In In V C7% 0 
0ý 
p, l ý, 
Wä 06 o Oý owo CO ri 
Ox U) NMNM . -1 MNN 
O 
ß'' O 
In co ýO 0% 
4,3 .. 
. 0O OMN In 
.NNNNN 
r. Ln ä .Q +ý +ý +i +ý v . -. 
cu en -r fV 
3ýýA ýfl M ýO M 
'II ý 
ni ýf 
Ln 
M ýD 
Ln N 
,.., 
M 
ý 
r-r 
cd 
H 
ý", ' ý C. °ý° -- 
V 
q ý-, oW 
mfn 
ý ý. 
,-"" 
7- 
. ý"' ^+ N 
f. 
ýa ý ý'' . -ý ". 
fd NN+ 
ý 00 00 
ii't %0 00 
ývNN 
ý ý'. 
l- er N ^+ 0.... 
N. ý el+ C0 M CO 
O` t11 M ýO M t- 
`Qe 00 M 
+1 'i^ 1 
""""" 
00 [- M CJ% 
O ýO M . -ý er ýO 
MN "-+ MMM 
mý ti Oý O Oý 
to c 
=3. "+ NNN G4 O . --ý Oý,! ] ft}1 -ý- 1+1 
1-4 Gi l- co 0v ý 
cd ." O cd +' Oý er 00 U1 w 
'ti V4 1 Ln I 
0) 14 ý. M++ eM 0M tn 00 (` en .O 
L'0, m0 co 
OO 00 oO O` 
4 4. b En r- vi 0 r- 
rý m ^" i--I N -4 cV t) 
" ßi cd f1 +I +1fi +1 -F 1fI+1 wý I` 'O 
co 00 eM O, vq -. 0 1` `O 4' m 
1--1 ti Ci """"" 111 O Oý". ýi Ln co (n et" 000 .0 . 
ý0 
0* ºn ýý ý. 
-N-c . -ý rl 
CT 0N "-1 M .0 
-4 P-4 N r1 -4 -4 -4 M 
ý 
". i. ý 
44 5C 
º/ 0 S+" ýd + v ti NVI. 
-- 614 
dý"- 
-- 
V .a *1 -- 
-N º+ 
ý, rl 
ý+ '+ý, (ý 
ýý 
VO 
_O .. 
aa iý ýÖ 
. ýýa 
VýÖ 
. r7i V- 4-b T nt 'O R1 N1 ', 3 'ti ed ý :ü R7 cd ý-j y lÜ w GO cd L' ' UU j74 lu Gýý++) " 
i+ -1 UýUý++ ý^ U 
03 . -a cU. dý 
C 
.: 4 
ýL 
Li ,4O ;dR-. 4 O: d R 
ýl ""_Ni 
H ºý 'F' ++W+ 'F 
MW 
'} 'ý' 
ý 41 ý' 
92 1ý wa ul C: vi 
a ýý 0 a0 ao 
QI W . -1 
"" 
'O [ý N 
9ý 
W ": + +r w ^' W ;4W 
ý 
+ý 
V 
a) 
4-b ci 
11 A 
.. a 
00 
rl 
ý 
ai 
ci 
Lf) 
0 
. -r 
iG 
ý 
a) 
a) 
. -1 
a 
ý 
a) 
a 
Q) 
ý 4J ia 
0 
ro 
Ln N 
. -ý 
W 
in 
+1 
aý 
ro 
..., u . w{ 
:j rn 
W 
ý 
"o 
a) i4 
U 
a) 
.. "ý 
C7 
.. r 
ý 
-4 
-4 
C) U 
LA 
O 
. --1 
F-i 
a) a 
ý 
w 
0 
+y V. ý (d x cd """ :1O x"o 
xb 
b td 0 C) 44 1--i 
M "f 
ow tý +ý m 
U++-+ 
CHAPTERF0UR 
THE CONTROL OF GRANULOCYTE-MACROPHAGE 
PROGENITOR CELL PROLIFERATION 
1.11- 
CHAPTER FOUR : ABSTRACT 
At early stages (11-14 weeks) of gestation in human fetal 
liver few granulocyte-macrophage colony forming cells (GM-CFC) are 
in DNA synthesis, whereas later in gestation (>14 weeks) a large 
proportion of GM-CFC are in S-phase, Moore and Williams (1973b). 
Incubation of normal murine bone marrow GM-CFC (-40Z in DNA 
synthesis) with a supernatant from an early human fetal liver 
(11-14 weeks), reduced the proportion synthesising DNA to <5%. In 
contrast, the proportion of murine GM-CFC synthesising DNA was not 
affected by incubation with a supernatant from a late fetal liver 
(>14 weeks). GM-CFC that had been switched out of cycle by 
incubation with a supernatant from an early gestation human fetal 
liver were switched back into cycle during incubation with a late 
human fetal liver supernatant. It appears, therefore, that changes 
in the relative levels of a proliferation inhibitor and stimulator 
throughout gestation might control the proportion of GM-CFC in 
cycle. 
In normal murine bone marrow (NMBM) approximately 10% of the 
haemopoietic stem cells (CFU-S) are synthesising DNA. The 
proportion of CFU-S synthesising DNA was increased to approximately 
40% by incubation with a human fetal liver supernatant from all 
gestational ages tested (11-17 weeks). 
The specificity of these CFU-S and GM-CFC proliferation 
regulators is well demonstrated by an early gestation human fetal 
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liver supernatant which will stimulate CFU-S proliferation but 
inhibit GM-CFC proliferation. The inhibitor and stimulator of 
GM-CFC proliferation are both produced by non-adherent human fetal 
liver cells. The GM-CFC proliferation inhibitor has a molecular 
weight of >100K daltons, the stimulator 30-50K daltons. In 
contra-distinction, the CFU-S proliferation stimulator is produced 
by adherent human fetal liver cells and has a molecular weight of 
30-50K daltons. 
CHAPTER FOUR 
THE CONTROL OF GRANULOCYTE-MACROPHAGE PROGENITOR CELL PROLIFERATION 
4.1 INTRODUCTION 
4.1.1 The Granulocyte-Macrophage Colony Forming Cell (GM-CFC) 
The progenitor cells committed to granulocyte and monocyte 
differentiation can be assayed by virtue of their ability to form 
colonies of granulocytes and/or macrophages in vitro, (Pluznik and 
Sachs 1965), (Bradley and Metcalf 1966). The growth of these 
colonies is entirely dependent on the presence of specific 
stimulatory factors: Granulocyte-Macrophage Colony Stimulating 
factors (GM-CSF), (Burgess and Metcalf 1980). 
The GM-CFC are a heterogenous population of cells, (Metcalf 
1977 1978a), (Baum 1979). This is analogous to the arrangement 
of cells in the CFU-S compartment according to their generation 
age, (Micklem and Ogden 1976), (Rosendaal et al 1979), (Schofield 
1979). The heterogeneity of the GM-CFC may also be indicative of 
an age structure within this compartment, (Jacobsen et al 
1978 1979), (Bradley et al 1980), (Francis et al 1980 1981), 
(Standen et al '1980). There is also a spectrum of 
Granulocyte-Macrophage Colony Stimulating factors, which induce 
different patterns of GM-CFC proliferation and differentiation, 
(Metcalf 1979), (Burgess and Metcalf 1980). This heterogeneity of 
both the GM-CFC, and the factors which stimulate their 
proliferation and differentiation, confer a high degree of diverse 
responsiveness to the many demands made on the system, (Metcalf 
1977 1978c), (Moore 1979), (Verma et al 1981). 
4.1.2 Granulocyte-Macrophage Colony Stimulating Factors 
4.1.2.1 Cellular sources of GM-CSF 
All tissues synthesize detectable amounts of GM-CSF, (Burgess 
and Metcalf 1980). This suggested that either all cells or a 
cell(s) common to all tissues were capable of producing GM-CSF. 
With the advent of specialized culture techniques the following 
cells were shown to release GM-CSF: 
monocyte-macrophages, (Moore et al 1974) 
mitogen stimulated lymphocytes, (Parker and Metcalf 1974) 
vascular endothelial cells, (Quesenberry and Gimbrone 1980) 
thymic epithelial cells, (Ramsey and Hays 1979) 
fibroblasts, (Burgess and Metcalf 1980). 
4.1.2.2 Factors potentiating the production of GM-CSF 
GM-CSF production occurs at a basal level in most tissues; 
this is increased during bacterial, viral and protozoal infections, 
(Burgess and Metcalf 1980). Bacterial products such as endotoxin, 
(Quesenberry et al 1972), (Robinson et al 1977), and Lipid A, 
(Apte 
et al 1976), increase tissue production and serum levels of 
GM-CSF. Endotoxin enhancement of GM-CSF production is a radio 
resistant process involving macrophages, (Staber and Burgess 1980) 
and endothelial cells, (Quesenberry and Gimbrone . 
1980). The 
phagocytosis of particulate substances by macrophages also 
stimulates the production of GM-CSF, (Ramsey and Hays 1979). 
GM-CSF production by macrophages can therefore be stimulated in 
infections and allergic reactions, by the causative agent or one of 
its byproducts. This may have a physiological role in the 
production of more granulocytes and macrophages to combat these 
perturbations. 
T-lymphocyte production of GM-CSF can be stimulated in vitro 
by mitogens such as Concavalin A and phytohaemagglutinin, (Parker 
and Metcalf 1974). This is a radiosensitive process, (Metcalf 
1979). GM-CSF is also released by lymphocytes in the graft versus 
host reaction, (Hara et al 1974), (Singer et al 1977). This 
suggests that the release of GM-CSF by lymphocytes may also have 
some physiological significance, (Metcalf 1978b). 
4.1.2.3 Cellular interactions in the production of GM-CSF 
Relatively pure populations of lymphocytes, (Metcalf 1979), 
and macrophages, (Ramsey and Hays 1979), can produce GM-CSF under 
appropriate conditions. It now appears that interactions between 
two or more cell populations may in many circumstances be crucial 
events in the production of GM-CSF, (Metcalf 1978b). GM-CSF is 
produced by pokeweed mitogen (PWM) stimulated spleen cell cultures, 
(Parker and Metcalf 1974). Removal of the adherent cells from 
these cultures decreased GM-CSF production while the spleens from 
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nude mice produced no GM-CSF when stimulated with PWM, (Metcalf 
1978a). 
Francis et al (1980b) demonstrated that factors released from 
endotoxin stimulated lymphocytes could stimulate the release of 
GM-CSF by macrophages. Schreier and Iscove (1980) cultured clonal 
helper T-lymphocytes with their specific antigen. When these cells 
were incubated with H2IA region identical accessory cells from the 
spleen or peritoneal cavity (possibly macrophages) GM-CSF was 
released. 
These observations indicate that an interaction between 
T-lymphocytes and monocyte-macrophages is often a crucial event in 
GM-CSF production. These interactions could be similar to the 
cooperation between macrophages and lymphocytes in the production 
of a specific immune response to an antigen, (Nelson 1976), 
(Rosenstreich et al 1976), (Ruscetti and Gallo 1981). Thus the 
secondary immune response may not just be more rapid in terms of 
lymphocyte function but also in the production of GM-CSF and 
subsequent granulocyte and macrophage production. 
These interactions between antigenically primed lymphocytes 
and macrophages, (Schreier and Iscove 1980), also have the 
potential to produce specific types of CSF in response to certain 
antigens. This has been demonstrated in parasite infected mice, in 
which an eosinophilia is produced, (McGarry et al 1977). Spleen 
cells from these mice produce an eosinophil specific CSF (E0-CSF). 
This is dependent on a thymus derived lymphoid population. 
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Verma et al (1979)(1981) demonstrated that different sources 
of T-lymphocytes could both augment and suppress the production of 
GM-CSF by monocytes and macrophages. They postulated that this 
differential action might depend on the degree of prior activation 
of helper or suppressor T-lymphocyte subpopulations. This suggests 
another parallel with the immune response to antigens. 
4.1.3 Actions of GM-CSF 
4.1.3.1 GM-CSF effect on GM-CFC proliferation and 
differentiation 
GM-CSF is a specific stimulator of GM-CFC proliferation and it 
may trigger their differentiation, (Johnson 1981). It does not 
stimulate the proliferation of progenitor cells committed to other 
lines of differentiation, (Metcalf 1977), (Burgess and Metcalf 
1980). GM-CSF must be continuously present in GM-CFC cultures. 
If developing colonies are transferred to GM-CSF free cultures, 
growth stops and the colony dies, (Paran and Sachs 1968). The 
survival of. GM-CSF in liquid culture is also dependent on the 
continuous presence of GM-CSF, (Metcalf et al 1970), (Summer et al 
1972). 
GM-CSF can trigger non-cycling GM-CFC into cycle, (Moore and 
Williams 1973a), and is therefore not just an in vitro survival 
factor. GM-CSF causes a dose dependent increase in the growth rate 
of colonies, (Metcalf 1970), (Metcalf and Moore 1973). This is due 
to a combination of different GM-CSF actions on the GM-CFC and 
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their progeny. Increasing GM-CSF concentrations reduce the lag 
phase before the initiation of GM-CFC proliferation, (Metcalf 1970) 
and the mean cell cycle time of dividing colony cells, (Metcalf and 
Moore 1973). In a liquid bone marrow culture, a shortening of the 
generation time of granulocytes was also concomitant with 
increasing GM-CSF concentrations, (Winton et al 1977). Metcalf and 
Moore (1973) observed that GM-CFC colonies grown in the presence of 
high GM-CSF concentrations contained a high proportion of 
myeloblasts and promyelocytes (ie early myeloid precursors capable 
of cell division). In contrast colonies grown in low GM-CSF 
concentrations contained predominantly metamyelocytes and 
polymorphs. Increasing GM-CSF concentrations therefore cause 
colony cells to remain relatively undifferentiated and capable of 
further division. 
The GM-CFC and the recognisable myeloid and monocytic 
precursor compartments are sites of extensive potential 
amplification divisions, (Lajtha and Schofield 1974). GM-CSF in 
vitro has been shown to increase the size of these compartments by 
increasing the proportion of daughter cells of a preceding division 
which remain capable of further division, (Metcalf and Moore 1973). 
Concomitantly GM-CSF decreases the cell cycle time of these cells. 
The former effect of GM-CSF probably has the most significant 
effect on the production of differentiated cells, (Metcalf 1977). 
In vitro experiments therefore indicate that GM-CSF is a positive 
stimulus for granulocyte and macrophage production. 
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4.1.3.2 GM-CSF stimulation of biosynthetic pathways 
Burgess and Metcalf (1977a)(1977b) added GM-CSF to a bone 
marrow suspension. Within ten minutes RNA synthesis was detected 
in recognisable myeloid precursors and polymorphs, but not in 
lymphocytes or erythroid cells. A few hours later protein 
synthesis was detected in the same cells, (Burgess and Metcalf 
1980). The stimulation of cell proliferation differentiation and 
biosynthetic pathways unrelated to cell division by GM-CSF is 
analogous to the actions of erythropoietin. Erythropoietin 
stimulates the synthesis of haemoglobin in the late recognisable 
erythroid precursors, as well as shortening the cell cycle of the 
early erythroid precursors, (Hodgson 1970), (Lord 
. 
1979). GM-CSF 
also stimulates increased phagocytic and cytocidal action in 
macrophages, (Handman and Burgess 1979). 
4.1.3.3 Augmentation of GM-CSF actions 
The number of granulocyte and macrophage colonies produced as 
a function of the GM-CSF concentration has a sigmoid dose-response 
relationship, (Metcalf 1977). Thus once the plateau is reached 
increasing concentrations of GM-CSF in the cultures do not give 
rise to more colonies. But if human leucocyte conditioned media, 
(Wagemaker and Peters 1978), (Boyum et al 1980), serum or plasma, 
(Metcalf et al 1975), whole erythrocytes or erythrocyte lysates, 
(Bradley et al 1973), (Williams and Pluznik 1978), are added to 
cultures stimulated by plateau concentrations of GM-CSF more 
colonies are formed. This may be due to the stimulation of an 
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additional GM-CFC subpopulation which was not affected by GM-CSF 
alone, (Williams and Pluznik 1978), (Williams and Van Den Engh 
1975). 
The following observations suggest that haemolysates may 
enhance colony formation by reducing oxygen toxicity: 
(1) High oxygen tension suppresses colony development, (Bradley et 
al 1978). 
(2) Sulphidryl groups enhance colony formation, (Toohey 1975). 
(3) Removal of sulphydryl groups from haemolysates abrogated their 
enhancing effect on colony development, (Bertoncello and Bradley 
1977), (Chen and Lin 1980). 
These observations illustrate the sensitivity of in vitro 
assays, and emphasize the caution with which results must be 
interpreted. 
4.1.3.4 Heterogeneity of GM-colony stimulating factors 
Metcalf (1974) and Moore et al (1974) demonstrated that high 
concentrations of GM-CSF produced predominantly granulocyte or 
mixed colonies. Low concentrations of GM-CSF produced mainly 
macrophage colonies. It was therefore proposed that the 
concentration of GM-CSF determines the line of GM-CFC 
differentiation. 
Metcalf and MacDonald (1975) showed that rapidly sedimenting 
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GM-CFC in response to low GM-CSF concentrations, formed mainly 
macrophage colonies. Conversely the slowly sedimenting GM-CFC 
formed predominantly granulocytic colonies but only in the presence 
of high GM-CSF concentrations. This suggested that GM-CFC with 
different differentiation potentials could be stimulated by 
different GM-CSF concentrations. Alternatively two factors could 
have been present in the same GM-CSF preparation, which were able 
to stimulate different GM-CFC subpopulations. This later 
hypothesis was subsequently demonstrated. 
The two major forms of murine CSF are GM-CSF and M-CSF. 
GM-CSF stimulates both macrophage and granulocyte production and is 
the major form in adult tissues, (Burgess et al 1977). M-CSF 
stimulates the formation of macrophage colonies and is produced by 
L-cells, (Stanley and Heard 1977). M-CSF is also the major form of 
CSF in fetal tissues, where macrophage differentiation 
predominates, (Johnson and Burgess 1978). 
A myelomonocytic cell line (WEHI-3) produces GM-CSF capable of 
stimulating the formation of granulocyte, macrophage and mixed 
colonies, (Greenberger et al 1979), (Dexter et al 1980). Column 
chromatography of this GM-CSF separated material binding to the 
column, which stimulated predominantly macrophage colonies. In 
contrast low concentrations of the breakthrough fraction stimulated 
the formation of pure granulocytic colonies, (Williams et al 1978). 
Different fractions from the serum of mice injected with endotoxin, 
have also been separated, which stimulate predominantly macrophage 
or granulocyte colony formation, (Lotem et al 1980), (Staber and 
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Burgess 1980). 
These observations strongly suggest that GM-progenitor cell 
differentiation is regulated by separate factors and not by a 
differential response to a single factor, as suggested by Metcalf 
(1974) and Moore et al (1974). 
4.1.3.5 Biochemical properties of GM-CSF 
GM-CSF from different sources appear to be a heterogenous 
group of glycoproteins, (Metcalf 1978a), (Burgess and Metcalf 
1980). Conventional gel filtration of GM-CSF from many sources, 
indicates an extreme molecular weight heterogeneity, (Price et al 
1975), (Nicola et al 1979a 1979b). But gel filtration is often a 
poor reflection of the molecular weight of a protein, (Andrews 
1965), especially glycoproteins, (Spiro 1973). This is because 
the carbohydrate moiety associates with other molecules which then 
co-migrate with it, (Alhadeff 
. 
1978). This anomalous behaviour of 
glycoproteins can be abrogated by removing the carbohydrate moiety 
with neuraminidase. Alternatively the carbohydrate moieties can be 
sequestered inside the molecule by destroying its three dimensional 
structure with sodium-dodecylsulfate, (Lehninger 1975). 
Nicola et al (1979b) produced conditioned medium from murine 
tissues. The GM-CSF isolated from this medium had an apparent 
molecular weight of between 37,000 and 200,000 daltons. When these 
preparations were treated with neurominidase a single molecular 
weight species of 23,000 was obtained from all sources. This 
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stimulated both granulocyte and macrophage colony formation (ie 
GM-CSF). M-CSF has been isolated from L-cell conditioned medium, 
(Stanley et al 1976) and from murine yolk sac conditioned medium, 
(Johnson and Metcalf 1978b), (Johnson and Burgess 1978) and has an 
apparent molecular weight of 60-70,000 daltons. The molecular 
weights of GM-CSF acting on human GM-CFC are not as clearly 
defined, but appear similar to those isolated from murine tissues, 
41u 1979), (Burgess and Metcalf 1980). 
4.1.3.6 GM-CSF summary 
Granulocyte macrophage-colony stimulating factors are 
heterogenous in their tissue sources, species specifities, 
biochemical properties and in their ability to stimulate specific 
GM-CFC subpopulations, (Metcalf 1977 1979), (Burgess and Metcalf 
1980). 
4.1.4 Heterogeneity of GM-CFC 
The haemopoietic tissues contain a heterogenous population of 
cells capable of forming granulocyte and/or macrophage clones, 
(Metcalf 1977), (Baum 1979). GM-cluster forming cells produced 
clones of less than 50 cells, (Metcalf 1969). The normal GM-CFC 
form colonies of 50 to 5,000 cells and high proliferative potential 
GM-CFC (HPP-GM-CFC) form colonies of more than 5,000 cells, (Bradley 
et al 1980). 
The GM-cluster forming cells outnumber the GM-CFC by 5 to 
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10: 1. In NMBM these cells have a higher modal sedimentation 
velocity than the GM-CFC and are larger cells, (Metcalf and 
MacDonald 1975). The GM-cluster forming cells are therefore 
intermediate in size and numbers between the GM-CFC and the 
myeloblasts. It is probable that they are the direct progeny of 
the GM-CFC, (Metcalf 1977). 
The colonies formed by GM-CFC are scored after an incubation 
of 7 or 14 days, (Metcalf 1977). The day 7 colonies are composed 
of granulocytes and/or macrophages and the day 14 colonies entirely 
of macrophages. The GM-CFC forming day 7 colonies are rapidly 
sedimenting cells while those forming day 14 colonies are more 
slowly sedimenting cells, (Jacobsen et al 1978a 1978b). 
Normal human bone marrow contains cells which can form 
colonies in fibrin clot diffusion chambers, which are implanted 
into the peritoneum of sublethally irradiated mice, (Jacobsen and 
Fauerholdt 1976), (Jacobsen 1977). These cells are called colony 
forming units in diffusion chambers (CFU-D). They form 
granulocyte, eosinophil, megakaryocyte, and fibroblast like 
colonies, which are scored after 14 days in culture, (Jacobsen and 
Fauerholdt 1976). CFU-D have a similar sedimentation profile to 
the cells which give rise to GM-CFC in suspension culture, 
(Sutherland et al 1971), (Iscove et al 1972). They may represent 
the same cell. population. 
Jacobsen et al (1979) cultured different velocity 
sedimentation fractions from human bone marrow in diffusion 
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chambers. The CFU-D decreased in all fractions with time in 
culture. GM-CFC were only detected in cultures which had initially 
contained CFU-D, and the numbers of day 14 GM-CFC increased before 
the day 7 GM-CFC. It was therefore proposed that CFU-D give rise 
to day 14 GM-CFC which in turn give rise to day 7 GM-CFC. 
The observations of Bol et al (1979) fit in with this scheme; 
they separated three GM-CFC subpopulations from murine bone marrow. 
Mature cells. appeared first, in colonies derived from rapidly 
sedimenting GM-CFC. Undifferentiated cells persisted in colonies 
derived from slowly sedimenting GM-CFC. But the results obtained 
from different species are not always consistent, (Metcalf and 
MacDonald 1975), (Jacobsen et al 1979), (Gerhartz and Fliedner 
1980). 
Heterogeneity of the physical properties of GM-CFC appear to 
be concomitant with differences in their differentiation and 
proliferation potential and sensitivity to GM-CSF stimulation. 
Francis et al (1979)(1981) measured the clone size produced by 
GM-CFC of different densities, and their sensitivity to GM-CSF 
stimulation. An increasing sensitivity to GM-CSF was associated 
with increasing cell density and decreasing clone size. This data 
also complements that of Jacobsen et al (1978a)(1979), Metcalf and 
MacDonald (1975), Johnson and Metcalf (1978a). This is assuming 
that increasing cell density and sedimentation velocity are 
synonymous, as shown by Janoshwitz et al (1971), Metcalf and 
MacDonald (1975). 
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Thus a maturation sequence of cells from the CFU-D through day 
14 GM-CFC, day 7 GM-CFC, GM-cluster forming cell, to recognisable 
myeloid and monocyte precursors, can be constructed from this data. 
The maturation of these cells being accompanied by a decrease in 
the clone size which they produce, increasing sedimentation 
velocity, density, cell size and incidence in the haemopoietic 
tissues. The CFU-S can be inserted before the CFU-D in this 
sequence, by virtue of its slower sedimentation velocity, (Worton et 
al 1969), (Metcalf and MacDonald 1975); the larger clone size 
which it produces, (Micklem 1972), and its lower incidence in the 
bone marrow, (Metcalf 1977). The HPP-GM-CFC can then be 
intercalated between the CFU-S and CFU-D, because of its 
intermediate sedimentation velocity and clone size which it 
produces, (Bradley and Hodgson 1979), (Bradley et al 1980). 
Standen et al (1980) also proposed a model of the GM-CFC 
compartment. This was based on a compilation of murine and human 
data, (Bo and Williams 1976), (Bol et al 1979), (Wiseman et al 
1976), (Byrme et al 1978). Its conclusions do not agree with 
those of Francis et al (1981) or Metcalf and MacDonald (1975). 
The granulocyte-macrophage progenitor cell compartment is 
heterogenous, being composed of subpopulations with different 
proliferative and differentiation potential sensitivities to 
different forms of GM-CSF and physical properties, reviewed by 
Metcalf (1977), Baum (1978), Burgess and Metcalf (1980). This is 
analogous to the heterogeneity within the haemopoietic stem cell 
compartment, (Schofield and Lajtha 1969), (Schofield 1978 1979), 
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(Rosendaal et al 1979). 
4.1.5 The Physiological Significance of GM-CSF as a Regulator of 
Granulocyte and Macrophage Production 
4.1.5.1 GM-CSF, neutropenia and endotoxemia 
GM-CSF stimulates GM-CFC proliferation and differentiation, 
(Moore and Williams 1973a), (Metcalf 1977). Higher GM-CSF levels 
in vitro result in increased macrophage and granulocyte production, 
(Metcalf and Moore 1973). If GM-CSF is a physiological regulator 
of GM-CFC proliferation, increases in GM-CSF production and release 
would be predicted when there is an increased demand for 
granulocyte and macrophage production in vivo. This would occur 
when the size of the GM-CFC and recognizable myeloid and monocyte 
compartments was reduced; for example by irradiation. The 
increased demand for granulocyte and macrophage production should 
also be associated with increased GM-CSF release. 
In irradiated neutropenic mice serum GM-CSF levels are 
elevated, (Morley et al 1971). But the irradiation also damages 
the gastrointestinal tract and causes a bacteraemia and 
endotoxaemia, (Micklem and Loutit 1966), (Morley et al 1971,1972). 
Bacteria and endotoxin are both potent stimulators of GM-CSF 
production, (Quesenberry et al 1972), (Robinson et al 1977). In 
irradiated germ free mice a neutropenia develops, but there is no 
bacteraemia, endotoxaemia, or elevation of the serum GM-CSF 
concentration, (Morley et al 1972). This suggested that the 
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endotoxin and not the neutropenia had caused the elevated serum 
GM-CSF concentration, although the neutropenia would potentiate 
this because less inactivation of endotoxin by granulocytes and 
macrophages would occur, (Morley et al 1972), (Mahmood and Robinson 
1978). 
Cyclic neutropenia is a familial disease characterised by 
episodes of neutropenia at intervals of 15-30 days, followed by a 
monocytosis, (Moore et al 1974). Plasma GM-CSF levels were maximal 
during the nadir of neutrophils and the peaks of monocytes. It was 
suggested that GM-CSF was released by the monocytes in response to 
the neutropenia, (Moore et al 1974). Greenberg et al (1976) 
demonstrated that maximal GM-CSF production was correlated with an 
endotoxaemia. This was maximal during the neutrophil nadir. Thus 
in cyclic neutropenia, the raised GM-CSF production may also be due 
to the neutropenia and the concomitant endotoxaemia, (Greenberg et 
al 1976). From these experiments it is therefore not possible to 
establish whether the release of GM-CSF is a primary response to 
the neutropenia or is a result of the infections and endotoxaemia 
in the neutropenic animal. 
4.1.5.2 Local control of GM-CFC proliferation 
The relationship between increased serum GM-CSF levels and 
increased granulopoiesis does not always occur. Udupa and 
Reissmann (1975) injected mice with cytotoxic drugs, this produced 
a neutropenia. Granulopoietic recovery could be stimulated with 
androgens. But there was no concomitant rise in serum GM-CSF 
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levels. 
The local production of GM-CSF may be more significant in the 
regulation of granulopoiesis than serum GM-CSF levels, (Chan and 
Metcalf 1972,1973), (Francis et al 1980). Chan and Metcalf 
(1972) demonstrated that the small proportion of cells associated 
with the bone shaft after flushing out most of the bone marrow 
produced 20 times more GM-CSF than the extruded marrow cells. 
Following whole body irradiation the production of GM-CSF by the 
removable bone marrow cells remained constant. The production of 
GM-CSF by the shaft associated cells increased simultaneously with 
the onset of GM-CFC regeneration. There was also no change in the 
GM-CSF production by spleen or lung tissue, (Chan and Metcalf 
1973). This is an example of a local control mechanism; 
stimulating GM-CSF release in response to the loss of cells killed 
by the irradiation. This is in contrast to a non-specific 
stimulation of GM-CSF release, as by endotoxin, (Quesenberry et al 
1972). 
Francis et al (1980) demonstrated a factor in serum which 
stimulated GM-CSF production by adherent bone marrow cells. They 
called this adherent cell dependent indirect GM-CSF. This may be 
the same as a serum factor demonstrated by Baker and Galbraith 
(1979). This stimulated the release of GM-CSF from monocytes and 
macrophages, but it had no direct effect on GM-CFC proliferation. 
They suggested that this serum factor stimulated the local release 
of GM-CSF by monocytes and macrophages in the bone marrow. 
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In long term in vitro bone marrow cultures, granulopoiesis 
occurs and GM-CFC can be harvested from the cultures, (Dexter et al 
1976 1977a). Initially no GM-CSF could be detected in medium 
removed from these cultures, (Dexter 1979). Subsequently by 
concentrating medium from these cultures over amicon filters, it 
was possible to detect extremely low levels of GM-CSF, Dexter 
(unpublished observations). Gap junctions have been observed 
between the adjacent membranes of undifferentiated granulocyte 
precursors and epithelial cells, (Allen and Dexter 1976a). These 
would permit the passage of molecules such as GM-CSF between these 
cells with little leakage into the culture medium. Granulopoiesis 
may therefore be controlled at a local microenvironmental level in 
these cultures. 
Physiologically the local levels of GM-CSF in the bone marrow 
may be more important than its serum concentration in regulating 
GM-CFC proliferation. This is similar to the mechanism of CFU-S 
proliferation regulation (Section 1.1.7). 
4.1.5.3 GM-CSF: Role in vivo control of granulopoiesis and 
monocytopoiesis 
GM-CSF stimulates in vitro the proliferation and 
differentiation of the GM-CFC and the recognizable myeloid and 
monocytic precursors, (Metcalf and Moore 1973), (Burgess and Metcalf 
1980). GM-CSF is therefore a positive stimulus for the production 
of granulocytes and monocytes from the GM-CFC. Although no 
definitive demonstration of the role of GM-CSF in vivo has been 
252 
made, some experiments suggest it is equivalent to that in vitro. 
Metcalf and Stanley (1971) demonstrated a monocytosis and 
polymorph leucocytosis in mice injected with partially purified 
human urine GM-CSF. But this could have been an immunological 
reaction to impurities in the GM-CSF preparation. Asano et al 
(1977) removed a lung tumour from a patient with neutrophilia. The 
tumour released ' GM-CSF in vitro. In nude mice transplanted with 
this tumour a marked neutrophilia was detected. Concomitantly the 
numbers of GM-CFC in the bone marrow increased. The plasma of 
these mice had a much higher GM-CSF activity than appropriate 
controls. The GM-CSF activity and the neutrophilia increased as 
the tumour grew. This GM-CSF stimulated the growth of 
predominantly granulocyte and mixed colonies, a reflection of the 
neutrophilia produced in the tumour host. This is one of the few 
demonstrations of the in vivo activity of GM-CSF. But it does not 
eliminate the possibility that other factors released from the 
tumour may have caused the neutrophilia. 
Serum GM-CSF concentrations are not always correlated with the 
level of myelopoiesis, (Udupa and Reissmann 1975). The local 
concentration of GM-CSF in the bone may be more significant 
physiologically, (Chan and Metcalf 1973). Francis et al 
(1977)(1980) demonstrated factors in human serum which stimulated 
the production of GM-CSF by bone marrow adherent 
monocyte-macrophages. Some of these serum factors were produced by 
lymphocytes. This "adherent cell dependent GM-CSF" was distinct 
from direct acting GM-CSF. In patients with bacterial infections 
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the level of adherent cell dependent GM-CSF was raised, but the 
levels of direct acting GM-CSF were unchanged. 
Verma et al (1981) have proposed that two principal mechanisms 
control GM-CFC proliferation, an intrinsic and extrinsic system. 
The intrinsic system consists of feedback proliferation controls 
from cells within the granulocyte-macrophage complex, eg macrophage 
derived GM-CSF. The extrinsic, feedback controls from cells other 
than granulocytes or macrophages, eg lymphocytes, (Francis et al 
1977 1980). They proposed that the intrinsic system would 
provide a steady state control of myelopoiesis and monocytopoiesis. 
The extrinsic system would control the response to inflammatory and 
allergic stimuli. Lymphocytes may be a principal source of 
extrinsic GM-CSF, which stimulates granulocyte and macrophage 
production in specific immunological reactions, (Metcalf 
1978b 1979). 
GM-CSF is probably the principal positive stimulus for 
granulocyte and macropohage production and is produced by many 
types of cells. GM-CSF is a heterogenous group of molecules which 
have specific actions on GM-CFC proliferation and differentiation, 
(Burgess and Metcalf 1980). The GM-CFC themselves are also a 
heterogenous population, with different proliferation and 
differentiation potentials. This combined heterogeneity produces a 
system which can respond specifically to the different demands made 
upon it. But to maintain a steady state system negative feedback 
controls of myelopoiesis and monocytopoiesis are also needed, (Baum 
1977), (Broxmeyer and Moore 1978), (Metcalf 1978b). 
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4.1.6 The Negative Feedback Control of Granulocyte and Monocyte 
Production 
Factors which inhibit the production of granulocyte and 
monocyte have been demonstrated. These have different sites of 
action, some inhibiting GM-CFC proliferation, others the 
proliferation of the recognizable myeloid and monocyte precursors. 
But as with GM-CSF"the physiological significance of these factors 
has not been definitively demonstrated, (Broxmeyer and Moore 1978). 
4.1.6.1 Granulocyte chalone 
Granulocyte chalone is a species non-specific, tissue 
specific, reversible inhibitor of its recognizable precursor cell 
proliferation, (Paukovits 1973), (Rytomaa 1973), (Lord et al 
1974b). It therefore reduces the number of amplification 
divisions within this compartment, and consequently the output of 
granulocytes. The granulocyte chalone has a low molecular weight, 
4000 daltons, (Paukovits 1973). 
In the initial experiments a short term bone marrow culture 
system was used. The granulocyte chalone reduced the uptake of 
tritiated thymidine by these bone marrow cells. - But Maurer et al 
(1976) showed that bone marrow cells did not divide in this culture 
system. But Benestad et al (1980) demonstrated that under optimal 
conditions they did divide. A system in which bone marrow cells 
are only dividing for a short period and is rapidly running down is 
not suitable for the assaying of cell proliferation inhibitors. 
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A granulocyte extract has also been shown to inhibit 
granulopoiesis in diffusion chambers, (Laerum and Maurer 1973), 
(Benestad et al 1973 1980). In this system the granulocyte 
extract had no effect on macrophage or lymphocyte tritiated 
thymidine uptake. 
By definition, a granulocyte chalone should reversibly inhibit 
the proliferation of its own recognisable precursors, but not those 
of other haemopoietic lineages. These qualities of a granulocyte 
extract were demonstrated by Lord et al (1974b)(1974c). They 
measured the structuredness of the cytoplasmic matrix (SCM) of bone 
marrow cells as an index of their proliferative state. The SCM of 
a cell decreases as it progresses from a resting into a 
proliferative state. Extracts were prepared from granulocytes, 
erythrocytes and lymphocytes. The extracts from these cells only 
increased the SCM of their respective precursors, ie proliferation 
inhibition. This effect was reversed by washing the cells in fresh 
medium. These experiments demonstrated that granulocytes release a 
factor which specifically but reversibly inhibits the proliferation 
of their recognizable precursors. The granulocyte extract did not 
affect GM-CFC proliferation, but it did reduce the labelling index 
of the cells in the developing colonies, ie the recognizable 
myeloid precursors. Extracts from erythrocytes and lymphocytes. did 
not have this effect, (Lord et al 1977c). 
Lord (1975) demonstrated that the granulocyte extract had a 
similar effect in vivo as it did in vitro. Lethally irradiated 
mice were grafted with bone marrow cells and hypertransfused to 
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prevent erythroid spleen colony formation. In these animals about 
50% of the spleen cells were granulocytic. Repeated labelling 
experiments, (Aherne et al 1977), indicated that the mean cell 
cycle time of these cells was 15 hours. In mice which had been 
previously injected with the granulocyte extract this was increased 
to 30 hours. Thus the granulocyte extract reduced the number of 
amplification divisions within the recognizable myeloid precursor 
compartment and therefore the output of granulocytes. This is 
analogous to the action of an erythrocyte extract on the 
recognizable erythroid precursors, (Lord et al 1977a). 
4.1.6.2 Serum inhibitors of myelopoiesis 
High molecular weight, >400,000 daltons, lipoprotein, heat 
labile inhibitors of granulopoiesis have been demonstrated in 
human, (Chan et al 1971), and murine serum, (Chan 1970). The 
cellular origin of these inhibitors is not known, (Broxmeyer and 
Moore 1978). These serum inhibitors block the action of GM-CSF on 
the GM-CFC, (Chan and Metcalf 1970), (Beran 1975). But some of 
these preparations were not cell lineage specific, also inhibiting 
colony formation by BL-CFC and leukaemic CFC, (Metcalf and Russel 
1976). 
A serum inhibitor also caused a premature transformation of 
granulocytic colonies to macrophage colonies, (Chan 1970). In 
endotoxin injected mice a concomitant rise of GM-CSF and serum 
inhibitor levels was detected, (Shah et al 1978). Baker and 
Galbraith (1979) also demonstrated a serum lipoprotein inhibitor of 
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the actions of GM-CSF. The level of this inhibitor was correlated 
with the number of circulating neutrophils. They therefore 
suggested that the lipoprotein inhibitor was released by 
neutrophils to act as a negative feedback inhibitor of their 
production. The physiological significance of these serum 
inhibitors is not clear because of their non cell lineage specific 
action. 
4.1.6.3 Inhibition of GM-CSF production: colony inhibiting 
activity, lactoferrin 
Mature granulocytes from normal humans and mice release a 
substance which inhibits GM-CSF production and/or release by 
monocytes and macrophages, (Haskill et al 1972), (Broxmeyer et al 
1977). This factor is called colony inhibiting activity (CIA). 
It is species non-specific and it is not cytotoxic. Broxmeyer et 
al (1977) removed adherent GM-CSF producing cells from bone marrow. 
Exogenous GM-CSF was then used to stimulate colony formation by 
GM-CFC. CIA had no effect on the number or size of colonies that 
were formed in these cultures. CIA also had no effect on colony 
formation by other committed progenitor cells, (Broxmeyer and Moore 
1978). 
CIA also has an action in vivo. Broxmeyer and Moore (1978) 
injected mice with cyclophosphamide which kills a lot of 
haemopoietic cells, but subsequently a rebound granulopoiesis 
occurs. GM-CSF production and the GM-CFC content of the bone 
marrow and spleen were also raised. Injection of CIA into these 
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mice prior to the rebound granulopoiesis, substantially decreased 
the production of GM-CSF and GM-CFC. This treatment did not affect 
the numbers of B lymphocyte progenitors (BL-CFC). 
CIA was heat stable and contained in a 102K to 128K daltons 
molecular weight fraction, (Mendelsohn et al 1978). CIA was 
subsequently shown to be lactoferrin an iron binding protein 
present in granulocytes, (Massum et al 1969), (Broxmeyer et al 
1978). The maximum inhibition of GM-CSF production by monocytes 
and macrophages occurred when the lactoferrin was fully saturated 
with iron. In this state it was active at concentrations as low as 
10-17 moles, (Broxmeyer et al 1978). But lactoferrin did not 
inhibit the production of GM-CSF by lymphocytes, or other 
macrophage metabolic processes, (Broxmeyer et al 1980). 
Lactoferrin also had no effect on the production of GM-CFC from 
CFU-D, (Jacobsen et al 1979), or the production by adherent 
mononuclear cells of a factor necessary for this transition, 
(Broxmeyer et al 1980). Mouse fetal liver cells produce both 
erythropoietin and GM-CSF in vitro, (Zucali et al 1977). 
Lactoferrin inhibited the production of GM-CSF but not 
erythropoietin by these cells, (Zucali et al 1979). 
Lactoferrin had no effect on the production of GM-CSF by 
lymphoid cells which only produce it upon activation by substances 
such as endotoxin, (Broxmeyer and Moore 1978). The effect of 
lactoferrin was abrogated by bacterial endotoxin, lithium and 
testosterone which stimulate GM-CSF production. Lactoferrin may be 
implicated in the intrinsic regulation of granulocyte production, 
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(Verma et al 1981). Lactoferrin constitutes a negative feedback 
from the granulocytes to the GM-CFC via the inhibition of GM-CSF 
production by monocytes and macrophages. The lack of effect of 
lactoferrin on the production of GM-CSF by lymphocytes may be 
important in infective inflammatory situations. In these 
circumstances the number of circulating neutrophils would be very 
high, yet more would be needed to combat the infection. The 
lymphocyte production of GM-CSF would rise in these conditions 
stimulated by endotoxin and not affected by lactoferrin. 
4.1.6.4 Prostaglandin E inhibition of GM-CSF actions 
E type prostaglandins (PGE) at concentrations as low as 10-10 
moles inhibit GM-CFC proliferation in vitro. The PGE had to be 
present continuously throughout the culture period to have this 
effect. Pre-incubation of the bone marrow cells with PGE prior to 
plating had no effect on the subsequent colony formation, (Kurland 
and Moore 1977). In the presence of PGE the GM-CFC required an 8 
to 9 fold higher GM-CSF concentration to proliferate to the same 
extent as in the absence of PGE. PGE therefore decreased the 
responsiveness of GM-CFC to stimulation by GM-CSF. 
PGE and GM-CSF are both produced by macrophages, monocytes 
also produce PGE, (Kurland and Bockman 1978). Kurland et al (1977) 
demonstrated that the production of PGE by monocytes and 
macrophages increased in response to increasing GM-CSF 
concentrations. But Pelus et al (1979) demonstrated that it was 
only the M-CSF which stimulated PGE production. PGE specifically 
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inhibited macrophage colony formation, (Pelus et al 1979), (Williams 
1979). PGE concentrations as low as 10-10 moles inhibited 
macrophage colony formation, while mixed and granulocyte colony 
formation was only inhibited by 10-7 moles. Macrophages therefore 
specifically regulate their own production via a positive factor 
M-CSF and a negative factor PGE. In contrast to PGE lactoferrin 
caused a decrease in the production of all forms of CSF by 
macrophages, ('elus et al 1979). 
Indirect evidence suggests that the actions of PGE and GM-CSF 
on GM-CFC are mediated by changes in the relative intracellular 
concentration of cyclic nucleotides, (Kurland et al 1977), (Kurland 
1978). The enzyme Cyclic AMP phosphodiesterase inactivates Cyclic 
AMP. Theophyline, a Cyclic AMP phosphodiesterase inhibitor 
potentiated the action of PGE on GM-CFC proliferation. In contrast 
imidazole, an activator of Cyclic AMP phosphodiesterase, reversed 
the inhibition of GM-CFC proliferation by PGE. Agents such as 
lithium, which increase the intracellular levels of Cyclic GMP 
augmented the stimulation of GM-CFC proliferation by GM-CSF, (Ramsey 
and Hays 1979). This suggests that the antagonistic actions of 
PGE and GM-CSF may be mediated by the intracellular balance between 
Cyclic AMP and Cyclic GMP. The regulation of biological processes 
thorugh the opposing actions of Cyclic AMP and Cyclic GMP is common 
to many systems, (Goldberg et al 1975). 
The PGE concentration in normal plasma is about 10-10 M, (Jaffe 
et al 1973). Within the area of an infection the PGE 
concentration may reach 10-7 M, (Berenbaum et al 1976). PGE may 
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therefore be a physiological negative feedback regulator of 
macrophage production. 
4.1.7 The Regulation of GM-CFC Proliferation in Human Fetal Tissues 
The investigation of CFU-S proliferation control mechanisms 
was assisted by the existence of cycling and non-cycling CFU-S 
populations, (Rencricca et al 1970), (Wright and Lord 1977 1978). 
A large proportion of GM-CFC are cycling in most haemopoietic 
tissues, (Metcalf 1977). In human fetal livers of different 
gestational ages the GM-CFC exist in two distinct kinetic states, 
(Moore and Williams 1973b), (Figure 4.1). 
1.11-14 weeks of gestation <5% GM-CFC in S-phase 
2. >14 weeks of gestation >30% GM-CFC in S-phase. 
In contrast in the bone marrow from human fetuses of all 
gestational ages a large proportion of GM-CFC are in S-phase. The 
regulation of GM-CFC proliferation in human fetal haemopoietic 
tissues may therefore be controlled locally in a similar manner to 
the control of CFU-S proliferation, (Gidali and Lajtha 1972), 
(Rencricca et al 1970), (Wright and Lord 1977). 
The kinetic state of the GM-CFC in human fetal liver appears 
to be related to their concentration. This is initially low and 
increases to reach a maximum at about 13 weeks of gestation and 
then decreases again. The initial increase is probably due to the 
migration of GM-CFC into the fetal liver from the yolk sac. The 
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The proportion of human fetal liver GM-CFC in S-phase 
throughout gestation. 
fall in the fetal liver concentration of GM-CFC coincides with the 
onset of haemopoiesis in the fetal bone marrow. This is probably 
due to a migration of GM-CFC from the fetal liver to the fetal bone 
marrow. This migration stream of haemopoietic cells was 
demonstrated in murine fetal haemopoietic tissues, (Moore and 
Metcalf 1970), see Section 3.1. The concentration of GM-CFC in 
the fetal bone marrow increases from 14 weeks of gestation. 
The percentage of haemopoietic activity in the fetal liver and 
bone marrow throughout gestation are illustrated in Figure 4.22. 
Onto this is superimposed the percentage of fetal liver GM-CFC in 
S-phase. 
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It was postulated that in human fetal haemopoietic tissues the 
proportion of &M-CFC in cycle is regulated by a local concentration 
dependent mechanism similar to that demonstrated for the CFU-S by 
Wright and Lord (1978). This hypothesis was investigated. 
Conditioned medium was produced from the liver and bone marrow of 
human fetuses of different gestational ages, and the presence of 
specific GM-CFC proliferation regulators was assayed. 
4.1.8 Leukaemic Cell Associated Inhibitors of GM-CFC Proliferation 
Olofsson and Olsson (1980a) demonstrated that the bone marrow 
and blood cells from patients with leukaemia released a factor 
which reduced the proportion of normal bone marrow GM-CFC in 
S-phase. This factor was not released by the same cells from 
normal control patients. This factor has been called leukaemic 
associated inhibitor (LAI). LAI was shown to be a glycoprotein of 
>500,000 daltons, produced by light density (<1.077g/ml) leukaemic 
cells, (Olofsson and Olsson 1980b). SDS gel electrophoresis 
indicated that the biological activity of the LAI was contained in 
a 150-170,000 daltons subunit. LAI was released from the leukaemic 
cells during a3 to 5 hour incubation at 37°C. Using the tritiated 
thymidine suicide technique LAI was directly shown to reduce the 
proportion of normal bone marrow GM-CFC in S-phase. LAI did not 
reduce the absolute number of colonies formed. 
Broxmeyer et al (1978b) also extracted a factor from the bone 
marrow and blood of leukaemic patients. This factor reduced the 
absolute number of colonies formed by normal bone marrow GM-CFC. 
It was called leukaemic inhibitory activity (LIA). The maximum 
production of LIA was achieved by incubating the leukaemic cells 
for 3 to 4 days at 37 °C. Normal bone marrow depleted of GM-CFC in 
S-phase with tritiated thymidine was subsequently exposed to LIA. 
In this experiment the LIA caused no reduction of GM-CFC colony 
formation. This suggested that LIA acted on the GM-CFC during 
S-phase to inhibit their subsequent proliferation. 
Normal bone marrow cells did not release LIA. The GM-CFC from 
patients with both acute and chronic leukaemias were not affected 
by LIA, (Broxmeyer et al 1979). The release of LIA by leukaemic 
cells could explain the suppression of normal haemopoiesis which 
occurs in patients with leukaemia. The concentration of LIA 
produced was higher in acute leukaemias (but not if in remission) 
than chronic leukaemias. This indicates that the concentration of 
LIA may be related to the degree of suppression of normal 
haemopoiesis, which is greatest in acute leukaemias in relapse, 
(Broxmeyer et al 1978b). LIA has also been shown to be active in 
vivo. In mice recovering from treatment with cyclophosphamide a 
rebound myelopoiesis occurs. If these mice were injected with 
microgram quantities of LIA, both the number of GM-CFC per femur 
and the. proportion in S-phase were reduced, (Broxmeyer 1981). 
LIA is released by non-T, non-B FC receptor positive 
lymphoid-like cells or promonocytes, (Broxmeyer et al 1979). A 
similar factor was eluted from the bone marrow of mice infected 
with a Friend virus. The production of this factor was concomitant 
with the development of an erythroleukaemia, (Marcelleti and 
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Furmonski 1980), LIA has been shown to be identical to acidic 
isoferritin. This is an iron binding glycoprotein. LIA and acidic 
isoferritin have similar isoelectric points and on SDS 
polycrylamide gel electrophoresis have apparent molecular weights 
of 550,000. Purified acidic isoferritin is active as an inhibitor 
of GM-CFC colony formation at concentrations as low as 10-17 to 
10-19 moles, (Bognacki et al 1981), (Broxmeyer et al 1981b). 
Ia-antigens are gene products of the major histocompatability 
complex. In long term bone marrow cultures, they are absent on the 
probable haemopoietic stem cell but are acquired when commitment to 
the different progenitor cells occurs, (Moore et al 1980). 
Broxmeyer (1981) has demonstrated an association between the 
expression of human Ia-like antigenic determinants on GM-CFC during 
DNA synthesis, and the actions of acidic isoferritins. A similar 
reduction of GM-colonies was produced by incubating human bone 
marrow cells with an anti-Ia monoclonal antibody and complement; 
tritiated thymidine or acidic isoferritin. A second incubation 
with any of these substances did not produce any further reduction 
of the number of GM-colonies formed. The anti-Ia monoclonal 
antibody without complement did not reduce colony formation but it 
blocked the inhibitory action of acidic isoferritin. The absence 
of Ia-antigens on the GM-CFC from patients with leukaemia was 
associated with non-responsiveness to inhibition by acidic 
isoferritins. These observations implicate Ia-antigens in the 
regulation of myelopoiesis in vitro. The loss of Ia-antigens on 
the GM-CFC of patients with leukaemia could be implicit in the 
breakdown of normal haemopoietic regulatory mechanisms. 
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The release of acidic isoferritin from promonocytes is 
influenced by many factors, (Broxmeyer 1981). Iron saturated 
lactoferrin and medium conditioned by Ia+, OKT3+, OKT8+ 
subpopulations of T-lymphocytes inhibit its production. In 
contrast GM-CSF and medium conditioned by Ia+, OKT3+, OKT4+ 
subpopulations of T-lymphocytes stimulate acidic isoferritin 
production. The production and release of acidic isoferritin is 
therefore probably regulated by the balance between these enhancing 
and inhibiting factors. Ia-surface antigens appear to be implicit 
in this regulatory network. 
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4.2 EXPERIMENTAL DESIGN 
4.2.1 Human Fetal Tissues 
The crown rump length and equivalent gestational age in weeks 
of the fetuses used in this study are listed in Table 4.1. The 
fetus number is used when referring to any tissue removed from a 
particular fetus. Details of the preparation of cell suspensions 
from fetal tissues are described in Section 1.2.4. 
4.2.2 Human Fetal Tissue Conditioned Media 
Two types of conditioned media were obtained from human fetal 
tissue cell suspensions: 
(1). Human fetal cells were incubated for 2 hours at 370C. The 
suspension was then centrifuged and the cell free supernatant (one) 
removed. 
(2). These fetal cells were then resuspended in fresh medium, 
incubated for a further 5 hours at 37°C and then centrifuged. The 
cell free supernatant (two) was removed. 
The supernatant number is indicated by the suffix Si and S2 
following the fetus number (see sections 1.2.6.1 and 3.2.1). 
The Amicon fractionation 'of these supernatants and the 
production of supernatants from plastic adherent and non-adherent 
human fetal liver cell suspensions are described in. Section 1.2.6. 
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TABLE 4.1 Fetal Crown Rump Lengths and Equivalent 
Gestational Ages 
Fetus Number Crown Rump Length cm Fetus Age - Weeks 
1 
2 
13.2 16.0 
9.2 13.0 
3 7.6 
4 
5 
6 
7 
8 
8.5 
11.2 
9.7 
12.0 
14.5 
9 7.6 
10 9.5 
11 11.8 
12 14.9 
13 15.6 
14 11.4 
15 10.8 
16 10.6 
17 11.9 
18 7.2 
19 12.0 
12.0 
12.5 
14.5 
13.4 
15.0 
16.9 
11.8 
13.1 
14.9 
17.1 
17.6 
14.6 
14.1 
14.0 
15.0 
11.5 
15.0 
269 
4.2.3 Assay of Medium Conditioned Human Fetal Liver Cells 
4.2.3.1 Assay for HFLS GM-CFC proliferation inhibitor 
Normal 'CD1 mice pooled bone marrow cells suspended at 
5x106 cells per ml in Fischer's medium were used as the assay 
population. To 1. Oml of this bone marrow suspension, 0.5mis of 
horse serum and 1. Oml of the test supernatant (or medium as a 
control) were added (Figure 4.2). The human fetal liver 
supernatants were normally conditioned by 15x106 cells per ml. 
They were therefore assayed at a 3: 1 test responder cell ratio. In 
dose response experiments the concentration of human fetal liver 
cells used to produce conditioned medium were varied 
(5-30x106 cells/ml). This allowed the testing of HFL Supernatant 
at different test responder cell ratios. 
The supernatant from one early gestational age human fetal 
liver (HFLS6), was separated into two Amicon fractions, <100,000 
and >100,000 daltons. These fractions were not lyophilized; 1.0ml 
of each fraction was tested as described above for the HFLS. 
Paired incubation mixtures consisting of 1. Oml assay cells, 
0.5mis horse serum and 1. Oml of a test supernatant or medium as a 
control were incubated at 37°C for 5 hours shaking continuously 
(Figure 4.2). For the last hour 20ug/ml of Ara-C was added to one 
tube in each pair. The cells were then washed twice prior to 
plating (see Section 1.2.10 and Figure 1.6). (Total incubation 
time 5 hours. ) 
/I) 
Assay of Early Gestational Age HFLS Inhibitor of GM-CFC Proliferation 
Incubate for 1 hour 
Assay 
For 
GM-CFC 
Figure 4.2 
Early gestational age (11-14 weeks) human fetal liver cell 
conditioned medium, assay for GM-CFC proliferation inhibitors. The 
top tube represents the pair of tubes in which assay NMBM cells 
were incubated with the test HFL supernatant. The bottom tube 
represents the pair of control tubes in which the assay cells were 
incubated with medium. 0.5mis of horse serum was also added to 
each tube but has been omitted for clarity. One tube in each pair 
was incubated with Ara-C as a suicide agent and the other with 
medium. The cells were washed twice prior to plating. See Section 
4.2.3.1. 
4.2.3.2 Assay for GM-CFC proliferation stimulator 
The technique described in Section 4.2.3.1 was modified to 
assay supernatants from late gestational age human fetal liver 
cells for stimulators of GM-CFC proliferation. 1. Oml of a NMBM 
suspension and O. 5mis of horse serum were put into 3 pairs of 
tubes. To the first pair 1. Oml of medium was added. To the other 
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four tubes 1. Oml of an early gestational age HFL supernatant (11-14 
weeks) was added (Figure 4.3). The six tubes were incubated for 4 
hours at 37°C. 2. Omis of Fischer's medium was then added to the 
first and second pairs of tubes. To the third pair, 2. Omls of a 
supernatant from a late gestational age HFL (>14 weeks) was added. 
O. 5mis of horse serum was also added to each tube. The incubation 
was continued for a further 2 hours. To one tube in each pair 
20ug/ml of Ara-C was added. The tubes were incubated for a final 
hour. The cells were washed twice prior to plating. (Total 
incubation time 7 hours. ) 
Lyophilized Amicon fractions from a late gestational HFL 
supernatant were dissolved in Fischers medium at 250pg/ml. 1. Oml 
of this solution was added to 1. Oml of the assay cells and 0.5mis 
of horse serum as for the HFL supernatant. A final concentration 
of 100vg/ml was therefore produced. 
4.2.4 Human Fetal Bone Marrow, Thymus and Adult Bone Marrow: Assay 
for GM-CFC Proliferation Regulators 
Medium was conditioned by human fetal thymus, bone marrow and 
adult rib bone marrow as described in Sections 4.2.3. and 1.2.6. 
These supernatants were assayed for GM-CFC proliferation inhibiting 
and stimulating activity, using the methods described in Sections 
4.2.3.1 and 4.2.3.2 respectively. 
Assay of Late Gestational Age HFLS Stimulator of GM-CFC Proliferation 
m 
Incubate tcr 4 ncurs 
EarlyGesldlionHfLS (l fl t yror) 
Normal Munne 
Bone Marrow 
Incubate for 4 hours 
+Late Gestation 
HFLS (Stimulator) 
2 hours Incubatio 
. 
+ArAraa--C 
In'/cub ate 
for 1 hour 
+Med um 
Assay 
For 
GM-CFC 
0 .« 
400 
+Ara-C 
q 
S. « 
Early Gestation HFLS(Inhibitor) 
Figure 4.3 
+Medium (Control) 
2 hours Incubation 
.. 
Incubate 
for 1 hour 
+Medium 
Late gestational age (>14 weeks) human fetal liver cell 
conditioned medium, assay for stimulators of GM-CFC proliferation. 
The top and bottom tubes in this diagram represent the pair of 
tubes, which initially both contained 1. Oml of the assay NMBM cells 
and 1. Oml of an early gestational age (11-14 weeks) HFL 
supernatant. After the first 4 hours of incubation the two pairs 
of tubes were treated differently. One pair was incubated with a 
late gestational age HFL supernatant (top tube), the other pair 
with medium (bottom tube). Then one tube in each pair was 
incubated with Ara-C as a suicide agent, the other tube with 
medium. The cells were washed twice prior to plating. A third 
pair of tubes (not represented) containing NMBM cells, was 
incubated with medium for 6 hours. Ara-C was then added to one 
tube and medium to the other. Horse serum was also added to the 
cultures, see Section 4.2.3.2. 
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4.2.5 Late Gestational Age Human Fetal Liver and Thymus 
Supernatants: Assay for GM-CSA 
Supernatants from late gestational age (>14 weeks) human fetal 
liver and thymus cells were assayed for GM-CSA. The supernatants 
were serially diluted with Fischer's medium and O. lml was added to 
each GM-CFC culture. The supernatants were tested at final 
concentrations of 10,8,6.6,5, and 2.5%. 
A similar dose response assay for endotoxin serum GM-CSA was 
set up concomitantly. The GM-CSA was tested at final 
concentrations of between 2.5 and 0.62% in the cultures. 
4.2.6 Normal and Post Irradiation Murine Bone Marrow: Assay for 
GM-CFC Proliferation Regulators 
Conditioned medium from normal murine bone marrow suspensions 
and bone marrow suspensions from mice exposed to 450 rads 66 hours 
previously were prepared. These supernatants and Amicon fractions 
from them were assayed for both stimulators and inhibitors of 
GM-CFC proliferation, using the same techniques that were used to 
assay HFL supernatants (see Sections 4.2.3.1 and 4.2.3.2). 
4.2.7 Human Fetal Liver Cultures: Assay of Conditioned Medium 
Livers from human fetuses of different gestational ages were 
cultured in vitro. lml of a partially aspirated human fetal liver 
cell suspension was added to 9mls of supplemented Fischer's medium. 
Half the medium was removed after 4 days of culture and replaced 
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with fresh medium. These day 4 supernatants from human fetal liver 
cultures were assayed for stimulators and inhibitors of NMBM GM-CFC 
proliferation as described in Sections 4.2.1 and 4.2.2. These 
supernatants were not diluted prior to testing (ie used at 40% 
final concentration). 
4.2.8 Regulation of the Resynthesis of the CFU-S and GM-CFC 
Proliferation Stimulators 
Human fetal liver 19 (Crl 12.0cm, age 15 weeks) was initially 
incubated for one hour at 37°C. The cells were then spun down at 
1000rpm for 10 minutes and the supernatant (Si) removed. These 
cells were resuspended at 12x106cells/ml. This cell suspension was 
divided into three aliquots (A, B, C). To A nothing was added, the 
control. To B 1000pg of a 50-100K daltons NBME fraction was added. 
To C 1000pg of a 50-100K daltons fraction of an extract of the bone 
marrow of mice exposed to 450 rads 5 days previously. These 
extracts were dissolved in Fischer's medium at 1000pg/ml, ie lml 
added to each group. An equal volume of medium was added to group 
A. 
The three cell suspensions were incubated for 5 hours at 37°c. 
The cell free supernatants were then obtained. The supernatants 
were passed through XM50 Amicon filters. This prevented the 
passage of the 50-100K daltons fractions which had been added 
previously. These filtered supernatants were then tested for the 
presence of both the CFU-S proliferation stimulator (see Section 
3.1) and the GM-CFC proliferation stimulator (see Section 4.2.3.2). 
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4.3 RESULTS 
4.3.1 Human Fetal Liver Cell Conditioned Media: Effect on the 
Proportion of NMBM GM-CFC Synthesizing DNA 
4.3.1.1 Early gestational age human fetal liver supernatants 
NMBM was incubated for 5 or 7 hours with medium conditioned 
for 2 hours by early gestational age HFL cells (Supernatant one). 
This treatment reduced the proportion of GM-CFC synthesizing DNA 
from >33% to <10% (Table 4.2, Figure 4.4). A second supernatant 
was removed from the resuspended HFL cells (Supernatant two). This 
also reduced the proportion of GM-CFC synthesizing DNA (Table 4.2). 
The number of GM-CFC per 105 cells plated was only reduced 
significantly if the cells had been incubated, at a high test 
responder cell ratio (above 3: 1). This effect was larger with the 
first HFL cell supernatant (eg fetus 3(S1), Table 4.2). The NMBM 
cells incubated for 7 hours with an early gestational age HFLS 
constituted one of the control groups in the assay for GM-CFC 
proliferation stimulators (see Section 4.2.3.2). 
4.3.1.2 Late gestational age human fetal liver supernatant 
NMBM was incubated with the first or second supernatants from 
late gestational age (>14 weeks) HFL cells. This treatment did not 
significantly alter the proportion of GM-CFC which were 
synthesizing DNA (Figure 4.5, Table 4.3). A reduction of the 
absolute numbers of GM-CFC per 105 cells plated only occurred when 
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Early Gestational Age HFLS 
Inhibition of GM-CFC Proliferation 
I AI a-C II* medium 
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Cant, ýi HFLS 
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Figure 4.4 
2 6±4.5 
Im 
Second supernatant obtained from early gestational age human 
fetal liver cells: effect on the proportion of NMBM GM-CFC 
synthesizing DNA. (Fetus 6: 13.4 weeks gestational age) (suicide 
% mean-SE) 
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Late Gestational Age HFLS 
Effect on GM-CFC Proliferation 
Cr' :i 
Figure 4.5 
Suicide% 33.6 ! 6.0 
HFLS 16 
34 7 '_6 2 
+ Ara-C + medium 
Second supernatant obtained from late gestational age human 
fetal liver cells: effect on the proportion of NMBM GM-CFC 
synthesizing DNA. (Fetus 16: 14.0 weeks gestational age)(Suicide 
% mean± SE). 
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the test responder cell ratio was high (eg Experiment 3, Table 
4.3). 
4.3.1.3 Human fetal thymus, bone marrow and adult rib bone 
marrow supernatants 
The supernatants from thymus and bone marrow cell suspensions, 
from late gestational age fetuses (>14 weeks) did not alter the 
proportion of NMBM GM-CFC synthesizing DNA. A supernatant from 
normal human rib bone marrow, also had no effect on the proportion 
of NMBM GM-CFC in S-phase (Table 4.4). 
Incubation of NMBM with these supernatants at high test 
responder cell ratios reduced the number of GM-CFC per 105 cells 
plated to a smaller extent, than supernatants from HFL cells 
(Tables 4.4 and 4.2, fetus 3(S1)). The thymus and bone marrow from 
early gestational age fetuses contained insufficient cells to 
produce conditioned media. 
4.3.2 Supernatants from Early Gestational Age HFL Cells: Effect on 
the Morphology of Colonies Produced by NMBM Cells 
The granulocyte-macrophage colonies formed by NMBM cells in 
seven days were classified into three gross morphological types, 
after Metcalf (1977): 
1. Tight granulocytic colonies. 
2. Loose macrophage colonies. 
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Early Gestational Age HFLS 
Effect on Colony Morphology 
° 90 
H 
T 
C 
O 
0 
U 
Z 80 
m 
O 
Co 
C 
(3) 
U 
a 30 
Ara-C Control Ara-C HFLS 
+HFLS 
Loose Tight 
. Mixed 
Figure 4.6 
First supernatant from early gestational age human fetal liver 
cells: effect on the morphology of the day 7 GM-CFC colonies 
produced by NMBM. (Fetus 10: 13.1 weeks gestational age). 
3. Mixed colonies consisting of a tight granulocytic centre and 
loose periphery of macrophages. 
(See Plates 4.1,4.2,4.3) 
The actual morphology of the cells was confirmed in 
hematoxylin and eosin stained preparations of the colonies (Plates 
4.1,4.2,4.3). 
The proportions of the three colony types produced by NMBM 
cells after incubation with different factors is illustrated in 
Figure 4.6 and Table 4.5. The proportions of the three colony 
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PLATE 4.1 
A mixed granulocyte and macrophage day 7 colony, grown from normal 
murine bone marrow cells. The colony has a tight centre of 
granulocytes surrounded by a loose periphery of macrophages. Stained 
with Haematoxylin and Eosin. Magnification x300. 
PLATE 4.2 
A 'tight' granulocyte day 7 colony, grown from normal murine bone 
marrow cells. These colonies consist of closely packed granulocytes 
and their recognizable precursors. Stained with Haematoxylin and 
Eosin. Magnification x780. 
PLATE 4.3 
A 'loose' macrophage day 7 colony, grown from normal murine bone 
marrow cells. The mobile macrophages spread out form the centre of 
the colony. Stained with Haematoxylin and Eosin. Magnification x780. 
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types produced by NMBM cells which had been incubated with a 
supernatant from early gestational age HFL cells and/or Ara-C were 
not significantly different from controls. 
4.3.3 Dose Responses of the Effect of HFL Cell Supernatants on the 
Proportion of NMBM GM-CFC Synthesizing DNA 
The supernatants from four livers from human fetuses of 
different gestational ages were diluted with medium. These were 
incubated with a set concentration of NMBM cells. The effect of 
the HFL supernatants at three test responder ratios on the 
proportion of NMBM GM-CFC synthesizing DNA was determined (Table 
4.6, Figures 4.7,4.8,4.9 and 4.10). The control NMBM GM-CFC 
suicide is indicated on each Figure. The number of GM-CFC per 105 
cells plated was only reduced significantly when high test 
responder cell ratios were used (Table 4.6). 
All dilutions of a supernatant from a late gestational age HFL 
(14) had no effect on the proportion of NMBM GM-CFC synthesizing 
DNA (Figure 4.7). When supernatants from early gestational age HFL 
cells (HF, 3,4,10) were used at high test responder cell ratios, 
the proportion of GM-CFC synthesizing DNA was reduced from >38% to 
<18% (Figures 4.8,4.9,4.10). When the HFL cell supernatants were 
tested at lower test responder cell ratios, the reduction of the 
proportion of GM-CFC synthesizing DNA compared to controls was 
less. But HFLS 3 and 4 (Figures 4.8 and 4.9) even at a test 
responder cell ratio of 1: 1 still significantly inhibited GM-CFC 
proliferation. 
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Figure 4.7 
Late Gestational Age HFLS Dilutions: 
Effect on GM-CFC Proliferation 
.......................... 
Control Control 
1: 1 2: 1 3: 1 4: 1 5: 1 
Test / Responder Cell Ratio 
First supernatant from late gestational age HFL cells. Dose 
response of test responder cell ratio against proportion of NMBM 
GM-CFC synthesizing DNA. (Fetus 14: 14.6 weeks gestational age) 
(Suicide %± SE). 
Early Gestational Age HFLS Dilutions: 
Effect on GM-CFC Proliferation 
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Figure 4.8 
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1: 1 2: 1 3: 1 
Test / Responder Cell Ratio 
First supernatant from early gestational age HFL cells. Dose 
response of test responder cell ratio against proportion of NMBM 
GM-CFC synthesizing DNA. (Fetus 3: 12.0 weeks gestational age) 
(Suicide %, Mean ± SE) 
Early Gestational Age HFLS Dilutions: 
Effect on GM-CFC Proliferation 
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Figure 4.9 
First supernatant from early gestational age HFL cells. Dose 
response of test responder cell ratio, against proportion of NMBM 
GM-CFC synthesizing DNA. (Fetus 4: 12.5 weeks gestational age) 
(Suicide % Mean ± SE) 
Early Gestational Age HFLS Dilutions: 
Effect on GM-CFC Proliferation 
Figure 4.10 
50 ý 
30i 
101 
1: 1 2: 1 3: 1 
Test/Responder Cell Ratio 
First supernatant from early gestational age HFL cells: dose 
response of test responder cell ratio against proportion of GM-CFC 
synthesizing DNA. (Fetus 10: 13.1 weeks gestational age) (Suicide 
% Mean ± SE) 
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4.3.4 Early Gestational Age HFL Cell Supernatants: Variation in 
GM-CFC Proliferation Inhibiting Activity 
4.3.4.1 Figure 4.11 : structure 
Figure 4.11 shows the proportions of human GM-CFC in S-phase 
(left Y axis) in livers from fetuses of different gestational ages 
(expressed as crown rump length) from Moore and Williams (1973b). 
This is indicated by the continuous under-shaded black line. 
The right Y axis indicates the proportion of NMBM GM-CFC in 
S-phase and the discontinuous black line is the control value for 
this. The black dots indicate the proportion of NMBM GM-CFC in 
S-phase after incubation with a supernatant from a fetal liver 
indicated on the X axis. The three lines joining these dots, 
broken, complete and dotted, indicate the test responder cell ratio 
(3: 1,2: 1 and 1: 1 respectively) at which the HFL supernatants were 
used. The control NMBM GM-CFC suicides were normalised to 40% and 
the treated groups adjusted accordingly. 
4.3.4.2 Figure 4.11 : key observations 
Two key observations should be drawn from Figure 4.11. 
1. HFLS 4 maximally reduced the proportion of GM-CFC in S-phase at 
both a 3: 1 and 2: 1 test responder cell ratio. HFLS 3 and HFLS 10 
caused a smaller reduction than HFLS 4 of the proportion of GM-CFC 
in S-phase. This was only maximal at a 3: 1 test responder cell 
ratio. 
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HFLS Test/Responder Ratios: 
Effect on Proportion of NMBM GM-CFC in S-Phase 
50 
m 
40 
z 
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ý 20 ý 
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30 40 50 60 7HFLSPHF'LS490HFLS1O1P96,15110HFLS1130 1! 
HUMAN FOETAL-crow, rump length (mm) 
2: 1 1: 1 Test/Responder Ratios 
Figure 4.11 
Supernatants from early and late gestational age HFL cells: 
dose response graphs of test responder cell ratio against 
proportion of GM-CFC in S-phase after incubation. These are 
superimposed onto a graph of the proportion of human GM-CFC in 
S-phase throughout gestation. Gestational age expressed as crown 
rump length, from Moore and Williams (1973b). 
2. The proportion of GM-CFC in S-phase in a liver from a human 
fetus of corresponding crown rump length to fetus 4 was less than 
that in livers from fetuses of corresponding crown rump lengths to 
fetuses 3 and 10. Human fetal GM-CFC data from Moore and Williams 
(1973b). 
Supernatants from the livers of fetuses 16,15, and 14 had no 
effect on the proportion of GM-CFC in S-phase, at all test resonder 
cell ratios used. In human fetal livers of corresponding 
gestational ages to HF 16,15 and 14, the proportion of GM-CFC in 
S-phase was increasing, Moore and Williams (1973b). 
70 HFLS3: 7.6cm 80 HFLS4: 8.5cm 90 HFLS10: 9.5cm 100 
Human Fetal crown-rump length(cm) 
Figure 4.12 
Supernatants from early gestational age HFL Cells: test 
responder cell ratio at which these supernatants were used to 
reduce the proportion of NMBM GM-CFC in S-phase to 25%, 33% and 50% 
of the control value. (Fetuses 3,4 and 10: gestational ages 12.0, 
12.5 and 13.1 weeks) 
4.3.4.3 Figure 4.12 
This figure shows the test responder cell ratio at which 
supernatants from early gestational age HFL cells had to be used at 
to reduce the proportion of NMBM GM-CFC in S-phase to 25%, 33% and 
50% of the control value. Consistently a lower concentration of 
HFLS 4 (crl 8.5cm) was needed to reduce the proportion of NMBM 
GM-CFC in S-phase than either HFLS 10 (crl 9.5cm) or HFLS 3 (crl 
7.6cm). This corresponds with the observations made from Figure 
4.11. 
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4.3.5 Supernatants from Late Gestational Age HFL Cells: Effect on 
GM-CFC Proliferation 
NMBM was incubated with a supernatant from an early 
gestational age (11-14 weeks) human fetal liver. This reduced the 
proportion of GM-CFC synthesizing DNA to <10% (Table 4.7, Figure 
4.13). These non-cycling GM-CFC were used as an assay population 
to detect stimulators of GM-CFC proliferation (Figure 4.3). This 
source of non-cycling GM-CFC was incubated with supernatants from 
late gestational age human fetal livers (>14 weeks). This 
treatment increased the proportion of GM-CFC synthesizing DNA from 
<10% to >43% (Table 4.7, Figure 4.13). Incubation of non-cycling 
GM-CFC with a thymus cell supernatant from a late gestational age 
human fetus did not increase the proportion of GM-CFC in S-phase 
(Table 4.7). 
4.3.6 HFL Supernatants: Inhibition, Stimulation, Inhibition of 
GM-CFC Proliferation 
Figure 4.14 illustrates the result of an experiment in which 
NMBM cells were incubated with three HFL cell supernatants in 
succession, initially with a supernatant from an early gestational 
age HFL (10) for 4 hours. This was followed by a2 hour incubation 
with a supernatant from a late gestational age HFL (11). Finally 
the NMBM cells were incubated with a supernatant from an early 
gestational age HFL (10) for 4 hours. These three supernatants 
were used at 3: 1,6: 1 and 12: 1 test responder cell ratios 
respectively. These treatments decreased, increased and. decreased 
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Figure 4.13 
10 ý 
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aý 
2 
+ Ara-C 
Control 
'medium 
HFLS 10 
EM 
HFLS10 
HFLS19 
(Stimulator) 
Suicide% 56.6±2.6 1.4±0.7 54.0±4.0 
NMBM incubated initially with an early gestational age HFL 
supernatant (HFLS 10) and then a late gestational age HFL 
supernatant (HFLS 19). Controls incubated with just medium or just 
HFLS 10. (Suicide % Mean ±SE) 
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Figure 4.14 
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Control HFLS10 HFLS10 HFLS10 
HFLS11 HFLS11 
HFLS10 
Suicide% 58.5±7.1 4.5*_4.5 30.7±8.3 8.8! 9.5 
NMBM incubated initially with an early gestational age HFLS 
(10) then a late gestational age HFLS (11) and finally with an 
early gestational age HFLS (10). Controls incubated with HFLS 10 + 
HFLS 11, with just HFLS 10, or with medium. (Suicide % Mean ± SE) 
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respectively the proportion of GM-CFC in S-phase (Figure 4.14). 
In this experiment the number of GM-CFC per 105 cells plated 
was significantly less in the groups treated with HFL supernatants 
than in the controls (Figure 4.14). The reduction was greatest in 
the groups which were incubated with more than one supernatant. 
4.3.7 Human Fetal Liver Supernatants: Effect on CFU-S 
Proliferation 
Incubation of NMBM cells with supernatants from human fetal 
livers of all gestational ages tested increased the proportion of 
CFU-S in S-phase from <18% to >33% (Table 4.8) (see Chapter Three). 
4.3.8 Adherent and Non-Adherent HFL Cell Supernatants: Effect on 
GM-CFC Proliferation 
4.3.8.1 AD/NA. HFLS from early gestational age fetuses 
Supernatants from plastic non-adherent but not plastic 
adherent liver cells from early gestational age fetuses reduced the 
proportion of NMBM GM-CFC synthesizing DNA from >33% to <6% (Table 
4.9, Figure 4.15). This inhibition occurred when the HFL 
supernatants were used at a 3: 1 test responder cell ratio. One HFL 
supernatant (18) was also assayed at a 1: 1 test responder cell 
ratio. This caused a smaller reduction of the proportion of GM-CFC 
synthesixing DNA, >37% to <23% (Table 4.9). 
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Table 4.8 The Effect of Human Fetal Liver Supernatants from 11-17 
Week Gestational Age Fetuses on the Proportion of NMBM 
CFU-S Synthesizing DNA 
Fetal Number 
Fetal Age 
(Weeks) 
5 
4 
8 
9 
7 
3 
To CFU-S Synthesizing DNA ± SE 
Control Incubated with HFLS 
14.5 
12.5 
17.0 
11.8 
15.0 
12.0 
17.7 + 13.6 
9.6 ± 12.6 
0.4 ± 6.7 
16.6 ± 11.2 
5.3 ± 9,. 4 
6.0±12.7 
45.0 ± 13.2 
36.9 ± 13.0 
43.9 f 7.3 
40.7 ± 9.9 
52.3 ± 11.3 
33.3 ± 9.2 
Difference between To CFU-S synthesizing DNA, in Controls and 
HFLS treated groups: Significance, P=<0.001 
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suicide% 33.6±6.0 5.3±3.0 32.5'-4.6 
Figure 4.15 
Supernatants from plastic adherent (AD) and plastic 
non-adherent (NA) early gestational age 
HFL cells: effect on the 
proportion of NMBM GM-CFC synthesizing DNA. 
(Fetus 18: 11.5 weeks 
gestational age) (Suicide % Mean± SE) 
Control HFLS18 HFLS18 HFLS18 
HFL8: NAS HFL8: ADS 
Figure 4.16 
Suicide%40.4± 5.6 11.0± 6.4 43.9±8.6 11.0 ± 7.1 
NMBM incubated initially with an early gestational age HFL 
(18) supernatant, ie inhibition of GM-CFC proliferation. These 
non-cycling GM-CFC subsequently incubated with a supernatant from 
either plastic adherent (HFL 8, ADS) or plastic non-adherent (HFL 
8, NAS) late gestational age HFL cells. (Gestational ages, fetus 
18,11.5 weeks; fetus 8,16.9 weeks) (Suicide % Mean ±SE) 
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4.3.8.2 AD/NA. HFLS from late gestational a fetuses 
NMBM cells were incubated with a supernatant from an early 
gestational age HFL (18). This treatment reduced the proportion of 
GM-CFC in S-phase to <12%. These non-cycling GM-CFC were used as 
the assay population. Eleven supernatants from plastic 
non-adherent and adherent liver cells from a late gestational age 
fetus were prepared. Only the supernatant from the non-adherent 
HFL cells increased the proportion of GM-CFC in S-phase, <12% to 
>43% (Figure 4.16). 
4.3.9 Amicon Fractions from Human Fetal Liver Supernatants: Effect 
on GM-CFC Proliferation 
4.3.9.1 HFLS: 6.13.4 weeks gestational age 
A supernatant from an early gestational age HFL was separated 
into two fractions by ultrafiltration <100K and >100K daltons. The 
>100K daltons fraction reduced the proportion of NMBM GM-CFC which 
were synthesizing DNA from >34% to <11% (Figure 4.17). This 
fraction also reduced the number of GM-CFC per 105 cells plated 
compared to controls. 
4.3.9.2 HFLS: 7.15.0 weeks gestational age 
NMBM cells were incubated with an early gestational age HFL 
(6) supernatant to produce a population of non-cycling GM-CFC (<3% 
in S-phase). The 30-50K daltons fraction from a late gestational 
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control >100K <100K 
suicide% 34.4±7.5 10.2±8.0 31.2±8.2 
Figure 4.17 
Amicon fractions (>100,000 and <100,000 daltons) from an early 
gestational age HFL (6) supernatant: effect on the proportion of 
NM, BM GM-CFC Synthesizing DNA. (Fetus 6: 13.4 weeks gestational 
age) (Suicide % Mean± SE) 
- Ara-C U med, um 
90 
m 
ä 
Vi 
U 
'b 
60 
v 
U 
ý 
U 
L1 
0 
- 30 v a 
E 
z 
c 
ý 
a 
2 
Control HFLS6 
Figure 4.18 Suicide°6 50 7±8.3 2 6*_4 5 
Im 
kM 
I 
HFLS6 HFLS6 
HFLS7 HFLS7 
10-30K 30-50K 
10.2*_43 4 77294 
NMBM incubated initially with an early gestational age HFL (6) 
supernatant, ie inhibition of GM-CFC proliferation. These 
non-cycling GM-CFC subsequently incubated with Amicon fractions 
from a late gestational age HFL (7) supernatant. (Gestational 
ages, fetus 6: 13.4 weeks; fetus 7: 15.0 weeks) (Suicide % Mean 
±SE) 
300 
age HFL supernatant increased the proportion of these GM-CFC that 
were synthesizing DNA from <3% to >47% (Figure 4.18, Table 4.10). 
NMBM cells were also incubated with the Amicon fractions from 
this late gestational age HFL supernatant. Only the 50-100K 
daltons fraction produced a small reduction in the proportion of 
GM-CFC in S-phase (36.8 to 29.8%) (Figure 4.19). 
4.3.10 Stimulators of GM-CFC Proliferation 
The proportion of GM-CFC synthesizing DNA was also increased 
by incubation with supernatants from NMBM day 15 murine fetal 
liver, bone marrow from mice exposed to 450rads 66 hours previously 
and LPS-GM-CSA from <9% to >36% (Table 4.11). Incubation with the 
30-50K daltons but not the 50-100K daltons fraction from either a 
NMBM or 66 hours post 450 rads murine bone marrow supernatant 
increased the proportion of GM-CFC in S-phase from <9% to >33% 
(Table 4.12, Figures 4.20 and 4.21). 
4.3.11 Human Fetal Tissue Supernatants: GM-CSA Activity 
Supernatants from late gestational age (>14 weeks) human fetal 
livers and thymuses were assayed for GM-CSA. When used at final 
concentrations in the cultures from 10% to 2.5% no colonies or 
clusters were produced. Dilutions of LPS endotoxin serum 
(LPS-GM-CSA) from 2.5% to 0.6% final concentration produced 
decreasing numbers of colonies 160 to 53 and 95 to 6 GM-CFC per 
105 cells plated (Tables 4.13 and 4.14). 
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Figure 4.19 
90 
0 60 
30 
Control 10-30K 30-50K 50-100K 
Suicice% 36.8±8.3 40.4±5.1 42.9±3.7 29.8±5.9 
Amicon fractions from a late gestational age HFL (7) 
supernatant: effect on NMBM GM-CFC proliferation. (Fetus 7: 15.0 
weeks gestational age) (Suicide % Mean ± SE) 
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Figure 4.20 
SuiciOe% 56 9t4 8 9.0t4 8 437t65 3.3+3 9 
NMBM incubated initially with an early gestational age HFL (6) 
supernatant, ie inhibition of GM-CFC proliferation. These 
non-cycling GM-CFC incubated with Amicon fractions from a normal 
murine bone marrow supernatant. (Fetus 6: 13.4 weeks gestational 
age) (Suicide % Mean I -SE) 
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Table 4.12 Effect of NMBMS and 66 hours post 450R MBMS amicon 
fractions, on the proliferation of NMBM GM-CFC, a 
small proportion of which were synthesizing DNA because 
or prior exposure to an early gestational age HFLS 
Normal 
Mu rive 
Bone 
Marrow 
HFLS 18/NMBMS Fractions HFLS 6/66 hr post 450R 
Test/Responder Test/resp- MBMS 
Cell Ratio 100 ug/ml 
onder Cell Fractions 
3: 1 Ratio 3: 1 (100 ug/ml) 
Treatment GM-CFC/ 
During 
Incubation 
Control 
+ Early 
(11-14 
weeks) 
HF LS 
+ Murine 
bone 
marrow 
supernatant 
30-50 K 
fraction 
+ Murine 
bone 
marrow 
supernatant 
50-100 K 
fraction 
* 
105 Cells 
Plated ± SE 
92.8 + 4.2 
174.2 + 5.2 
150.3 + 2.3 
Suicide 
+ SE 
GM-CFC/ 
105 Cells 
Plated +SE 
Suicide O/o 
+ SE 
46.7 ± 5.4 
48.9 ± 1. Z 
113.5 + 4.8 
85.3 ± 3.6 
-4.6±2.6 
143.3± 3.0 93.7±2.3 
114.1 ± 3.6 
171.1 +4.2 
33.3 13.5 
70.3 ± 3.2 
124.8 ± 5.9 
169.4 + 6.3 
175.6±2.9 
3.5 ± 4.0 
88.1 ± 2.6 
91.1 ± 2.4 
First tube in each group with cytosine arabinoside 
NMBMS :- Normal murine bone marrow supernatant 
56.9 ± 4.8 
q. 0±4.8 
43.7 ± 6.5 
3.3 ± 3.9 
66 hours post 450R MBMS: - A supernatant (conditioned medium) 
from the bone marrow of mice exposed to 450 Rads 66 hours 
previously 
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Figure 4.21 
NMBM incubated initially with an early gestational age HFL 
(18) supernatant, ie inhibition of GM-CFC proliferation. These 
non-cycling GM-CFC subsequently incubated with Amicon fractions of 
a supernatant from the bone marrow of mice exposed to 450 rads four 
days previously. (Fetus 18: 11.5 weeks gestational age) (Suicide 
Mean ± SE) 
4.3.12 Human Fetal Liver and Bone Marrow Cultures 
Day 4 supernatants from early gestation HFL cultures (11.5 
weeks) reduced the proportion of NMBM GM-CFC synthesizing DNA from 
>33% to <3% (Table 4.15). Incubation with a day 4 supernatant from 
a late gestational age HFL culture caused a small increase in the 
proportion of NMBM GM-CFC synthesizing DNA , 
39.4 to 47.7%. 
Incubation with day 4 supernatants from early and late gestation 
HFL cultures produced a significant reduction in the number of 
GM-CFC per 105 cells plated compared to controls. 
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Human fetal liver cultures were initially maintained by 
changing half the growth medium every 7 days. But the cells became 
very vaculated and the medium yellow indicative of a build up of 
cellular metabolic waste products to toxic levels. Subsequently 
the medium was changed every 3 days. The fetal liver cells usually 
progressed to cover the entire base of the culture flask within 7 
to 10 days. Subculturing was then necessary to maintain the cells 
in good condition... 
Bone marrow from late gestational age fetuses was cultured in 
a similar manner to the liver. Optimal cell growth was achieved if 
rather than pushing the marrow out of the femur with medium, the 
bone was crushed into approximately 10 fragments. and cultured. The 
bone marrow cells also grew to cover the entire base of the culture 
flask within 7 to 10 days. 
4.3.13 Regulation of the Resynthesis of the CFU-S and GM-CFC 
Proliferation Stimulators 
Table 4.16 illustrates the effect of the presence of 50-100K 
daltons fractions from normal and irradiated bone marrow extracts 
on the resynthesis of a CFU-S proliferation stimulator by late 
gestational age human fetal liver cells. The supernatant from the 
fetal liver cells reincubated in the presence of medium (A) or the 
50-100K daltons fraction from the irradiated bone marrow extract 
(C), stimulated the proliferation of NMBM CFU-S. In contrast the 
supernatant from the fetal liver cells reincubated in the presence 
of a 50-100K daltons fraction from the normal bone marrow extract 
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Table 4.16 The effect of the 50-100 K dalton NMBM CFU-S 
proliferation inhibitor (and other factors) on the resynthesis 
of a stimulator of CFU-S proliferation by late gestational 
age human fetal liver cells 
NMBM treatment 
during incubation 
CFU-S per 105 
cells plated ± SE 
Suicide %± SE 
31.0 ± 22.9 
-6.2 ± 16.0 
34.6 + 12.4 
4.8 ± 20.3 
19.5 + 3.2 
+ HFLS 19 (s2) A 
+ HFLS 19 (s2) B 
+ HFLS 19 (s2) C 
C ontrol 
28.2 ±4.5 
24.2 + 3.2 
22.7 1 2.0 
15.7 ± 1.7 
2A. 0 ± 1.5 
19.5 + 2.5 
20.5 ± 3.2 
NMBM: - Normal murine bone marrow 
HFLS 19 (s2) A: - 
HFLS 19 (s2) B: - 
HFLS 19 (s2) C: - 
supernatant (control) from washed human fetal 
liver 19 cells reincubated for 5 hours in the 
presence of medium 
supernatant from washed human fetal liver 19 
cells reincubated for 5 hours in the presence of 
a 50-100 K dalton NBME fraction CFU-S 
proliferation inhibitor 
supernatant from washed human fetal liver 19 
cells reincubated for 5 hours in the presence of 
a 50- 100 K dalton fraction from medium 
conditioned by the bone marrow from mice 
exposed to 450 Rads 66 hours previously 
did not stimulate CFU-S proliferation (B). 
Table 4.17 illustrates the effect of the presence of a 50-100K 
daltons fraction from a normal bone marrow extract on the 
resynthesis of the GM-CFC proliferation stimulator by late 
gestational age human fetal liver cells. The late gestational age 
HFL cells were reincubated in the presence of medium (A) or a 
50-100K daltons fraction from a NBME. Supernatants from both these 
cell suspensions stimulated GM-CFC proliferation to the same extent 
as the first supernatant from these cells (Table 4.17, +HFLS10, 
+HFLS19S1). 
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Table 4.17 The effect of the 50-100 K dalton NMBM CFU-S 
proliferation inhibitor on the resynthesis of a stimulator 
of murine GM-CFC proliferation by late gestational age 
human fetal liver cells 
NMBM treatment 
during incubation 
GM-CFC per 105 
cells plated - SE 
Suicide %± SE 
42.5 ± 2.3 
Control 
+ HFLS 10 
+ HF LS 10 
+ HFLS 19 (sl) 
104.7 ± 1.4 
102.0 + 1.3 
103.6 ± 0.8 
49.5±2.7 
107.5 ± 6.3 
+ HFLS 10 
+ HFLS 19 (sZ)A 
+ HFLS 10 
+ HFLS 19 (s2)B 
51.7 + 1.9 
110.1 ± 2.2 
50.3 ± 2.2 
109.2 ± 3.2 
56.6 ± 2.6 
1.4 ± 0.7 
54.0 ± 4.0 
53.1 ± 2.0 
53.9 + 2.7 
NMBM :- Normal murine bone marrow 
HFLS 10: - 13.1 weeks gestational age 
HFLS 19: - 15.0 weeks gestational age 
HFLS 19 (s2)A: - 
HFLS 19 (s2)B: - 
supernatant (control) from washed human fetal 
liver 19 cells reincubated for 5 hours in the 
presence of medium 
supernatant from washed human fetal liver 19 
cells reincubated for 5 hours in the presence of a 
50-100 K dalton NBME fraction CFU-S 
proliferation inhibitor 
4.4 DISCUSSION 
4.4.1 Human Fetal Liver GM-CFC Kinetics 
In the liver of human fetuses of 11-14 weeks gestational age, 
the proportion of GM-CFC synthesizing DNA is low (<10%).. After 14 
weeks gestational age the proportion of GM-CFC in S-phase is high 
(>35%). In contrast, in human fetal bone marrow the proportion of 
GM-CFC synthesizing DNA is high (>35%) throughout gestation, (Moore 
and Williams 1973b). Thus in an 11-14 week gestational age fetus 
a small proportion of GM-CFC are in S-phase in the liver, but a 
large proportion are in S-phase in the bone marrow. This inter 
organ variation suggests that the GM-CFC proliferation is under 
local control. 
The changes in the kinetic state of GM-CFC in human fetal 
liver throughout gestation are probably related to changes in their 
concentration. The concentration of GM-CFC in human fetal liver is 
initially low and increases progressively up to the thirteenth week 
of gestation, Moore and Williams 1973b). This is probably due to 
the migration of CFU-S and GM-CFC from the yolk sac to the liver 
and their subsequent proliferation therein. This assumes that the 
CFU-S and GM-CFC migration demonstrated in culcutred murine embryos 
also occurs in the human ambryo, (Moore and Metcalf 1970), (see 
Section 3.1.3). Thus the inhibition of GM-CFC proliferation, nadir 
at 12.5 weeks gestational age is concomitant with the highest 
GM-CFC concentration. After 13 weeks of gestation the numbers of 
GM-CFC in the fetal liver decrease. This is accompanied by a 
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progressive increase in the proportion of GM-CFC in S-phase. The 
fetal liver GM, --CFC probably migrate to the bone marrow where 
haemopoiesis is commencing at this time, (Wickramasinghe 1975), 
(Keleman et al 1979). Figure 4.22 illustrates the relationship of 
the fetal liver GM-CFC kinetic state to the initiation of 
haemopoiesis in the fetal bone marrow. 
It appears that the proportion of human fetal liver GM-CFC 
synthesizing DNA is related to their concentration, as both these 
parameters change in a reciprocal relationship throughout 
gestation. A high concentration of GM-CFC corresponds to a low 
proportion in S-phase and vice versa. The data here indicate that 
these changes may be due to changes in the levels of a specific 
GM-CFC proliferation inhibitor and stimulator. This situation is 
analogous to the spleen and bone marrow of phenylhydrazine treated 
mice, QJright and Lord 1977 , 1978), (Wright et al 
1979). In these 
mice a high concentration of CFU-S in the spleen is associated with 
a small proportion of CFU-S in S-phase and a high concentration of 
a specific proliferation inhibitor. In contrast in the bone marrow 
there was a low CFU-S concentration, a large proportion in S-phase 
and a high concentration of a specific proliferation stimulator. 
4.4.2 An Inhibitor of GM-CFC Proliferation 
The results of this study indicate that liver cells from 11-14 
week gestational age human fetuses release an inhibitor of normal 
murine bone marrow (NMBM) GM-CFC proliferation. In contrast medium 
conditioned by liver cells from human fetuses of more than 14 weeks 
j15 
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Development of Haemopoietic Tissue and 
Proportion of HFL GM-CFC Synthesizing DNA 
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Figure 4.22 
7 8 9 10 
The development of the fetal liver and bone marrow during 
gestation. Superimposed onto this graph is the proportion of 
GM-CFC in fetal liver which are synthesizing DNA, from Moore and 
Williams (1973b). This graph is indicated by the broken line 
undershaded with black dots. Development of fetal haemopoietic 
tissue based on data from Wickramasinghe (1975) and Kelemen et al 
(1979). 
gestational age did not affect NMBM GM-CFC proliferation. Dose 
response assays of medium conditioned by liver cells from human 
fetuses of different gestational ages were performed. The highest 
levels of the GM-CFC proliferation inhibitory activity were found 
in livers from human fetuses in which Metcalf and Moore (1973b) had 
shown the smallest proportion of GM-CFC to be in S-phase. This 
suggests that the inhibitor of NMBM GM-CFC proliferation released 
by liver cells from early gestational age human fetuses may have a 
physiological role. 
Liver cell supernatants from early gestational age fetuses 
only reduced the absolute number of GM-CFC per 105 cells plated 
when used at high test/responder cell ratios. This is probably due 
to the presence of cell breakdown products in the supernatants. 
Inhibitors of CFU-S proliferation are also toxic at high test 
responder cell ratios, (Wright 1981). Some supernatants from 
freshly aspirated fetal liver cells reduced the numbers of GM-CFC 
per 105 cells plated. The second supernatant from these fetal 
liver cells, ie after washing in fresh medium did not have this 
effect. This was probably due to the high levels of tissue 
breakdown products in the fetal liver. Tissue breakdown occurs 
rapidly in the liver because of the 'presence of hepatocyte 
metabolic enzymes, (Lehninger 1975). These liver breakdown 
products would be removed by washing the cells. 
Mendehlsohn et al (1978) reported a similar phenomenon with 
neutrophil derived colony inhibitory activity (CIA) (Section 
4.1.6.3). The CIA was contained in a granulocyte lysate. The 
activity was enhanced by removing cellular debris and by adding 
protease inhibitors to it. Protease inhibitors also inhibit the 
breakdown of lymphokines, (Burden et al 1979). Human fetal thymus 
cell supernatants only reduced the number of GM-CFC per 105 cells 
plated when used at very high test responder cell ratios (Table 
4.4). This is probably because fetal thymus contains lower levels 
of metabolic enzymes than fetal liver, (Ham 1981). Incubation of 
NMBM with medium conditioned by human fetal liver cultures (Section 
4.3.12) significantly reduced the number of GM-colonies produced. 
This is also probably related to the presence of cell breakdown 
products in the conditioned medium. 
4.4.3 An Assay for GM-CFC Proliferation Stimulators 
The medium conditioned by early gestational age human fetal 
liver cells (11-14 weeks) was used to produce a population of NMBM 
GM-CFC a small proportion of which were in S-phase. This provided 
an assay system--for stimulators of GM-CFC proliferation. The 
non-cycling GM-CFC were incubated with medium conditioned by cells 
from late gestational age fetuses (>14 weeks). This increased the 
proportion of GM-CFC in S-phase to NMBM control levels. Thymus 
cell supernatants from late gestational age human fetuses did not 
affect GM-CFC proliferation. This is an indication of the source 
specificity of the GM-CFC proliferation stimulator. Insufficient 
cells were present in the bone marrow and thymus of 11-14 week 
fetuses to produce supernatants. The tissue source specificty of 
the GM-CFC proliferation inhibitor could not therefore be 
demonstrated. 
A large proportion of the GM-CFC in the liver of late 
gestational age human fetuses (> 14 weeks) are in cycle, (Moore and 
Williams 1973b). This may be due to the presence of a GM-CFC 
proliferation stimulator. The effects of this stimulator may be 
accentuated by the absence or lower levels of the GM-CFC 
proliferation inhibitor. High concentrations of this inhibitor 
were present in early gestational age human fetal livers. In these 
livers a small proportion of the GM-CFC were in cycle. 
These observations suggest that in human fetal liver the 
proportion of GM-CFC in cycle is regulated by a proliferation 
stimulator and inhibitor. A large number of fetuses of 12-15 weeks 
gestational age are needed to determine the mechanism which 
controls the gradual increase of the proportion of GM-CFC in cycle. 
Dose response studies of the inhibitor and stimulator could 
elucidate this mechanism. This could be due to a gradual shift in 
the balance between the GM-CFC proliferation stimulator and 
inhibitor. This would be similar to the control of CFU-S 
proliferation by the balance between a specific stimulator and 
inhibitor, (Wright and Lord 1978), (Toksoz et al 1980). This 
balance between the stimulator and inhibitor could be directly 
related to the concentration of GM-CFC in the fetal liver. Thus as 
the concentration of GM-CFC in the liver rises up to 11 weeks of 
gestation, the release of the GM-CFC proliferation inhibitor 
increases and the proportion in cycle decreases. Subsequently at 
about 13 to 14 weeks of gestation as the GM-CFC migrate from the 
liver to the bone marrow their concentration in the liver falls. 
This is accompanied by an increased release of the proliferation 
stimulator and an increased proportion of GM-CFC in cycle. 
Alternatively, the release of the GM-CFC proliferation 
regulators could be genetically programmed events which occur at 
set times during gestation. A programmed sequential development of 
primitive and definitive erythrocytes may occur. Beaupain et al 
(1979) have investigated the production of primitive and definitive 
erythrocytes in quail embryo, chick yolk sac chimeras. It was 
initially thought that primitive and definitive erythrocytes were 
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derived from vitelline (yolk sac) and intraembryonic stem cells 
respectively, (Wickramasinghe 1975). Beaupain et al (1979) 
demonstrated that vitelline and intraembryonic stem cells were both 
capable of forming primitive and definitive erythrocytes. They 
suggested that erythropoiesis followed a chronological program 
during ontogeny. 
A programmed-haemopoietic ontogeny is plausible, because the 
demands for cell production are sequential and predictable. In 
contrast during adult life the differing demands for haemopoietic 
cell production are enormous and unpredictable. In vivo 
perturbations of fetal haemopoiesis could differentiate between 
these two control mechanisms, eg partial hepatectomy at different 
stages of gestation. 
4.4.4 Specificity of Proliferation Regulators 
4.4.4.1 Specificity of GM-CFC proliferation regulators 
The inhibitor and stimulator of GM-CFC proliferation were both 
produced by non-adherent human fetal liver cells. The inhibitor 
was contained in a >100k daltons Amicon fraction, the stimulator in 
a 30-50k daltons fraction. Adherent liver cells from human fetuses 
of all gestational ages tested produced a stimulator of NMBM CFU-S 
proliferation. As discussed in Chapter Three this CFU-S 
proliferation stimulator had similar properties to that 
demonstrated in murine fetal liver, post-irradiation and 
post-phenylhydrazine bone marrow, (Lord et al 1977b), (Wright and 
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Lord 1978), (Wright et al 1979). 
An important property of any physiological proliferation 
regulator is cell line specificity. A liver cell supernatant from 
an early gestational age (11-14 weeks) human fetus stimulated NMBM 
CFU-S proliferation and inhibited NMBM GM-CFC proliferation. Thus 
one supernatant had opposite effects on the CFU-S and GM-CFC. 
These cells are closely related only separated by one 
differentation event. This is an excellent, demonstration of 
specific proliferation regulators. These two activities were 
separable. They were produced by different cell populations and 
were contained in different Amicon molecular weight fractions. 
Liver cells from late gestational age human fetuses produced a 
stimulator of both GM-CFC and CFU-S proliferation. Although both 
factors were contained in a 30-50K daltons fraction, they were 
produced by non-adherent and adherent cells respectively. 
4.4.4.2 Specificity of the CFU-S proliferation stimulator 
A CFU-S proliferation stimulator has been demonstrated in 
murine haemopoietic tissues in which a large proportion of the 
CFU-S are in cycle, eg post phenylhydrazine bone marrow and murine 
fetal liver, (Wright and Lord 1977), (Wright et al 1979). This 
proliferation stimulator was produced by adherent cells and 
contained in a 30-50K daltons fraction, (Wright 1981). A CFU-S 
proliferation stimulator has also been demonstrated in human fetal 
liver (see Chapter Three). This stimulator had similar properties 
Jcl 
to that demonstrated in murine haemopoietic tissues. 
It has previously not been possible to test the cell line 
specificity of the CFU-S proliferation stimulator, (Wright et al 
1979). This is because the committed progenitors are all rapidly 
proliferating cells. Normal murine bone marrow has been incubated 
with liver cell supernatants from early gestational age human 
fetuses. This treatment produced a population of GM-CFC a small 
proportion of which were in S-phase. These GM-CFC were not 
triggered into cycle during an incubation with the 30-50K daltons 
adherent human fetal liver cell derived CFU-S proliferation 
stimulator. This population of non-cycling GM-CFC therefore 
provides an assay for demonstrating CFU-S proliferation stimulator 
specificity. 
4.4.5 Relationship of the Human Fetal Liver Derived Factors to 
Other GM-CFC Proliferation Regulators 
4.4.5.1 GM-CFC proliferation inhibitors 
Several factors have been demonstrated which inhibit GM-CFC 
proliferation, reviewed by Broxmeyer (1978), Metcalf (1978b) and 
Cline et al (1978). E-type prostaglandins (PGE) inhibit GM-CFC 
proliferation in vitro by decreasing their sensitivity to GM-CSF, 
(Kurland and Moore 1977 1978). Lactoferrin inhibits the 
production of GM-CSF by monocytes and macrophages, (Broxmeyer et al 
1977), (Pelus et al 1979). Leukaemic cells release factors which 
inhibit GM-CFC proliferation directly LAI, (Olofsson and Olsson 
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1980a) and LIA, (Broxmeyer et al 1978). The granulocyte chalone 
inhibits the proliferation of the recognizable myeloid precursors, 
(Lord et al 1974b) but not the GM-CFC, (Lord et al 1977c). 
Lipoprotein inhibitors of granulopoiesis have been demonstrated in 
human and murine serum. These factors inhibit GM-CFC 
proliferation, (Chan et al 1971), (Fraser et al 1979). 
PGE as prostin E2 (Upjohn Ltd) was used to induce fetal 
abortion. PGE has similar effects on CFU-S and GM-CFC 
proliferation as a liver cell supernatant from an early gestational 
age human fetal liver. That is, stimulation of CFU-S 
proliferation, (Feher and Gidali 1974), and inhibition of GM-CFC 
proliferation, (Kurland et al 1978). It is therefore important to 
eliminate PGE as a source of these proliferation regulators in 
human fetal tissues. PGE has a plasma half life of less than 30 
seconds, (Hamberg and Samuelsson 1971). Recently a radioimmuno 
assay for PGE has become commercially available, (Gordon et al 
1977), (Clinical Assays Inc 1981). This could be used to 
demonstrate absolutely that no PGE is present in the fetal tissues. 
Even if PGE was present in the human fetal liver it would not 
produce inhibition of GM-CFC proliferation in the system used in 
these investigations because: - 
(1) Kurland et al (1977) only demonstrated inhibition of colony 
formation by GM-CFC if PGE was present throughout the culture 
period. Pre-incubation of bone marrow (techique used in this 
study), with PGE for two and a half hours had no effect on the 
subsequent colony formation. 
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(2) The E-type prostaglandins are dialyzable low molecular weight 
molecules (<1000 daltons), (Kurland et al 1978). In contrast the 
liver cell derived inhibitor of GM-CFC proliferation, from early 
gestational age human fetuses, had a molecular weight of >100,000 
daltons. 
(3) The E-type prostaglandins are produced by adherent 
macrophages, (Kurland et al 1978). In early gestational age 
fetuses, non-adherent liver cells produced the GM-CFC proiferation 
inhibitor. 
(4) The formation of macrophage colonies is more sensitive to 
inhibition by PGE than granulocytic colonies, (Pelus et al 1979), 
(Williams 1979). The presence of PGE in a GM-CFC culture would 
therefore reduce the proportion of macrophage colonies formed. 
Incubation of NMBM GM-CFC with an early gestational age HFLS had no 
effect on the proportion of the different colony types formed. 
Lactoferrin inhibits the production of GM-CSF by monocytes and 
macrophages, (Broxmeyer et al 1977), (Pelus et al 1979). 
Lactoferrin has no direct action on GM-CFC proliferation. It also 
does not influence the effect of exogenous GM-CSF on GM-CFC, 
(Broxmeyer et al 1977). Exogenous GM-CSA was used in all the 
experiments reported here. The inhibitor of GM-CFC proliferation 
detected in early gestational age human fetal livers is therefore 
probably not lactoferrin. 
The inhibitor of GM-CFC proliferation found in early 
gestational age human fetal livers has similar properties to 
factors released by leukaemic cells. In leukaemic patients normal 
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haemopoiesis is suppressed as the leukaemic clone enlarges. Two 
groups have isolated factors from leukaemic cells which inhibit 
normal GM-CFC proliferation. Olofsson and Olsson (1980a) 
demonstrated that leukaemic cells release a factor which reduces 
the proportion of normal bone marrow GM-CFC in S-phase. This 
factor is not released by normal bone marrow cells and has 
therefore been termed leukaemic associated inhibitor (LAI). LAI is 
a glycoprotein of. >300,000 daltons produced by light density 
leukaemic cells, (Oloffson and Olsson 1980b). LAI reduces the 
proportion of GM-CFC in S-phase and does not affect the absolute 
number of colonies produced. 
Broxmeyer et al (1978b) has also isolated a factor from 
leukaemic cells which inhibits GM-CFC proliferation. He has called 
this leukaemic inhibitory activity (LIA). LIA, unlike LAI, reduces 
the absolute number of colonies produced by normal bone marrow 
GM-CFC. The results strongly suggested that the GM-CFC were 
inhibited during DNA synthesis. LIA is a glycoprotein of 
450-550,000 daltons molecular weight. It has been identified as 
acidic isoferritin an iron binding protein, (Broxmeyer et al 1981). 
The inhibitor of GM-CFC proliferation found in early 
gestational age human fetal livers and those released by leukaemic 
cells have similar properties: - 
(1) They have molecular weights of >100,000 daltons. 
(2) They are produced by non-adherent macrophage like cells. 
(3) These inhibitors appear to act directly on GM-CFC because a 
source of exogenous GM-CSA was used in these investigations. 
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Inhibition of GM-CFC proliferation was therefore not mediated by 
suppression of endogenous GM-CSA production. 
(4) The early gestational age HLFS inhibitor and the LAI detected 
by Olofsson and Olsson (1980a) both reduced the proportion of 
GM-CFC synthesizing DNA, but did not decrease the absolute number 
of colonies formed. The LIA demonstrated by Broxmeyer et al (1978) 
did reduce the absolute number of colonies formed by normal bone 
marrow GM-CFC, but only GM-CFC in S-phase were inhibited. Although 
the early gestational age HFL only reduced the proportion of GM-CFC 
in S-phase, the >100,000 daltons fraction from this supernatant 
also reduced the absolute number of colonies formed. This could be 
a toxic effect. Alternatively, it could be due to higher 
concentrations of the inhibitory factor. Thus the HFLS inhibitor 
transiently reduces the proportion of GM-CFC in S-phase, so they 
are not killed by the suicide agent. If the HFLS is concentrated, 
ie the >100,000 dalton fraction, some of the GM-CFC are inhibited 
long enough to prevent colony formation. LIA is released from 
leukaemic cells maximally during a5 day incubation, (Broxmeyer et 
al 1978). In contrast the HFLS inhibitor is produced during a2 
hour incubation. It is therefore probable that the concentration 
of the inhibitory factor in LIA preparations is much greater than 
in a HFLS. Consequently LIA inhibit GM-CFC which are in S-phase 
for long enough to prevent colony formation. 
Further purification of the proliferation inhibitor is needed, 
to determine if it is acidic isoferritin, ie LIA. If this is 
demonstrated, the production of LIA by leukaemic cells would have a 
new significance. The release of the GM-CFC proliferation 
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inhibitor in human fetal liver probably represents a physiological 
process. The release of LIA could be the expression of a genetic 
derepression event, (Uriel 1979). That is, a factor normally only 
produced during fetal development is released by transformed adult 
cells. This situation would be analogous to the release of various 
onco-fetal products like Carcino-embryonic antigen by some colonic 
carcinomas, (Neville et al 1978). Pertinent to this hypothesis is 
the production of fetal haemoglobin by erythroleukaemic cells, 
(Thompson 1977). 
4.4.5.2 GM-CFC proliferation stimulators 
LPS-GM-CSA stimulated the proliferation of non-cycling GM-CFC. 
This is in agreement with the observations of Moore and Williams 
(1973a). This is compatible with the role of GM-CSF. as an 
essential factor for GM-colony formation. Some of the different 
forms of GM-CSF have molecular weights within the range of 
30-50,000 daltons, (Nicola et al 1979a), Burgess and Metcalf 
1980). It is therefore possible that the 30-50,000 dalton late 
gestational age HFL stimulator of GM-CFC proliferation is GM-CSF. 
. 
Supernatants from late gestational age fetal livers did not 
support GM-CFC colony formation over a wide range of 
concentrations. This does not exclude the presence of some GM-CSF 
in this conditioned medium. The concentration of GM-CSF needed to 
stimulate GM-CFC proliferation is probably less than that necessary 
to support colony formation. Dexter (1979) could not initially 
detect GM-CSF in long term bone marrow cultures, which contained 
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large numbers of GM-CFC and recognisable myeloid precursors. 
Subsequent concentration of the growth medium from these cultures 
demonstrated low concentrations of GM-CSF, (Wright 1981). The late 
gestational age HFL supernatants could be concentrated over Amicon 
filters to demonstrate the presence of GM-CSF. Dose response 
studies of the concentration of GM-CSF necessary to stimulate 
GM-CFC proliferation are needed. These may equate with the level 
of GM-CSF detectable in the late gestational age livers. These 
experiments are limited by the supply of early gestational age 
human fetal livers. The supernatants from these livers are needed 
to inhibit NMBM GM-CFC proliferation . These provide an assay 
population for GM-CFC proliferation stimulators. The majority of 
early gestational age fetuses are terminated using the suction 
method, from which no material can be recovered. The minority are 
induced using E-type prostaglandins. 
The results of preliminary experiments suggest that human 
fetal liver cultures may provide an answer to this problem. Day 4 
supernatants from early and late gestational age human fetal liver 
cell cultures inhibited and stimulated GM-CFC proliferation 
respectively. If supernatants could be removed from these cultures 
repeatedly, this would provide a large source of the GM-CFC 
proliferation inhibitor. This would be analogous to the production 
of CFU-S proliferation regulators in long term bone marrow 
cultures, (Toksoz et al 1980). The supernatants from the fetal 
liver cultures also reduced the number of GM-CFC per 105 cells 
plated. This was probably due to toxic cell breakdown products. 
These could be removed by Amicon fractionation. 
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Normal murine bone marrow, day 15 murine fetal liver and the 
bone marrow of mice irradiated 66 hours previously with 450 rads 
contained a GM-CFC proliferation stimulator. This was contained in 
a 30-50,000 daltons fraction. This correlates with the large 
proportion of GM-CFC synthesizing DNA in these tissues, (Metcalf 
1977). 
4.4.6 Regulation of the Resynthesis of CFU-S and GM-CFC 
Proliferation Stimulators 
After haemopoietic cells have been washed in medium they start 
releasing and/or resynthesizing the haemopoietic proliferation 
regulators. Wright et al (1980a) demonstrated that the production 
of the CFU-S proliferation inhibitor was inhibited by cyclohexamide 
and was therefore dependent on protein synthesis. The stimulator 
of CFU-S proliferation was 'resynthesised' by washed liver cells 
from fetuses of all gestational ages tested. The GM-CFC 
proliferation inhibitor and stimulator were 'resynthesised' by 
early (11-14 weeks) and late (>14 weeks) gestational age washed 
human fetal liver cells respectively. The GM-CFC and CFU-S 
proliferation regulators were both resynthesised within 5 hours. 
Wright and Lord (1978) demonstrated that the CFU-S proliferation 
stimulator and inhibitor were resynthesised within 3 and 5 hours 
respectively. 
The resynthesis of the CFU-S proliferation stimulator can be 
prevented by the presence of the antagonistic inhibitor. Lord and 
Wright (unpublished observations) incubated washed regenerating 
I 
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bone marrow cells with exogenous CFU-S proliferation inhibitor. 
The medium conditioned by these cells was fractionated by Amicon 
ultrafiltration to remove the CFU-S proliferation inhibitor. No 
CFU-S proliferation stimulatory activity was detected in the 30-50K 
daltons fraction. In this study the 50-100K daltons fraction from 
a normal, but not from a regenerating bone marrow supernatant, 
inhibited the resynthesis of the CFU-S proliferation stimulator by 
late gestational age HFL cells. In contrast this treatment did not 
affect the resynthesis of the GM-CFC proliferation stimulator by 
the same cell suspension. Thus the CFU-S proliferation inhibitor 
(50-100K NBME) specifically prevented the resynthesis of the CFU-S 
proliferation stimulator by human fetal liver cells of >14 weeks 
gestational age. 
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CHAPTER FIVE 
CONCLUDING SUMMARY 
5.1 AN INHIBITOR OF HAEMOPIETIC STEM CELL PROLIFERATION 
In normal murine bone marrow (NMBM) a small proportion of the 
haemopoietic stem cells (CFU-S) are. in cycle. In contrast, in 
regenerating bone marrow from mice exposed to cytotoxic drugs or 
irradiation and in developing haemopoietic tissues a large 
proportion of the CFU-S are in cycle, (Becker et al 1965). A lot 
of evidence suggests that CFU-S proliferation is controlled locally 
because the CFU-S can exist in two distinct kinetic states in the 
same mouse, (Rencricca et al 1970), (Gidali and Lajtha 1972). 
A specific CFU-S proliferation inhibitor was extracted from 
NMBM, (Lord et al 1976). In contrast a stimulator of CFU-S 
proliferation was extracted from regenerating bone marrow and fetal 
liver, (Lord et al 1977), (Wright et al 1979). The proportion of 
CFU-S in cycle appeared to be controlled by a balance between these 
two factors, (Wright and Lord 1977 , 1978). 
This study confirms the observations of Lord et al (1976). A 
50-100K daltons CFU-S proliferation inhibitor was extracted from 
rat and guinea pig bone marrow, but the rat NBME 50-100K daltons 
fraction did not inhibit GM-CFC proliferation. A rat thymus 
50-100K daltons fraction did not inhibit CFU-S proliferation. This 
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inhibitor was therefore source and cell line specific but species 
non-specific. 
5.2 AN ASSAY FOR STUDYING THE REGULATION OF HAEMOPOIETIC STEM 
CELL PROLIFERATION - THE 
1251UdR ASSAY 
CFU-S proliferation regulators have been assayed using the 
spleen colony suicide technique, (Becker et al 1965), (Lord et al 
1976), (Section 1.2.12). The seeding of CFU-S to the spleen and 
the subsequent colony formation is a random process, (Hendry 1973). 
The number of colonies per spleen is limited by confluence. Large 
numbers of mice are therefore needed to achieve statistical 
accuracy in the suicide assay, (Hazout and Valleron 1977). 
Biochemical characterisation of any putative CFU-S proliferation 
regulator would require the testing of many sub-fractions. An 
alternative rapid screening assay for these regulators was needed. 
1251-iododeoxyuridine (1251UdR) is selectively incorporated 
into cells which are synthesizing DNA, (Hughes et al 1964). 
Instead of assaying the number of injected CFU-S directly by 
counting the colonies which they form in the spleen, the total 
number of dividing cells which they produce was assayed by 
measuring the uptake of 125IUdR into the spleen. 
Different numbers of haemopoietic cells were injected into 
lethally irradiated mice. Five days later the mice were injected 
with 2. Ci of 125IUdR and sacrificed 2 hours later. There was a 
linear relationship between the log 125IUdR uptake into the spleen 
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and femur and the log cell dose injected. Haemopoietic cells were 
incubated with or without an S-phase speciifc cytotoxic drug (ie 
suicide). A cell dose in the middle of the linear range (5x105) 
was injected into separate groups of lethally irradiated mice. 
This resulted in a reduction in the spleen 
125IUdR incorporation 
which was similar to the suicide value obtained using the spleen 
colony technique. The 
125. UdR assay was therefore used to 
investigate the kinetic properties of CFU-S from different 
haemopoietic tissues and to assay the CFU-S proliferation inhibitor 
and stimulator. Equivalent results were obtained with both 
techniques. Ten times (5x105) as many cells were injected for the 
125IUdR assay than for the spleen colony technique (5x104). It was 
therefore postulated that the standard errors obtained with the 
125IUdR 
assay would be smaller than with the spleen colony 
technique. But the standard errors of the suicide values obtained 
from the two techniques were in most experiments the same for 
equivalent numbers of mice and in some were higher in the 
125IUdR 
assay. 
The 125IUdR assay measures the total number of proliferating 
cells produced by the injected CFU-S. This is dependent on both 
CFU-S self replication and differentiation and the number of 
amplification divisions within the progenitor and recognizable 
precursor compartments. In contrast, the spleen colony technique 
is an all or none assay, the size of the colonies not being 
relevant to the colony count (unless they are too small to count). 
The 125IUdR assay is consequently sensitive to any perturbation 
which alters the clonal expansion from each CFU-S. Infection of 
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the mice probably influences this, which occurred in this study. 
Wien the mice appeared to be infection free, much smaller errors 
were obtained with the 125IUdR assay. 
The extreme sensitivity of the 125IUdR assay is illustrated by 
the effect of the CFU-S proliferation regulators on the 125IUdR 
uptake per 105 cells injected. Incubation of regenerating bone 
marrow with the CFU-S proliferation inhibitor resulted in a 
reduction in the 125IUdR uptake per 105 cells injected compared to 
controls. Incubation of NMBM with the CFU-S proliferation 
stimulator had the converse effect. These factors appear to alter 
the subsequent behaviour of cells in the irradiated recipients. 
This provides a potential screening assay for CFU-S proliferation 
regulators which eliminates the need for a suicide assay and hence 
halves the number of mice needed. The maintenance of infection 
free mice would be necessary for the success of this technique. 
5.3 REGULATION OF HAEMOPOIESIS IN HUMAN FETAL LIVER 
Haemopoiesis develops sequentially in three main anatomical 
sites, the extra embryonic mesoderm, fetal liver and fetal bone 
marrow, (Wickramsinghe 1975). The liver is the principal site of 
haemopoiesis in the human fetus from the third to sixth month of 
gestation. The haemopoiesis is predominantly erythroblastic with 
some megakaryopoiesis, but there is no significant 
granulocytopoiesis, (Gilmour 1941), (Thomas and Yoffey 1962), 
(Kelemen et al 1979). Macrophages are present in the human fetal 
liver; Kelemen and Janossa (1980) demonstrated that they were the 
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first differentiated cells to be found there. GM-CFC are present 
in the fetal liver throughout gestation, (Moore and Williams 
1973b). The absence of granulocyte production may be related to 
the predominance of M-CSF rather than GM-CSF in fetal liver, 
(Johnson and Burgess 1978). The GM-CFC from fetal liver also have 
an intrinsic bias to form macrophage rather than granulocyte or 
mixed colonies, (Moore and Williams 1973b). 
5.3.1 The Regulation of Haemopoietic Stem Cell Proliferation in 
Human Fetal Liver 
The human fetus increases in weight from lg at 2 months of 
gestation to 3,300g at term, (Arey 1954). The haemopoietic system 
must therefore undergo an enormous expansion during gestation. The 
fetal tissues therefore expand rapidly, and consequently in murine 
fetal liver a large proportion of the CFU-S are in cycle, (Becker et 
al 1965). There is no definitive assay for the human haemopoietic 
stem cell but presumably they are in a similar kinetic state. The 
cells forming mixed haemopoietic colonies in culture (CFU-MIX), 
(Fauser and Messner 1979a), (Johnson and Metcalf 1980), may 
correspond to the haemopoietic stem cell or to a pluripotential 
precursor. The latter would be interposed between the stem cells 
and progenitors. In normal human bone marrow a small proportion of 
the CFU-MIX are synthesising DNA. In contrast in the regenerating 
bone marrow from recently transplanted patients a large proportion 
are synthesising DNA, (Fauser and Messner 1979b). The kinetic 
state of the CFU-MIX therefore corresponds to that of the CFU-S in 
equivalent murine haemopoietic tissues. But there is no evidence 
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that the CFU-MIX can self-replicate, a mandatory property of a stem 
cell. 
Medium conditioned by human fetal liver cells from fetuses of 
all gestational ages tested (11-17 weeks) stimulated NMBM CFU-S 
proliferation. The stimulator was produced by non-adherent cells 
and was contained in a 30-50K daltons Amicon fraction. This CFU-S 
proliferation stimulator has properties similar to that 
demonstrated in murine fetal liver and regenerating bone marrow, 
(Wright et al 1979). 
Medium conditioned by human fetal bone marrow also stimulated 
N14BM CFU-S proliferation. This is also a rapidly expanding 
haemopoietic tissue and the haemopoietic stem cells would be 
rapdily proliferating. In contrast, medium conditioned by adult 
rib bone marrow inhibited rapidly cycling CFU-S but not GM-CFC 
proliferation, in agreement with Wright et al (1980b). 
Haemopoietic stem cell proliferation may therefore be controlled by 
the same mechanism in human and murine haemopoietic tissues. 
5.3.2 The Regulation of Granulocyte Macrophage Progenitor Cell 
(GM-CFC) Prolifereation in Human Fetal Liver 
In the liver of early gestational age human fetuses (11-14 
weeks) few granulocyte macrophage colony-forming cells GM-CFC are 
synthesising DNA, whereas later in gestation (>14 weeks) a large 
proportion of the GM-CFC are in S-phase. In contrast, in the bone 
marrow from human fetuses the proportion of GM-CFC synthesising DNA 
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is high throughout gestation, (Moore and Williams 1973b). The 
changes in the proportion of GM-CFC in cycle appear to be related 
to their concentration in the human fetal haemopoietic tissues. 
The concentration of GM-CFC in the bone marrow is very low at 12 
weeks and then increases progressively throughout the rest of 
gestation. In contrast, in the liver GM-CFC are detected by 8 
weeks, increase to a peak concentration at 12 weeks and then 
decline throughout -the rest of gestation, (Moore and Williams 
1973b). The initial increase in the concentration of GM-CFC in 
the human fetal liver may be due to a migration of GM-CFC and 
haemopoietic stem cells from the yolk sac to the liver. This 
migration stream has been demonstrated in murine embryos, (Moore and 
Metcalf 1970). A further increase in GM-CFC concentration could 
then be produced by differentiation from the haemopoietic stem 
cells. The concentration of GM-CFC may be maintained at a high 
level by a partial differentiation block. Fetal liver contains a 
lot of macrophages but very few granulocytes or their recognisable 
precursors, (Kelemen et al 1979). After the twelfth week of 
gestation the concentration of GM-CFC in the human fetal liver 
decreases. This coincides with the onset of haemopoiesis in the 
fetal bone marrow, (Wickramsinghe 1975), and is therefore probably 
due to the migration of GM-CFC from the liver to the bone marrow. 
In human fetuses of <14 weeks gestation, the proportion of 
GM-CFC synthesising DNA in the liver is low, but in the bone marrow 
it is high. This inter-organ variation of the GM-CFC kinetic state 
suggests that a local proliferation control mechanism exists. This 
is analogous to the different kinetic states of CFU-S in the spleen 
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and bone marrow of mice previously treated with phenylhydrazine, 
(Wright and Lord 1977). These observations initiated the search 
for humoral regulators which might mediate the local control of 
GM-CFC proliferation in human fetal liver. 
Incubation of normal murine bone marrow GM-CFC (approximately 
40% synthesising DNA) with a supernatant from an early gestational 
age (11-14 weeks) human fetal liver reduced the proportion 
synthesising DNA to <5%. In contrast, the proportion of murine 
GM-CFC synthesising DNA was not affected by incubation with a 
supernatant from a late gestational age (>14 weeks) fetal liver or 
bone marrow cells. GM-CFC that had been switched out of cycle by 
incubation with a supernatant from an early gestation human fetal 
liver were switched back into cycle following incubation with a 
late human fetal liver supernatant. It seemed likely that changes 
in the relative levels of a proliferation inhibitor and stimulator 
throughout gestation might control the proportion of GM-CFC in 
cycle. The GM-CFC proliferation inhibitor and stimulator were both 
produced by non-adherent cells. The GM-CFC proliferation inhibitor 
was contained in a >100K daltons fraction and the stimulator in a 
30-50K daltons fraction. 
Many factors influence cell proliferation. It is therefore 
essential to demonstrate that putative proliferation regulatory 
factors act specifically on particular cells in one lineage. The 
specificity of the CFU-S and GM-CFC proliferation regulators was 
well demonstrated by an early gestation human fetal liver 
supernatant (HFLS) which stimulated CFU-S proliferation but 
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inhibited GM-CFC proliferation. Thus one supernatant had opposite 
effects on haemopoietic cells only separated by one differentiation 
event. These factors were separable because they were produced by 
adherent and non-adherent cells respectively and also had different 
molecular weights. In a supernatant from a late gestational age 
human fetal liver a stimulator of both CFU-S and GM-CFC 
proliferation was detected. These were both contained in. a 30-50K 
daltons fraction but were produced by adherent and non-adherent 
cells respectively. The specificity of the CFU-S proliferation 
stimulator extracted from murine regenerating bone marrow and fetal 
liver could not be demonstrated, (Lord et al 1977b), (Wright et al 
1979). This was because GM-CFC from most haemopoietic tissues are 
rapidly proliferating. The production of a non-cycling population 
of GM-CFC using the early gestational age HFLS is therefore a 
useful tool for demonstrating the specificity of CFU-S 
proliferation stimulators. 
5.3.2.1 Identity of the human fetal liver GM-CFC 
proliferation regulators 
In Section 4.4.5 the relationship of the human fetal liver 
derived factors to other GM-CFC proliferation regulators is 
discussed. The inhibitor of GM-CFC proliferation from an early 
gestational age human fetal liver appears to have similar 
propoerties to factors released by leukaemic cells, (Broxmeyer et al 
1978b), (Olofsson and Olsson 1980a). In leukaemic patients normal 
haemopoiesis is suppressed, this causes the anaemia, 
thrombocytopenia and immunoincompetence which lead to the demise of 
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the patient. Two groups have isolated factors from leukaemic cells 
which inhibit normal GM-CFC proliferation but not leukaemic colony 
formation. These factors have been called Leukaemic inhibitory 
activity (LIA), (Broxmeyer et al 1978b), and Leukaemic associated 
inhibitor (LAI), (Olofsson and Olsson 1980a). These factors are 
not released by normal bone marrow cells. These factors may be 
identical, the term LIA will be used here. The specific 
suppression of normal haemopoiesis by LIA gives the leukaemic cells 
a proliferative advantage. 
The early gestation HFLS GM-CFC proliferation inhibitor and 
LIA have similar properties. They have molecular weights of >100K 
daltons, are produced by non-adherent cells, and act directly on 
GM-CFC, i. e. do not influence GM-CSF production, because exogenous 
source of GM-CSA was used in these studies. LIA has been shown to 
be identical to acidic isoferritin, an iron binding protein. They 
both have apparent molecular weights of 550K daltons on SDS 
polyacrylamide gel electrophoresis, (Bognacki et al 1981), 
(Broxmeyer et al 1981). Purification of the HFLS GM-CFC 
proliferation inhibitor is needed to determine if it is also acidic 
isoferritin. The GM-CFC proliferation inhibitor in early 
gestational age human fetal livers is probably a physiological 
regulator. If it is also. shown to be acidic isoferritin, the 
release of LIA could represent a genetic derepression event. This 
means that a substance normally only produced during fetal 
development is produced by transformed adult cells, (Uriel 1979). 
Under normal circumstances the gene coding for the production of 
the substance is suppressed late in fetal or early in neonatal 
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life. When a cell becomes transformed these genes may be 
derepressed and the products they code for synthesised again. The 
production of fetal haemoglobin by erythroleukaemic cells is an 
example of this process, (Thompson 1977). 
The production of Alphafetoprotein is increased during fetal 
life and in the presence of some tumours, especially hepatomas and 
teratomas. Alphafetoprotein causes a selective suppression of 
T-cell proliferation in vitro, (O'Neil et al 1982). This may be 
repsonsible for the suppression of the immune response in 
pregnancy. This suppression may be involved in the maternal 
tolerance of the fetus. Alphafetoprotein may also help prevent the 
destruction of a tumour by suppressing the T-cell response to it. 
LIA also confers a proliferative advantage on the transformed, 
leukaemic cells. Some oncofetal products may therefore not just be 
convenient tumour markers, (Neville et al 1978), but essential for 
the survival of the tumour. 
GM-CFC which had been switched out of cycle during an 
incubation with an early gestational age HFLS were stimulated by 
GM-CSA. This confirms the observations of Moore and Williams 
(1973a). It is probable that the GM-CFC proliferation stimulator 
in late gestational age human fetal livers is GM-CSF. But these 
supernatants did not support the growth of murine GM-CFC. This 
does not mean no GM-CSF was present, because much lower 
concentrations of GM-CSF would be needed to initiate DNA synthesis 
than to support colony growth. 
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5.3.3 Modulation of the resynthesis of the CFU-S Proliferation 
Stimulator by Human Fetal Liver Cells 
Wright and Lord (1978) demonstrated that the CFU-S 
proliferation stimulator and inhibitor were resynthesised/ 
rereleased by washed haemopoietic cells within 3 and 5 hours 
respectively. This was probably resynthesis rather than rerelease 
because it did not occur if cyclohexamide was present and was 
therefore dependent upon protein synthesis, (Wright et al 1980a). 
The CFU-S proliferation stimulator was resynthesised/rereleased by 
liver cells from human fetuses of 11-17 weeks gestational age 
within 5 hours. The CN-CFC proliferation inhibitor and stimulator 
were resynthesised/rereleased by early (11-14 weeks) and late (>14 
weeks) gestational age human fetal liver cells respectively. 
This study implied that the inhibitor and stimulator of GM-CFC 
proliferation were only found in early and late gestational age 
livers respectively. Extensive dose response studies using 
fractionated supernatants from livers of 11-16 weeks gestational 
age need to be performed to confirm this. These studies could 
establish whether a sudden switch from production of GM-CFC 
proliferation inhibitor to stimulator occurs at around 14 weeks of 
gestation. Alternatively, the balance between these two regulators 
may change over a period of a few weeks. This study would require 
a large number of fetuses of 11-14 weeks gestational age. These 
are difficult to obtain because this period of gestation falls in 
the grey area between suction termination and prostaglandin 
induction, material is only recoverable from the latter. The 
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errors involved in fetal ageing and inter-fetus variation would 
mean that very large numbers of fetuses would be needed to produce 
meaningful results. 
When washed late gestational age human fetal liver cells were 
reincubated in the presence of the 50-100K daltons NBME fraction no 
CFU-S proliferation stimulatory activity was detected in the 30-50K 
daltons fraction from the conditioned medium. In contrast, a 
50-100K daltons fraction from an irradiated BME did not prevent the 
production of CFU-S stimulatory activity. Thus washed human fetal 
liver cells do not resynthesise the CFU-S proliferation stimulator 
in the presence of the antagonistic inhibitor. This also occurred 
when washed regenerating murine bone marrow cells were reincubated 
in the presence of the 50-100K daltons NBME fraction, (Lord and 
Wright unpublished observations). The presence of the CFU-S 
proliferation inhibitor did not prevent the resynthesis of the 
GM-CFC proliferation stimulator by washed late gestational age 
human fetal liver cells. This indicates that the CFU-S 
proliferation inhibitor specifically inhibits the production of its 
antagonistic stimulator. It would be interesting to see if the 
GM-CFC proliferation inhibitor has a similar effect on the 
resynthesis of the GM-CFC proliferation stimulator. 
Wright and Lord (1978) showed that when spleen cells from PHZ 
treated mice (approximately 10% CFU-S in S-phase) were reincubated 
in fresh medium the stimulator appeared after 3 hours. This 
produced a transient autostimulation of the CFU-S in this cell 
suspension. The inhibitor was resynthesised within 5 hours. The 
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kinetic state of the CFU-S then returned to normal for post PHZ 
spleen (ie approximately 10% in S-phase), under the influence of 
the inhibitor. In this situation, the CFU-S proliferation 
inhibitor might also act to decrease the production of the CFU-S 
proliferation stimulator. This mechanism might serve to maintain 
the CFU-S in the kinetic state which corresponds to the CFU-S 
concentration. The levels of the inhibitor and stimulator are 
probably related to--the CFU-S concentration in a haemopoietic 
tissue. There must therefore be signals passing from the CFU-S to 
the factor producing cells which indicate the size of the CFU-S 
population. The mixing of CFU-S and factor producing cells 
separated from haemopoietic tissues in which. the CFU-S are in 
different kinetic states could help identify these signals. 
REFERENCE S 
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